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DANKWOORD 
 
 Na jaren van wetenschappelijk onderzoek is eindelijk het moment aangebroken 
waarop ik vele mensen mag bedanken die, rechtstreeks of onrechtstreeks, hebben 
bijgedragen tot het tot stand komen van dit proefschrift. 
 Vooreerst had ik graag mijn promotoren Prof. Dr. Stefaan De Smedt en Prof. Dr. Jo 
Demeester bedankt om me de kans te geven een doctoraat aan te vatten aan het Labo 
Algemene Biochemie en Fysische Farmacie. Tijdens het vierde jaar van mijn studies kwam 
ik reeds bij jullie terecht voor het uitvoeren van een onderzoeksstage. Een goed jaar later 
kreeg ik de kans om te beginnen aan mijn ‘eigen’ onderzoeksproject met een ‘eigen’ bureau 
en (mits wat vertraging) een ‘eigen’ computer. Dit ‘eigen’ project bleek toch meer te vereisen 
dan het uitvoeren van een min of meer afgelijnde onderzoeksstage, maar na enkele 
maanden van artikels doorworstelen en het verkennen van het nieuwe onderzoeksdomein 
kon het wetenschappelijk onderzoek echt van start gaan. Stefaan, gedurende vele jaren kon 
ik rekenen op je niet aflatende enthousiasme en begeleiding. Je leerde me de koe bij de 
horens te vatten en steeds opnieuw op zoek te gaan naar dat ‘one good idea’. Als geen 
ander slaag je erin om contacten te leggen met de ‘groten der aarde’ en je studenten uit te 
sturen over deze aardbol, steeds nieuwsgierig naar wat ze hebben bijgeleerd bij hun 
terugkomst. Jo, je was als tweede begeleider in de doctoraats-tandem misschien minder 
betrokken in de rechtstreekse begeleiding van mijn onderzoeksproject. Toch zijn er heel wat 
zaken waarvoor ik je wens te bedanken. Als hoofd van het labo heb je een cruciale rol in het 
leggen van de fundamenten waarop het wetenschappelijk onderzoek is gebouwd. Zonder 
jouw algemeen ‘management’ van het labo was er van onderzoeksinstrumenten zelfs geen 
sprake. Het aanvragen van kredieten, het spijzen van de labokas, de aankoop van nieuwe 
instrumenten (met extra garantie!), stuk voor stuk zijn ze onmisbaar voor de goede werking 
van het labo. Bovendien kregen we als doctoraatsstudent steeds de kans om interessante 
congressen bij te wonen, zowel binnen als buiten Europa. En laten we zeker onze jaarlijkse 
labo-uitstap niet vergeten. Bedankt hiervoor. Een persoonlijk woordje van dank is zeker op 
zijn plaats voor de mogelijkheid die je me gaf om gedurende twee extra jaren mijn onderzoek 
tot een goed einde te brengen. Het zou een moeilijke klus geweest zijn zonder deze blijk van 
vertrouwen die je in me had.   
I would also like to take the opportunity to thank Prof. Dr. Rainer Pepperkok from the 
Advanced Light Microscopy Facility at the EMBL in Heidelberg. Rainer, you gave me the 
opportunity to come to the EMBL up to three times to benefit from the unbelievably 
productive research environment. For two months I was isolated with my oligonucleotides, 
the FCS instrument and the silence of the night, as the instrument was too occupied during 
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the day. I learned a lot about myself and my research project, and although it was sometimes 
a demanding period, I wouldn’t want to have missed it!  
 Uiteraard was ik niet de enige die op het labo rondliep om zijn of haar doctoraat tot 
een goed einde te brengen. Er zijn bijgevolg verschillende mede-doctoraatsstudenten die ik 
wens te bedanken voor de leuke momenten, zowel binnen als buiten het labo. De meeste tijd 
bracht ik ongetwijfeld door met mijn bureau-genoten Kevin en Tinneke. Dankzij Tinneke nam 
mijn kennis van het programma Word significant toe, wat dit doctoraat natuurlijk alleen maar 
ten goede komt. Kevin op zijn beurt wijdde me in in de wereld van de pixels en de 
beeldverwerking, onontbeerlijk bij de verwerking van de vele celfoto’s. Ons concentratie- en 
stiltegebied werd op de gepaste tijdstippen onderbroken voor een luchtige babbel of 
anekdote, al dan niet gevolgd door een lachsalvo. Ik verdenk er Kevin trouwens van om 
stiekem aandachtig te luisteren als Tinneke en ik het weer eens hadden over de strijk-, 
opruim- en zoekcapaciteiten van onze ‘ideale mannen’ thuis.  
 Een deur meer naar links bevindt zich mijn ex-FCS partner Bart. Bedankt om me in 
de startblokken te krijgen door me de geheimen en de beperkingen van het FCS instrument 
te leren kennen. Nu heb je, in vervanging van Jurgen, de rol van ‘laboduizendpoot’ op je 
genomen. Geen moeite of vraag is je te veel en je deur staat steeds open voor iedereen. 
Indien er een prijs zou bestaan voor de meest verdienstelijke labo-persoonlijkheid denk ik dat 
je zeker een nominatie verdient.   
 De ‘polyvalente zaal’ wordt sinds enkele jaren bevolkt door Roos, Lies, Bruno en Ine. 
Dat deze zaal haar naam niet gestolen heeft, blijkt uit de vele persoons-verschuivingen en 
bureau-herindelingen die er zich gedurende de afgelopen jaren hebben afgespeeld. De 
naam ‘polyvalent’ weerspiegelt zich ook in de verschillende zaken waarvoor je in jullie 
bureau-knooppunt terecht kon, van koetjes en kalfjes over nuttige onderzoekstips tot heus 
crisis-overleg. Een speciaal woordje van dank is ook op zijn plaats voor Roos, dankzij wie we 
nu over een heus bacterie-lokaal beschikken. Ook mag ik er niet aan denken hoe ik nu nog 
mijn figuren zou maken als je me de basisprincipes van het programma Coreldraw niet had 
getoond.  
 Door de exponentiële groei van het labo zagen we Niek, Koen, Farzaneh, Stefaan D., 
Kevin B. en Barbara hun eigen bureau-eiland oprichten in onze nieuw-veroverde labolokalen. 
Bij deze wens ik Barbara nog eens te bedanken om als thesisbegeleider me de gevaren en 
geneugten van het wetenschappelijk onderzoek te leren kennen. Ook Koen en Farzaneh 
nemen een speciale plaats in als ex-stagiairs tijdens mijn eigen onderzoek. Ik kan toch 
zeggen dat Koen een belangrijke rol gespeeld heeft bij het tot stand komen van het begrip 
‘R/G ratio’, wat toch vele malen in dit proefschrift aan bod komt. Bij deze zou ik ook Sofie 
wensen te bedanken, met wie ik kon kennismaken op weg naar het bureau-eiland voor het 
stellen van mijn vele vragen, en die algauw een aangename ‘infiltrant’ bleek te zijn voor de 
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dagelijkse middagpauzes. Verder wens ik onze nieuwste aanwinsten Dries en Marie-Luce te 
bedanken voor de korte, maar toch al leuke tijd dat we hebben samengewerkt. Naast de 
mede-onderzoeksstudenten, waren er ook nog mijn stagiairs Karlien, Annika, Fleur, 
Farzaneh, Koen, Ine D., Philippe, Maria, Marta en Elke die elk, in meer of mindere mate, 
hebben bijgedragen aan dit werk.  
 Een speciaal woordje van dank gaat uit naar ons secretariaatsteam Katharine en 
Bruno. Dank zij jullie hoefden we ons geen zorgen te maken over vliegtuig, trein, hotel of 
registratie wanneer we, vaak maar net op tijd, kwamen melden dat we weer eens op congres 
gingen. Ook wanneer we achteraf onze uitgaven en briefjes kwamen binnenbrengen, konden 
we erop rekenen dat alles door jullie deskundig werd geSAPt. Jullie hulp in het papieren 
doolhof wordt enorm geäpprecieerd.  
 Een bijzonder woord van dank gaat uit naar mijn ouders. Reeds van kleinsaf was de 
‘onderzoeks-spirit’ aanwezig in mijn leefomgeving. Het eerste doctoraat dat ik heb kunnen 
bijwonen, kwam dan ook heel vroeg, toen ik als ongeboren kindje de proefschriftverdediging 
van mijn moeder kon aanhoren. Ook mijn vader schakelde me reeds vroeg in in het 
wetenschappelijk onderzoek. Als ik eens een dagje ziek was mocht ik mee naar het labo, 
waar ik gekleurde plastieken doosjes mocht opvullen met de bijpassende gekleurde 
plastieken tipjes. Het is pas nu, vele jaren later, dat ik besef wat ik eigenlijk aan het doen 
was… Ook tijdens mijn studies kon ik steeds op jullie rekenen om me te stimuleren wanneer 
nodig of gewoon om te zien dat jullie best wel trots waren op jullie dochter. Uiteraard kon ik 
ook steeds rekenen op jullie steun bij die andere mijlpalen in mijn leven, zoals de start van 
mijn eigen ‘huisje, tuintje, boompje’. Natuurlijk wens ik ook mijn broer niet te vergeten, wiens 
onnozele buien menig examenperiode een vrolijke toets hebben gegeven. Tenslotte zijn er 
nog de vele vrienden en familie buiten de werkomgeving. Jullie zijn reeds vele jaren 
‘omnipresent’ in mijn leefwereld en dit mag nog vele jaren zo blijven! 
 Als laatst, maar zeker niet het minst, wens ik mijn man Wim te bedanken. Dankzij jou 
kregen de figuren in dit proefschrift de juiste kleur en plaats, had ik plots een voorblad en 
curriculum, bleken de referenties geen fouten meer te bevatten en noem maar op... Maar 
eigenlijk wens ik je vooral te bedanken voor wie je bent en wat je voor mij iedere dag 
opnieuw betekent. Jij zorgt ervoor dat ik na een goede of minder goede dag steeds kan 
thuiskomen in een liefdevolle omgeving. Onze vele hilarische momenten samen zorgen 
ervoor dat ik met plezier door het leven ga. Ook zou ik graag ons kleintje hier in mijn buik 
willen bedanken voor de vele kleine schopjes tijdens het schrijven van dit proefschrift. En 
zoals het leven eens voor mij begon zet het zich nu voor jou weer verder. Het eerste 
doctoraat dat je zal kunnen bijwonen, komt dan ook heel vroeg, wanneer je als ongeboren 
kindje de proefschriftverdediging van je mama zal kunnen aanhoren… De herhaling, zou je 
papa zeggen, is nooit ver weg.   
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GENERAL INTRODUCTION,  
AIMS AND OUTLINE  
OF THIS THESIS 
 
Advances in biotechnology have lead to an accelerated discovery of macromolecular 
therapeutics such as peptides, proteins and polynucleotides. These macromolecules can be 
targeted against a variety of diseases, each requiring delivery to a well defined compartment 
of the body. Antisense oligonucleotides (ONs) and plasmid DNA (pDNA) show potential in 
the treatment of a wide variety of inherited and acquired genetic disorders, viral infections 
and cancer. Gene therapy aims to deliver these nucleic acids to cells to introduce novel 
genes or repair malfunctioning genes. Naked nucleic acids, however, are often prone to 
degradation before reaching their target site, or do not reach their target site at all. Therefore, 
they need the use of advanced drug delivery systems, such as viral or non-viral vectors. In 
general, viral vectors provide high transfection efficiencies but suffer from the limited size of 
the genetic material they can carry. Also, they can induce severe immune responses. Non-
viral vectors are advantageous over viral vectors in that they are less expensive, easier and 
safer to make and more suitable for long time storage. They can also deliver much larger 
pieces of DNA. When compared to viral vectors, however, the current transfection 
efficiencies of non-viral vectors are far from optimal.   
Non-viral vectors, such as cationic liposomes and cationic polymers, spontaneously 
form interpolyelectrolyte complexes with the negatively charged nucleic acids. These 
nanoparticles, which are respectively called lipoplexes and polyplexes, encounter different 
extra- and intracellular barriers during the delivery process. First of all, the nanoparticles 
should reach the target tissue, which, depending on the therapeutic application, could be the 
liver, the lung epithelium, muscle cells, tumor cells and so on. Once they have reached their 
target site, the nanoparticles mostly enter the cells by endocytosis. Following endocytosis, 
the nanoparticles are present in the endosomal compartment and should escape into the 
cytoplasm of the cells to avoid degradation in the lysosomes. Next, the nucleic acids mostly 
have to leave their pharmaceutical carriers before a therapeutic effect can be obtained. 
Furthermore, as the nucleic acid sequence is essential for their therapeutic effect, they 
should remain intact in the intracellular environment. Finally, the nucleic acids should reach 
their intracellular target, which can be situated in the cytoplasm (in the case of ONs) or in the 
nucleus (in the case of pDNA) of the cells.  
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The current generation of non-viral vectors in gene delivery are designed to facilitate 
entry into the cells and escape of the nucleic acids from the endosomal compartments. For 
successful nucleic acid delivery, the carriers should also protect the nucleic acids against 
enzymatic degradation by nucleases in the bloodstream and inside the cells. Viral vectors 
have evolved to optimally cross the biological barriers in order to deliver their DNA material. 
When compared to viral vectors, however, non-viral vectors are far less efficient in crossing 
the extracellular and intracellular space. Increasing attention has been paid to elucidate 
which of the above mentioned barriers limit the transfection efficiency of non-viral vectors the 
most. We believe that analyzing the different steps in the delivery process is crucial to allow 
optimization of the current generation of non-viral gene delivery systems. Unfortunately, the 
intracellular fate of the delivered nucleic acids is not very well known, mainly because of a 
lack of suitable methods that allow characterization of these critical steps in living cells.  
In this thesis, we aimed to elucidate the role of the intracellular degradation of the 
nucleic acids in limiting their therapeutic effect. Because of the limited methods that allow to 
follow the on site degradation of nucleic acids in living cells, we additionally aimed to 
evaluate the use of an advanced light microscopy technique, namely Fluorescence 
Correlation Spectroscopy (FCS), for that purpose.  
Chapter 1 gives an overview of the cationic lipids and cationic polymers that were 
used in this thesis to bind the nucleic acids. Also, the different intracellular barriers that are 
encountered by these non-viral vectors are discussed in more detail. A brief introduction on 
the basic principles of FCS is also given. In Chapter 2, the use of FCS to follow the 
degradation of naked antisense ONs was evaluated. Therefore, both nuclease resistant 
phosphothioate and nuclease sensitive phosphodiester ONs were fluorescently labeled and 
their integrity was followed both in buffer and in living cells. These fluorescently labeled ONs 
were subsequently complexed with non-pegylated and pegylated cationic liposomes in 
Chapter 3 and with non-pegylated and pegylated polymers (polyethyleneimine) in 
Chapter 4, in order to elucidate the protection of the ONs against enzymatic degadation as 
offered by these carriers. When possible, the physicochemical properties of the carriers were 
correlated with the observed protection efficiency. In Chapter 5 and Chapter 6, the 
relationship between the intracellular behavior of respectively non-pegylated and pegylated 
lipoplexes and their biological activity was investigated upon delivery of the antisense ONs to 
human lung epithelium cells. Special attention was given to the time and place of the 
intracellular degradation of the delivered ONs. Finally, in Chapter 7, we aimed to elucidate 
why supercoiled plasmid DNA appeared to be the best topology to generate gene expression 
upon delivery by non-pegylated cationic liposomes.   
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ABSTRACT 
 
Gene therapy aims to deliver DNA-based therapeutics such as antisense 
oligonucleotides (ONs), plasmid DNA (pDNA) and small interfering RNA (siRNA) to introduce 
novel genes or down-regulate malfunctioning genes. However, many problems remain to be 
resolved before gene therapy can become a standard clinical practice. The success of gene 
therapy is largely dependent on the development of a vector that can selectively, efficiently 
and safely deliver the DNA-based therapeutics to the target cells. On their delivery route, the 
vectors encounter different barriers. Indeed, they should be taken up by the cells, escape 
from the endosomal compartment, traffick through the cytoplasm and cross the nuclear 
membrane. Which of these barriers mainly limit the delivery process is currently not well 
understood and, very likely, depends strongly on the composition of the non-viral vector. In 
this chapter, we briefly discuss the nature of the DNA-based therapeutics and the non-viral 
gene delivery systems that were used in this thesis. Also, the different intracellular barriers 
that are encountered by these non-viral vectors are discussed in more detail. Finally, we 
introduce the reader to the basic principles of Fluorescence Correlation Spectroscopy (FCS), 
as this was the method of choice throughout this thesis to elucidate the effect of degradation 
of the DNA-based therapeutics on their transfection efficiency.      
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Chapter 1 
Intracellular Barriers to Oligonucleotide 
and Plasmid DNA Delivery 
 
 
DNA-BASED THERAPEUTICS 
 
Antisense Oligonucleotides 
 The aim of the antisense strategy is simply to down-regulate the expression of 
disease-causing proteins by the inhibition of gene expression. Protein synthesis requires 
transcription from DNA into mRNA and its translation into protein. Antisense ONs are short 
(12-28 nucleotides), synthetic strands of DNA that are complementary or antisense to a 
target sequence, designed to halt the production of proteins at the level of transcription, 
translation or splicing of the mRNA. The first strategy, namely blocking the transcription, can 
be achieved by triple helix forming ONs (TFOs). TFOs hybridize in the major groove of DNA 
by Hoogsteen bonding and prevent DNA read-out by preventing the binding of transcription 
factors, inhibiting the duplex unwinding or by inducing mutations in the targeted gene 1. The 
second strategy, namely blocking the translation, is more commonly used and is generally 
referred to as the ‘antisense’ strategy. Antisense ONs bind to their complementary target 
mRNA in a sequence specific manner through Watson-Crick hydrogen bonding. This can 
inhibit gene expression by several mechanisms, including translation arrest mediated by 
blockade of ribosomal read-through and hydrolysis of mRNA by recruitment of RNase H 2. 
For an antisense ON to hybridize with its target mRNA, it must find an accessible sequence, 
which is at least in part a function of the mRNA physical structure. Indeed, mRNA is not a 
single-stranded random coil but displays a secondary and tertiary structure, which may 
render large parts of the mRNA inaccessible towards interaction with the matching antisense 
ONs. Selection of active antisense molecules still remains largely a matter of trial and error, 
although the use of computer-predictive folding of mRNA has helped to identify hybridization-
accessible sites and thus the design of antisense ONs. The abundance and half-life of the 
target mRNA should also be considered when selecting a gene target. Indeed, the effect of 
the reduced protein expression will only be apparent after significant turnover of the pre-
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existing endogenous protein pool. Therefore, antisense ONs targeted at mRNAs with a short 
half-life are expected to be more successful in decreasing the level of the corresponding 
protein.  
The first generation of antisense ONs contained phosphodiester linkages (PO-ONs) 
(Figure 1A). PO-ONs are capable to recruit and activate RNase H, but are sensitive to 
nucleases and show relatively short half-lives. To overcome this problem, a variety of 
chemically modified ONs have been developed. The most frequently used chemically 
modified ONs are the phosphothioate ONs (PS-ONs) in which one of the non-bridging 
oxygens is replaced by a sulphur (Figure 1B). PS-ONs exhibit a long half-life in vitro and in 
vivo and retain the ability to recruit RNase H to degrade PS-ONs/mRNA hybrids 3. A 
disadvantage of the PS-linkage is its affinity for proteins, which can cause non-sequence-
specific antisense effects 4. Second generation antisense ONs were developed to overcome 
the disadvantageous properties of the phosphothioates, but frequently the modification of the 
nucleotides and/or changes in the backbone reduced or eliminated the RNase H recognition 
of the DNA/RNA duplex 5. Indeed, only phosphodiester, phosphothioate and chimeric ONs 
can activate RNase H. 
 
Figure 1.  Chemical structure of antisense ONs with (A) a phosphodiester or (B) a phosphothioate backbone.  
 
 There are several antisense ONs in phase II or III clinical trials 6. However, only few of 
them have made it to the market. VitraveneTM is the first antisense ON that was approved by 
European authorities in 1999, to treat an inflammatory viral infection of the eye that is caused 
by cytomegalovirus 7. A major problem that still prevents the use of antisense therapy is the 
inefficient delivery of ONs into cells. Therefore, suitable delivery systems need to be 
developed, as naked ONs only poorly cross cellular membranes 8. The aims for optimal 
delivery of ONs are to increase cellular uptake, improve exit from the endosomal 
compartment and to direct targeting to a particular site of action. Also, the required time 
frame of delivery needs to match the biological half-life of the target protein and the desired 
level of knock-down. 
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Plasmid DNA 
 Recombinant plasmids are high molecular weight, double-stranded DNA constructs, 
engineered to contain adventitious genes encoding specific proteins. Plasmid DNA (pDNA) 
molecules can be considered as pro-drugs that upon cellular internalization make use of the 
DNA transcription and translation apparatus to synthesize the desired protein. Gene therapy 
in this case involves the use of pDNA to introduce transgenes to cells that lack the ability to 
produce the desired protein or to correct functionally incompetent copies of a certain 
protein 1. In its early stage of development, pDNA-based gene therapy was attempted to 
correct inheritable disorders resulting from a single gene defect, such as the cystic fibrosis 
transmembrane conductance regulator gene in Cystic Fibrosis. In addition to disease 
treatment, pDNA can be used as a DNA vaccine for genetic immunization. Suicide gene 
therapy, in which gene expression leads to the convertment of a separately administered 
non-toxic prodrug into a chemotoxic drug, is another rapidly emerging strategy for cancer 
treatment. A pDNA-based therapeutic that is currently on the market is Gendicine, which acts 
by inserting the p53 gene into tumor cells, thereby stimulating cell death 9.   
 In addition to the transgene of interest, pDNA typically contains several regulatory 
signals such as promotor and enhancer sequences that play an important role in regulating 
gene expression. Promotor sequences offer recognition sites for the RNA polymerase to 
initiate the transcription process, while enhancer sequences can enhance the transcription of 
the gene of interest by as much as several hundred times. Like antisense ONs, the cellular 
uptake of naked pDNA molecules remains a very inefficient process. Delivery of pDNA is 
further reduced by its high molecular weight compared to shorter antisense ONs. Also, pDNA 
cannot be chemically modified to increase the resistance towards enzymatic degradation. 
Various types of synthetic vectors have been developed for gene transfer 10. Among the non-
viral vectors, cationic lipid- and cationic polymer-based systems have been the most 
extensively studied, both for antisense ONs and pDNA delivery. The general features of the 
non-viral gene delivery systems as used in this thesis are discussed below.  
 
 
NON-VIRAL GENE DELIVERY SYSTEMS 
 
Liposomes as Nucleic Acids Carriers  
 Liposomes have emerged as one of the most versatile tools for the delivery of DNA 
therapeutics. When dispersed in an aqueous medium, phospholipids, which consist of a 
hydrophilic polar head group and a hydrophobic hydrocarbon tail, form bilayered structures, 
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called liposomes. Liposomes are spherical, self-closed structures formed by one or more 
lipid bilayers with an aqueous phase inside and between the lipid bilayers 11. While 
multilamellar liposomes consist of a number of phospholipid bilayers and have a size 
typically ranging from about 200 to 800 nm, unilamellar liposomes consist of a single 
phospholipid bilayer and are above (large unilamellar vesicles) or below (small unilamellar 
vesicles) 200 nm in size. For DNA delivery, the nucleic acids are encapsulated into the 
liposomes’ interior or bound to the liposomes’ surface by electrostatic interactions. A variety 
of cationic, anionic and synthetically modified lipids and combinations thereof have been 
used to deliver a wide range of DNA-based therapeutics. The poor encapsulation efficiencies 
of the negatively charged nucleic acids in anionic liposomes has prevented their widespread 
use. Cationic liposomes, however, have been successful for achieving biological effects in 
cell culture. The first successful in vitro transfection with a cationic lipid was described in 
1987, by Felgner et al. 12. Due to their relative high efficiency, cationic lipids have been the 
most widely studied of the synthetic vectors. The effectiveness of the lipoplexes depends on 
the type and nature of the cationic lipid, the cell type, the type of nucleic acid (e.g. nucleic 
acids chemistry and lenght) and the method of formation of the lipoplexes.   
Cationic liposomes generally consist of a mixture of zwitterionic and positively 
charged lipids. Upon mixing cationic liposomes with the negatively charged nucleic acids, 
spontaneously so-called lipoplexes are formed through electrostatic interactions. Over the 
last few years, progress has been made in elucidating the structures of lipoplexes. 
Interaction between DNA and cationic lipids is a self-assembly process that is triggered by 
DNA-mediated fusion of liposomes, resulting in lipid-bilayers with the DNA sandwiched in 
between 13. While the positive charge on the polar head group of the cationic lipids is 
important for binding the negatively charged nucleic acids, the features of the alkyl chains 
play an important role in the organization of the lipoplexes. To promote the endosomal 
escape of lipoplexes, a cone-like lipid (with a small head group and expanding alkyl chains) 
should be incorporated in the liposomes. Cone-like lipids, such as the neutral 
dioleoylphosphatidylethanolamine (DOPE) can adopt a hexagonal phase that disturbs the 
endosomal membrane thereby provoking endosomal escape 14. The general structure of 
liposomes is depicted in Figure 2, together with the commonly used cationic lipid N-(1-(2,3-
dioleoyloxy)propyl)-N,N,N-trimethylammoniumchloride (DOTAP) and the neutral lipid DOPE.  
While a positive surface charge is favorable for gene transfer efficiency in vitro, upon 
systemic application, the charged particles interact with blood components and non-target 
tissue, triggering toxic effects and reducing circulation times and targeting ability 15. A 
common approach for masking the surface charge is to coat the lipoplexes with a hydrophilic 
polymer such as polyethyleneglycol (PEG). This ‘pegylation’ of lipoplexes prevents their 
aggregation, lowers their toxicity and increases the circulation time in the bloodstream 16. 
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Unfortunately, as discussed below, shielding appears to reduce the cell transfection activity. 
Besides the pegylation of the lipoplexes’ surface, also sugars, peptides and proteins are 
often bound to the surface in an effort to target them to specific cells. 
 
 
Figure 2.  Chemical structure of (A) the cationic lipid DOTAP, (B) the neutral lipid DOPE and (C) an unilamellar 
liposome.  
 
Polymers as Nucleic Acids Carriers 
 Another class of synthetic vectors that have been actively studied are cationic 
polymer-based gene delivery systems 17. Like cationic lipids, cationic polymers self-assemble 
with the negatively charged DNA into so-called polyplexes due to electrostatic interactions. 
Each polyplex often contains several DNA molecules along with many polymer chains. Many 
different types of polymers have been evaluated as gene delivery vehicles, like cationic 
polymethacrylates, cationic polypeptides and cationic celluloses 17-20. In this thesis, 
polyethyleneimine (PEI) was used as the cationic polymer of choice for gene delivery, as PEI 
has been reported to exhibit superior transfection efficiencies in many different types of 
cells 21.    
The repeating unit of PEI consists of two carbon atoms followed by a protonatable 
nitrogen atom. PEI is available in a linear and branched conformation and in a wide variety of 
molecular weights (Figure 3). At physiological pH, a fraction of the amine groups carries a 
positive surface charge, which allows binding and condensing the negatively charged DNA. 
The unprotonated amines give PEI the attribute of serving as an effective buffer over a wide 
variety of pH ranges, which is believed to be important to PEI’s success as a gene delivery 
vehicle by providing PEI with its endosomolytic properties. Due to its high charge density, 
PEI seems to compact DNA more efficiently than cationic lipids. The high charge density, 
however, also seems to be involved in the cytotoxicity of PEI. Both the molar mass and the 
backbone structure of PEI (being linear or branched) influence the transfection efficiency and 
cytotoxicity of the PEI/DNA polyplexes 22;23. Also, the ratio of PEI nitrogens to DNA 
phosphates (N/P ratio) at which the polyplexes are prepared influences the condensation of 
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the DNA, the transfection efficiency of the resulting polyplexes and their cell toxicity. 
Conflicting information is available regarding the structural requirements and the molecular 
weight of PEI necessary for efficient gene delivery. Indeed, the transfection efficiencies of 
PEI polymers have been reported to decrease 24 or increase 25 with increasing molecular 
weight. On the contrary, Von Harpe et al. concluded that there was no correlation between 
the physicochemical properties of a wide variety of commercially available PEIs and the 
observed transfection efficiencies 26.   
  
 
Figure 3.  Chemical structure of polyethyleneimine polymers with (A) a linear or (B) a branched backbone.  
 
As for cationic liposomes, adsorption of negatively charged serum proteins can cause 
aggregation and rapid clearance of the polyplexes from the bloodstream. Pegylation of the 
DNA/polycation polyplexes has been used to improve the solubility, reduce cytotoxicity, 
prevent aggregation and improve circulation times in the bloodstream 27. Unfortunately, 
pegylation may lower the transfection efficiency of the polyplexes by preventing the cellular 
uptake or the endosomal escape properties, as discussed below. Besides PEG, PEI can be 
coupled with different ligands such as antibodies, folate and transferrin with the purpose of 
cell targeting.  
 
 
INTRACELLULAR BARRIERS TO OLIGONUCLEOTIDE AND PLASMID 
DNA DELIVERY  
 
Once DNA nanoparticles have reached their target cells, they have to gain access to 
the intracellular environment. Furthermore, they have to deliver the nucleic acids to the 
required compartment of the cell, namely the cytoplasm in the case of ONs and siRNA and 
the nucleus in the case of pDNA. On their delivery route, DNA nanoparticles encounter 
different barriers as they have to be taken up by the cells, escape from the endosomal 
compartment, traffick through the cytoplasm and cross the nuclear membrane. In addition, 
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the nucleic acids should be released at the most appropriate time and location in the cells 
and remain intact in the intracellular environment. Each of these steps will be discussed 
below.  
 
Endocytosis: the Major Uptake Route  
 The cell is the smallest unit of life in our body. It can be seen as a complex 
organization of multiple intracellular structures that constantly receives and interprets signals 
from the environment in order to function and stay alive. The cytosol, in which the nucleus 
and a variety of organelles are embedded, is protected from the outside environment by a 
bilayer lipid plasmamembrane. Due to the complex organization of mammalian cells, it 
comes as no surprise that the income and output of molecules is highly organized. The 
traffick of newly synthesized molecules to their final destination (e.g. the lysosomes, the golgi 
apparatus, the extracellular space,…) is organized by different biosynthetic pathways. 
Likewise, the income of extracellular molecules is organized by endocytic pathways.  
 The plasmamembrane consists of a lipid bilayer which poses the first barrier in 
reaching the intracellular environment. Due to their negative charge, naked DNA molecules 
do not efficiently cross the plasmamembrane. Therefore, they rely on the use of a gene 
delivery system to gain access to the intracellular environment. Most of the time, DNA 
nanoparticles such as lipoplexes and polyplexes enter the cells by endocytosis (Figure 4, 1a 
and 1b). Sometimes, they can enter cells via fusion with the plasmamembrane with direct 
delivery of the DNA nanoparticles (Figure 4, 1c) or naked DNA (Figure 4, 1d) into the 
cytoplasm, thus avoiding the endolysosomal compartment. This fusion can occur due to the 
intrinsic properties of the DNA nanoparticles (e.g. a lipid bilayer around the DNA 
nanoparticles may facilitate their fusion with the plasmamembrane), or by the incorporation of 
cell penetrating peptides, such as TAT, into the DNA nanoparticles 28. The term endocytosis 
encompasses multiple methods of internalization such as clathrin-dependent endocytosis, 
clathrin-independent endocytosis, macropinocytosis and phagocytosis. The endocytic 
pathways control the transport of incoming molecules and determine their fate, such as 
recycling to the plasmamembrane, secretion in the extracellular space or delivery to specific 
compartments in the cytoplasm such as the lysosomes, the endoplasmatic reticulum and the 
golgi apparatus. Endocytosis is essentially the invagination of the plasmamembrane with the 
formation of endosomal vesicles. This invagination occurs at specific domains in the 
plasmamembrane, characterized by a specific lipid and/or protein composition for the 
different endocytic pathways.  
In clathrin-dependent endocytosis, this specific domain is characterized by the 
presence of clathrin and is called a ‘coated pit’ 29. Invagination at these coated pits, which 
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cover some 0.5-2% of the plasmamembrane surface, results in the formation of clathrin-
coated vesicles. These vesicles loose their clathrin coat upon internalization and fuse with 
each other or with pre-existing endosomal compartments to form ‘early endosomes’. Early 
endosomes can either recycle their cargo to the extracellular environment or mature to late 
endosomes, accompanied by a decrease in pH from neutral to pH 5.9-6.0. Late endosomes 
on their turn deliver their cargo to the lysosomes, accompanied by an additional pH drop 
from pH 6.0 to 5.0. The average time to mature from early to late endosomes is reported to 
be 5 minutes, while late endosomes progress to lysosomes in the range of 30 minutes 30. 
Rejman et al. found that particles of < 200 nm are taken up via the clathrin-dependent 
pathway 31. Also, targeting to specific receptors, which are mostly internalized by clathrin-
dependent endocytosis, should enhance uptake via this specific endocytic pathway. 
Examples of ligands that target to specific receptors are transferrin 32, asialoglycoproteins 
(targeting to hepatocytes) 33, epidermal growth factor 34 and folic acid 35 (targeting to cancer 
cells), low density lipoprotein 36 and so on.   
 Clathrin-independent endocytosis can be subdivided into lipid-raft mediated 
endocytosis and caveolae, both characterized by cholesterol and sphingolipid enriched 
domains in the plasmamembrane. These lipid domains are additionally associated with 
caveolin-1 in the case of caveolae. Caveolar vesicles are continuously docking on and fusing 
with at least two endocytic compartments, namely caveosomes and early endosomes. 
Caveosomes differ from early endosomes by their neutral pH and deliver their cargo to 
different intracellular organelles such as the endoplasmatic reticulum or the golgi apparatus. 
It has been suggested that the clathrin-independent pathway leads to more efficient 
transfection by DNA nanoparticles since it limits delivery to the lysosomes. Due to the 
potential fusion with early endosomes, however, cargo taken up by the clathrin-independent 
pathway can switch to the clathrin-dependent pathway, resulting in recycling to the 
extracellular space or eventual delivery to the lysosomes 37-39. It has been suggested that 
larger particles (200 – 500 nm) enter the cells through caveolae/lipid-raft mediated 
endocytosis 31. Particles larger than 500 nm would then preferably enter the cells via 
macropinocytosis, a mechanism of endocytosis in which large droplets of fluid are trapped 
underneath extensions (ruffles) of the cell surface. Phagocytosis is restricted to specialized 
cells, such as macrophages that function to clear large pathogens or cell debris from the 
circulation. 
So far there are only few studies that connect the entry mechanism of lipoplexes 
and/or polyplexes with the observed transfection efficiencies. Zuhorn et al. found that 
lipoplex-mediated transfection occurs through the cholesterol-dependent clathrin-mediated 
pathway of endocytosis, rather than through a simple fusion with the plasmamembrane 40. 
These observations were confirmed by Rejman et al. who found that DOTAP lipoplexes were 
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internalized by cells solely by means of clathrin-mediated endocytosis 41;42. Lipid-based DNA 
nanoparticles will thus be delivered to the lysosomes, unless they are able to escape from 
the endosomal vesicles. In contrast to lipoplexes, PEI polyplexes were found to be 
internalized both by clathrin-mediated endocytosis and by caveolae. However, only the 
caveolae-dependent route resulted in effective transfection 41;42. Von Gersdorff et al., 
however, found that the internalization route resulting in successful gene expression 
depended on both the cell line and the PEI polyplex type used 43. They also found that the 
most successful route for gene expression is not necessarily the most utilized internalization 
route of DNA nanoparticles. Indeed, linear PEI polyplexes were internalized for 70% by 
clathrin-independent endocytosis and for 30% by clathrin-dependent endocytosis, while only 
the latter resulted in gene expression.  
           
Escape from the Endosomes and Release of the Nucleic Acids 
 After internalization by a specific endocytic pathway, DNA nanoparticles are present 
in endosomal vesicles from which they should escape in order to exert a therapeutic effect. 
The mechanisms of endosomal escape differ between lipid-based and polymer-based DNA 
nanoparticles and are discussed below.  
Lipid-Based DNA Nanoparticles  
A possible mechanism for endosomal escape of lipid-based DNA nanoparticles has 
been proposed by Zelphati and Szoka 44-47. According to these authors, lipid contact occurs 
between cationic lipids from the lipoplex and anionic lipids from the inner face of the 
endosomal membrane resulting in flip-flop of anionic lipids from the cytoplasmic face of the 
endosomal membrane. These anionic lipids laterally diffuse into the lipoplex and form a 
charge neutralized ion-pair with the cationic lipids from the lipoplexes, resulting in 
destabilization of the lipoplexes and displacement of the negatively charged nucleic acids 
with their release into the cytoplasm of the cells. Recently, Gordon et al. demonstrated that 
anionic lipids in the endosomal membrane are not a primary prerequisite to trigger nucleic 
acids release 48. On the contrary, neutral helper lipids in the delivery system, such as DOPE, 
appear to play a crucial role in improving the endosomal escape by promoting the transition 
of the lipoplexes from the lamellar phase to the inverted hexagonal phase resulting in the 
destabilization of the endosomal membrane 14;49. Therefore, the presence of DOPE in a 
liposome formulation can be considered as an important trigger for endosomal escape with 
release of the nucleic acids in the cytoplasm of the transfected cells.   
As discussed above, pegylation of the liposomes ‘guides’ lipoplexes in a more 
effective way through the extracellular compartments of the body. Pegylation, however, 
appears to lower the transfection efficiency of lipoplexes at the intracellular level. This 
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decrease in transfection has been attributed to a decreased interaction of pegylated 
lipoplexes with cellular membranes and, subsequently, lower uptake of the pegylated 
lipoplexes by the cells 50. However, other groups showed that the cellular uptake of pegylated 
lipoplexes was unaltered and suggested that pegylation interferes at the step of endosomal 
escape 51;52. As for non-pegylated lipoplexes, pegylated lipoplexes have to escape from the 
endosomal compartment and release their nucleic acids in the cytoplasm of the cells. At this 
stage, however, the PEG-chains prevent close contact between the lipids from the pegylated 
lipoplexes and the endosomal membrane. Also, the incorporation of PEG-lipids stabilizes the 
lamellar phase of the lipoplexes so that DOPE is not able to destabilize the endosomal 
membrane. The nucleic acids thus remain entrapped in the endosomal compartment, 
precluding their delivery to the nucleus.  
Lipid mixing thus seems to be an important parameter to allow for endosomal escape. 
To overcome the inhibitory effect of pegylation, reversible pegylation has been considered by 
several groups. In this approach, the PEG-lipids are removed in the endosomal compartment 
in order to expose the endosomal escape properties of the lipoplexes. To be able to remove 
the PEG-chains on the liposomes’ surface, two strategies are commonly used. One 
approach makes use of PEG-lipids where a pH sensitive group links the PEG to the lipid. 
The PEG-chains are then removed in the endosomal compartment due to acidic-catalyzed 
hydrolysis 53-55. Another approach is the use of exchangeable PEG-lipids such as PEG-
ceramides that simply diffuse out of the lipoplexes as a function of time 56. The rate of PEG-
ceramide removal from the lipoplexes depends on the size of the PEG moiety as well as on 
the acyl chain length, with shorter acyl chains resulting in more rapid deshielding. When the 
amount of PEG-chains at the surface has decreased sufficiently, lipid mixing between the 
cationic liposomes and the endosomal membrane can occur, resulting in endosomal escape 
and release of the nucleic acids in the cytoplasm of the cells. An important aspect of cationic 
lipid-mediated delivery is that the nucleic acids are released in the cytoplasm as such, 
without the additional need to dissociate from their carrier (Figure 4, 3b and 3d). As a result, 
the naked DNA molecules become susceptible to cytoplasmic nucleases as soon as 
endosomal escape has occurred (Figure 4, 6a and 6b).  
Polymer-Based DNA Nanoparticles  
As mentioned above, a wide variety of cationic polymers are under investigation for 
the delivery of nucleic acids. Some polycations have an intrinsic endosomolytic activity, while  
others need the co-addition or covalent coupling of 'helper molecules' to induce the 
endosomal escape 57. Polymers with an intrinsic endosomolytic activity, like polyamidoamine 
dendrimers (PAM), poly(2-dimethylamino)ethylmethacrylate (pDMAEMA) and PEI, mostly 
have a high charge density and a highly branched structure, with the potential to be 
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protonated. At physiological pH, not all of the protonatable units of such polymers are 
protonated. Upon acidification of the endosomal compartment, however, the polymers 
become extensively protonated, inducing their endosomolytic activity. In general, these 
polymers are believed to escape from the endosomes via the proton sponge mechanism 22;58. 
The buffering capacity of the polymers causes protons to be pumped in the endosomes, 
accompanied with an influx of Cl- ions. This builds up the osmotic pressure with the 
accumulation of water in the endosomes. Also, because of repulsion between the protonated 
amine groups, swelling of the polymer can occur. This swelling of the polymer in combination 
with the osmotic swelling eventually causes the endosomes to rupture, with release of the 
polyplexes in the cytosol of the cells as such (Figure 4, 3a and 3c). Clearly, this is in contrast 
to lipoplexes where the nucleic acids are believed to be released at the step of endosomal 
escape. In theory, all polyplexes based on polymers containing basic groups with buffering 
capacity between pH 7 and 5 (in other words with a pKa at or below physiological pH) should 
be able to escape from the endosomes via the proton sponge mechanism. However, Funhoff 
et al. demonstrated that endosomal escape is not always enhanced by polymers buffering at 
low pH 59. Also, the proton sponge theory has recently been doubted by Godbey et al. who 
found that lysosomes were not buffered during transfection with polyplexes formed with 
PEI 60. Forrest et al. also found that acidification of endosomes still occurred when 
transfection experiments with PEI polyplexes were conducted. They concluded, however, 
that the proton sponge theory is still valid, but that acidification is a part of this process 61. On 
the other hand, Sonawane et al. clearly demonstrated the enhanced Cl- accumulation and 
swelling of the endosomes with the strongly buffering PEI and PAM, but not with the non-
buffering poly-L-lysine (PLL) 62.  
Cationic polymers without intrinsic endosomal escape properties, such as PLL, are 
devoid of a hydrophobic domain and cannot fuse and/or destabilize the endosomal 
membrane. Therefore, they require the co-addition or covalent coupling of fusogenic or 
endosome-disruptive molecules to induce their endosomal escape. These endosomotropic 
agents, which can be synthetic or virus-derived, mostly depend on the lowering of the 
endosomal pH for their activity, exposing more hydrophobic regions for interaction with the 
lipid bilayers from the endosomal membrane. Molecules with endosomal escape properties 
include polyethylacrylic acid and polypropylacrylic acid as well as virus-derived fusogenic 
peptides such as hemagglutinin HA-2 from the influenza virus 57;63.  
As for lipoplexes, shielding of the polyplexes with PEG-chains is advantageous on the 
extracellular level, but can lower the endosomal escape. Therefore, the use of removable 
PEG-chains is also recommended in the case of pegylated polyplexes 64. Acid-triggered 
deshielding of polyplexes can be achieved via cleavage of hydrozone-linked PEG or acetal-
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linked PEG 65. Other chemical linkages that may possess pH-dependent hydrolysis include 
vinyl ethers and orthoesters.      
Depending on the endosomal escape mechanism, the nucleic acids reach the cytosol 
in ‘naked’ form (Figure 4, 3b and 3d) or while still encapsulated in a nanoparticle (Figure 4, 
3a and 3c). In the latter case, the protection of the DNA against enzymatic degradation is 
expected to be maintained in the cytoplasm. On the other hand, most likely, an additional 
step of dissociation of the DNA from its carrier is needed to be able to establish a therapeutic 
effect (Figure 4, 4a and 4b). It has been suggested that PEI/DNA complexes can enter the 
nucleus as an associated complex 66. Also, the dissociation of pDNA from PEI appears 
unnecessary to establish a therapeutic effect 67;68. Itaka et al., however, found that linear PEI, 
which released its pDNA more easily, showed a higher transfection efficiency than branched 
PEI that formed more stable complexes 69. Also Bertschinger et al. demonstrated that 
branched PEIs have higher affinity for DNA than linear PEIs 70. For PLL/DNA polyplexes, 
again low-molecular-weight PLL polymers that released DNA more easily yielded better 
transfection efficiencies 71. These examples demonstrate that vector unpacking is a potential 
barrier for polyplex-mediated nucleic acid delivery.  
 
 
 
Figure 4.  Possible intracellular pathways and barriers as encountered by DNA nanoparticles. (1) Cellular entry, 
(2) intracellular transport, (3) endosomal escape of DNA nanoparticles or naked nucleic acids, (4) release of 
nucleic acids from the DNA nanoparticles, (5) nuclear entry of DNA nanoparticles or naked nucleic acids, (6) 
intracellular degradation of naked nucleic acids and (7, 8) release and degradation of the nucleic acids in the 
endosomal compartment. 
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Traveling Through the Cytosol 
The Intracellular Transport Machinery 
The cytoplasm is a viscous compartment containing a scaffold of filaments termed the 
cytoskeleton. The filaments divide into three types: actin filaments (7 nm), microtubules (25 
nm) and intermediate filaments (12 nm). These filaments are dynamic and can assemble and 
disassemble according to molecular cues. It appears that the composition of the cytoskeleton 
makes free diffusion of macromolecules limited 72;73. Therefore, most likely, DNA 
nanoparticles have to make use of the efficient intracellular transport mechanisms to reach 
their target site. The transport system in cells is composed of two main components, namely 
the actin filaments and the microtubules 74.   
Actin filaments are build up from actin monomers that have polymerized after binding 
ATP. Actin monomers bind to the plus, barbed end of the growing filaments and dissociate 
from the minus, pointed end. Additional crosslinking and branching of actin filaments allows 
cells to form specialized structures such as microvilli, stress fibers, ruffles, cortical actin, 
lamellipodia and filopodia. Underlying the plasmamembrane we find the cortical actin, a 
dense layer of branched actin filaments, which can serve as a barrier for incoming viral and 
non-viral particles. For trafficking, cargo can travel along the actin filaments using the myosin 
family of motor proteins, which generally move towards the plus end of the actin filaments 
while hydrolizing ATP 75. Alternatively, cargo can attach to the growing end of a polymerizing 
actin filament, which generates directional propulsion. In general, actin filaments are more 
involved in short, non-directed movement.  
Microtubules are assembled of α- and β-tubulin dimers that organize into hollow, 
cylindrical filaments while hydrolyzing GTP. The plus ends of microtubules are pointed 
towards the plasmamembrane, while the minus ends are anchored to the microtubule 
organizing center adjacent to the nucleus. Microtubules play an important role in cell division 
and the intracellular trafficking of organelles and other cargo, using the dynein and kinesin 
families of motor proteins for movement. Dyneins move cargo towards the minus end of the 
microtubules (e.g. towards the nucleus), while kinesins move cargo towards the plus end of 
the microtubules (e.g. towards the plasmamembrane) 76;77. Motors that move towards both 
minus- and plus-ends of microtubules have not been identified in nature. In contrast to actin 
filaments, microtubules are associated with long, directed movement in cells.  
Intracellular Transport of DNA Nanoparticles 
Microtubules and the kinesin and dynein motor proteins are responsible for the 
trafficking of endosomal vesicles 76. Therefore, incoming nanoparticles can traffick the 
cytoplasm while still present in the endosomal vesicles (Figure 4, 2a). The direction in which 
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the ‘endosomal nanoparticles’ move depends on which motor proteins are working on the 
endosomes, while the distance of cytoplasmic traveling depends on the time during which 
the motor proteins remain attached to the endosomal vesicles. Endosomes can also move 
bidirectionally, switching between the kinesin and dynein motor proteins on a time scale of 
once a minute 76. Of course, the distance traveled is also dependent on the time of 
endosomal escape, making it more likely to reach the nucleus when the nanoparticles do not 
escape from the endosomes too soon after entry. On the other hand, since endosomal 
vesicles are trafficked to the lysosomes, endosomal escape of the cargo at the appropriate 
time (e.g. traveled to the perinuclear region but not yet fused with lysosomes), remains 
important for cargo that is not resistant to the destructive lysosomal environment.  
Apart from in endosomal vesicles, DNA nanoparticles can diffuse to the perinuclear 
region as such (Figure 4, 2b). Passive diffusion through the cytoplasm, which is crowded with 
cell organelles and the actin and microtubules network, is expected to be limited. Directed 
transport of DNA nanoparticles by hijacking the dynein motors could be an interesting 
strategy to traffic from the cell periphery to the cell nucleus 33. Dynein has a head group, 
which binds the microtubules and a tale for binding of cargo. Which parameters determine 
recognition of cargo, such as DNA nanoparticles, by dynein remain unclear. Wang et al. 
demonstrated that coupling of cytoplasmic dynein to anionic latex beads stimulated their 
microtubules-assisted transport to the nucleus, demonstrating that dynein is indeed an 
interesting target for directed transport of DNA nanoparticles 78.  
Recently, real-time multiple particle tracking using video microscopy has gained 
interest to elucidate the intracellular transport of non-viral gene delivery systems 79. 
Bausinger et al. found that PEI/DNA polyplexes exhibit three different kinds of intracellular 
transport: ad random diffusion, active diffusion using the actin cytoskeleton and, most 
importantly, active diffusion to the cell nucleus within the endosomal vesicles using the 
microtubules 80. Also, Suh et al. observed that PEI/DNA polyplexes achieved rapid 
perinuclear accumulation due to their active transport along the microtubules 81. In the 
perinuclear region, however, most of the particles were immobile, with only limited access to 
the nuclear interior.    
Intracellular Transport of Naked Nucleic Acids 
Free DNA that is present in the cytoplasm can either passively diffuse or be actively 
transported to the nucleus (Figure 4, 2c). Lukacs et al. found that the diffusion of small 
nucleic acid fragments (<250 bp) in the cytoplasm was only modestly slowed down when 
compared with that in saline but was greatly reduced when larger DNA fragments such as 
pDNA were used 73. Later on Dauty et al. found that the actin cytoskeleton, which has a 
mesh size of about 150 nm, was the principal determinant of this size-dependent DNA 
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mobility in the cytoplasm 72. Small nucleic acid fragments like oligonucleotides and siRNA 
have no difficulties in reaching and entering the nucleus 82-84. Free plasmids, however, show 
only limited diffusion from the injection site. It has recently been shown that, apart from 
passive diffusion, free pDNA can utilize the microtubules network to traffick to the nucleus, 
probably using the dynein motor proteins 85. Also, molecules bearing nuclear localization 
signals (NLSs) arrive at the nuclear membrane by active transport along the microtubules, 
evoked by NLS recognition of the dynein motor proteins 86. This demonstrates that NLSs 
have not only an important function in nuclear import, but can also help to concentrate the 
NLS-bearing cargo at the perinuclear region before nuclear import takes place.   
  
Breaking Through the Nuclear Membrane 
 The nucleus is separated from the cytoplasm by a lipid bilayer membrane. The outer 
membrane is continuous with the endoplasmatic reticulum, while the inner membrane lies 
within the nucleus. On several locations throughout the nuclear envelope, the outer and inner 
membrane fuse, forming channels that connect the cytoplasm and the nucleoplasm. These 
channels are called the nuclear pore complexes (NPCs) and play an important role in 
transport into and out of the cell nucleus. The NPCs contain an aqueous channel of about 
9 nm that allows passive diffusion of small molecules up to 40 kDa. For larger molecules, an 
energy and signal-dependent mechanism is required, enlarging the NPCs to about 40 nm 87. 
This active transport is mediated by nuclear localization signals (NLSs) and specific carrier 
molecules such as members from the importine-β family. Molecules destined for nuclear 
import either bear their own NLSs or are recognized by endogenous NLSs. NLS containing 
cargo binds in the cytoplasm to the importine-α subunit of an importine-α/β dimer. 
Alternatively, the NLS containing cargo can directly bind to importine-β, without the need for 
the importine-α adaptor molecule. Then, the construct docks via the importine-β subunit to 
the cytoplasmic face of the NPCs, followed by translocation through the NPCs into the 
nucleus. Binding of the nuclear RanGTP to the importine-β subunit releases the 
importine-α/NLS-cargo in the nuclear environment, where the NLS-cargo is released from 
the importine-α subunit. The importine-α and -β subunits are then recycled back to the 
cytoplasm to mediate a new round of nuclear import 88-90.    
 For small nucleic acids like ONs, the nuclear envelope poses no barrier. Upon 
microinjection in the cytoplasm, free ONs can indeed rapidly accumulate in the nuclear 
environment 82;83. When delivered by DNA nanoparticles, most likely dissociation of the ONs 
from the carrier is needed before nuclear entry can occur. In the case of cationic lipids, as 
discussed above, this dissociation occurs at the step of endosomal escape 91;92. For cationic 
polymers, an additional dissociation step in the cytoplasm will be required. It has indeed 
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been shown that PEI improves the antisense activity of a phosphodiester but not of a 
phosphothioate ON, because the latter was not able to dissociate from the PEI polymers due 
to the stronger binding 93.  
 Several studies have pointed out that the nuclear membrane is an important barrier 
for larger DNA fragments such as pDNA 94-96. pDNA can reach the nuclear envelope in a free 
form or while being complexed to the DNA nanoparticles. DNA nanoparticles that are small 
enough could gain access to the nuclear environment via the NPCs, postponing the need for 
dissociation of the nucleic acids from the nanoparticles (Figure 4, 5a). In all other cases, an 
additional dissociation step is required before nuclear accumulation of the nucleic acids can 
take place. Microinjection experiments have demonstrated that only 0.1% of the cytoplasmic 
plasmids are able to reach the nuclear interior in non-dividing cells 97. Nuclear accumulation 
of pDNA is, however, greatly enhanced during cell division when the nuclear envelope is 
temporarily broken down 98;99. In non-dividing cells, pDNA needs a NLS to gain access to the 
nuclear interior via the NPCs 100. Therefore, coupling of NLSs to pDNA has been an 
attractive, although not so successful, strategy to increase nuclear transport 101. NLS 
peptides can also be coupled to the DNA nanoparticles instead of to the pDNA. In this case, 
however, the benefit from the NLS is lost when release of the nucleic acids from the DNA 
nanoparticles occurs. Apart from the need for a NLS, DNA size also plays an important role 
in nuclear delivery, making it easier for smaller DNA fragments 102;103. Indeed, DNA with a 
size up to 1 kb can enter the nucleus rather efficiently after coupling of a NLS peptide 104, 
while for larger DNA fragments coupling of NLSs has not always been successful 105.  
 
Surviving the Intracellular Environment 
Degradation of therapeutic DNA is believed to be one of the factors limiting gene and 
oligonucleotide therapy, since the destruction of incoming genes translates into a loss of 
gene expression. Glasspool-Malone et al. demonstrated that the co-administration of the 
nuclease inhibitor aurintricarboxylic acid greatly enhanced the transfection efficiency of 
naked pDNA administered to macaque and murine test animals 106. Also, Ross et al. reported 
an enhanced gene transfection in cells transfected in the presence of the acidic nuclease 
inhibitor DMI-2 107. Degradation of nucleic acids can occur in the cytoplasm or in the 
endosomal compartment (Figure 4, 6 and 8). Lechardeur et al. estimated the apparent half-
life of double-stranded DNA in the cytosol of HeLa cells between 50-90 minutes while Pollard 
et al. showed that the delivery of pDNA in COS-7 and A549 cells was prevented by Ca2+-
sensitive nucleases 108;109. Clearly, when using DNA nanoparticles to deliver pDNA, the time 
and place of release of the nucleic acids will play an important role in generating a 
therapeutic outcome. Ideally, the delivery system should release the pDNA close to the 
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nuclear membrane. Since the translocation of the pDNA to the cell nucleus is greatly 
enhanced upon cell division, the time between release of the pDNA and cell division should 
be as short as possible to avoid excessive degradation of the pDNA in the waiting period 
before cell division occurs. Therefore, delivery systems where the release of pDNA is 
triggered by cell division could greatly enhance the transfection efficiency. Another approach 
could be to develop delivery systems that become entrapped in the cell nucleus during cell 
division and release their pDNA directly in the cell nucleus afterwards (Figure 4, 4c).  
Also ONs are exposed to intracellular degradation. In 1991, Leonetti et al. 
microinjected fluorescently labeled antisense ONs in the cytoplasm of cells and found that 
the ONs accumulated in the nucleus within the first minutes after injection 82. The 
fluorescence signal could be detected for over 20 hours for a PS-ON, whereas it  
disappeared within 3 hours for a PO-ON, which was attributed to its degradation. The first 
intracellular study focusing on the degradation of ONs was performed by Uchiyama et al. 
using Fluorescence Resonance Energy Transfer (FRET) 110. They found that a PO-ON was 
degraded within 60 minutes, whereas a PS-ON remained intact. Both for antisense ONs and 
pDNA delivery, the use of suitable delivery vehicles that protect the nucleic acids against 
enzymatic degradation could enhance the therapeutic efficiency. In order to develop such 
delivery vehicles, it is important to gain knowledge on the time and place of degradation of 
the nucleic acids in living cells. Studies focusing on this intracellular degradation in ‘real-time’ 
are scarce, mainly because of the limited amount of available methods that allow 
characterization of this critical step in living cells. In this thesis, we aimed to elucidate the role 
of the intracellular degradation of the nucleic acids in limiting their therapeutic effect. 
Therefore, we evaluated the use of an advanced light microscopy technique, namely 
Fluorescence Correlation Spectroscopy (FCS). The basic principles of FCS are briefly 
discussed below.   
    
           
THEORETICAL ASPECTS OF FLUORESCENCE CORRELATION 
SPECTROSCOPY 
 
Experimental Setup 
Fluorescence Correlation Spectroscopy (FCS), which is a light microscopy based 
technique, was introduced in the early 1970s as a non invasive method to study interactions 
on the single molecule level 111-113. The basic concept of FCS is to keep the number of 
fluorescently labeled molecules low enough, so that each of them contributes substantially to 
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the measured fluorescence signal. By using a small focal volume, only a few fluorescent 
molecules are detected at any time. In these circumstances, diffusion of fluorescent 
molecules in and out of the focal volume leads to fluorescence fluctuations that give 
information on respectively the average number of fluorescent molecules present in the focal 
volume and their diffusion coefficient. In single-color FCS, the fluorescence fluctuations of 
only one type of fluorophore are monitored, while in dual-color FCS the fluorescence 
fluctuations of two spectrally different fluorophores are detected simultaneously with separate 
detectors.  
During the 90s, the size of the focal volume was further reduced to less than 1 
femtoliter by combining FCS with confocal detection. Figure 5 shows a schematic 
representation of a typical FCS instrument. The incoming laser light is reflected by a triple 
chroic mirror and is focused to a small diffraction limited spot in the sample by a high 
numerical aperture objective lens. Emission light coming from the sample passes the triple 
chroic mirror and is split by a subsequent dichroic mirror into a green and a red component 
that is detected by respectively the ‘green’ and ‘red’ detector of the FCS instrument. A 
pinhole in front of the detectors blocks all light coming from outside the focal region. By 
combining the focused laser beam and the confocal pinhole, the fluorescence coming from 
only a small volume will be detected, which is usually referred to as the ‘confocal detection 
volume’. The use of ultrasensitive avalanche photodiode detectors allow detecting the 
fluorescence of single molecules. Single molecules diffusing into and out of the confocal 
detection volume induce fluorescence fluctuations (Figure 5B). The duration of the 
fluctuations is determined by the degree of mobility of the diffusing species and the size of 
the confocal detection volume. From the fluorescence fluctuations, an auto- and/or cross-
correlation curve (see following sections) can be derived (Figure 5C). Both the average 
number of molecules in the focal volume as well as their diffusion characteristics can then be 
calculated by fitting of an appropriate model to the experimental auto- and/or cross-
correlation curves. 
Nowadays, FCS instruments are mostly available as add-on modules to confocal 
laser scanning microscopes (CLSMs). A CLSM allows high-resolution imaging of the 
fluorescent sample and accurate positioning in 3-D of the FCS focal volume. After selection 
of the point of interest, the laser beam of the CLSM is parked at that location and the 
fluorescence fluctuations are recorded for a certain period of time. The powerful combination 
of both instruments makes it possible to study molecule dynamics in small regions of living 
cells. 
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Figure 5.  (A) Schematic setup of the FCS instrument. The excitation light from the laser is reflected by a triple 
chroic mirror (TM) into the objective lens of the microscope. The light emitted by the fluorescent molecules in the 
excitation volume passes through the objective lens and the triple chroic mirror, to be split by the subsequent 
dichroic mirror (DM) into a red and a green component. The intensity of the emitted red and green light is 
measured by respectively the red and green detector. A pinhole (P) in front of the detector blocks the out-of-focus 
fluorescence. (B) Diffusion of molecules in and out of the confocal volume causes fluorescence intensity 
fluctuations. (C) From these fluorescence intensity fluctuations an auto-correlation curve can be derived from 
which the diffusion time τt (i.e. the time to pass through the confocal volume) and the amount N of the fluorescent 
molecules can be calculated. 
 
Auto-correlation Analysis 
FCS basically monitors fluorescence intensity fluctuations caused by the diffusion of 
fluorescently labeled molecules through the detection volume of a CLSM (Figure 5B). The 
diffusion speed of the fluorescent molecules directly determines the average residence time and 
the frequency of leaving and reentering the focal volume. This is reflected in the frequency and 
duration of single fluctuations in the fluorescence intensity measurements: fast diffusion results 
in a high frequency of short lasting fluctuations and vice versa. To be able to reliably calculate 
the diffusion coefficient from the fluorescence fluctuations, it is necessary to analyze a large 
number of fluctuations by calculating a fluorescence fluctuation auto-correlation function. 
Auto-correlation analysis is performed by multiplying the fluorescence intensity fluctuations 
with themselves at different delay times τ, and averaging this product in a statistical manner 
over a large number of fluctuation events: 
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where ( ) ( ) ( )tFtFtF −=δ  denotes the fluorescence intensity fluctuations. The average is 
calculated over the different time points t available in the experimental fluctuation profile. The 
resulting auto-correlation curve G(τ) then decays from a large value at τ = 0 to zero for large 
decay times τ (Figure 5C). The average residence time of the fluorescent molecules in the 
confocal detection volume can be determined as the time τ1/2 at which the amplitude of the 
auto-correlation curve has decayed to 50% of its original value. In other words, the auto-
correlation curve generated from slowly diffusing molecules will decay more slowly when 
compared to rapidly diffusing molecules. In addition, the amplitude of the auto-correlation 
curve is inversely proportional to the number of fluorescent molecules that reside on average 
in the confocal detection volume.   
In order to more accurately determine the number of molecules (N) in the confocal 
volume and their characteristic diffusion time (τt), the auto-correlation curve can be fitted with 
a single-species (eq. 1) or dual-species (eq. 2) model:  
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where 2ω1 and 2ω2 represent the diameter and the height of the detection volume, 
respectively. T represents the percentage of molecules in triplet state and τT represents the 
triplet relaxation time. For the dual-species model (eq. 2), there are N*y molecules with 
diffusion time τt1 and N*(1-y) molecules with diffusion timeτt2. The diffusion coefficient D can 
be calculated from the characteristic diffusion time according to equation 3: 
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Apart from a single-species or dual-species fit, the auto-correlation curve G(τ) can be 
fitted to other models such as a triple-species fit or anomalous diffusion. These models were, 
however, not used in the FCS experiments and will therefore not be discussed in this thesis. 
For a detailed review on FCS theory, we refer the interested reader elsewhere 114-117. 
A common application of auto-correlation analysis is to study the interaction of 
fluorescently labeled molecules with non-labeled substrates, based upon a change in the 
diffusion characteristics of the fluorescently labeled molecules upon binding to their reaction 
partner. Since, generally, there will be two diffusing subpopulations (a bound and unbound 
fraction), this application requires the use of the dual-species model (Eq. 2). It should be 
noted that the minimal difference in diffusion coefficients between both subpopulations 
should be at least a factor of two in order to be distinguishable by FCS 118. Assuming globular 
molecules, the diffusion coefficient D is proportional to ( ) 311 M , where M is the molecular 
weight 119. This implies that the molecular weight of the bound and unbound molecules 
should differ by at least a factor of 8 120, to be able to use auto-correlation analysis for 
studying the association and/or dissociation kinetics of fluorescent labeled molecules with 
their reaction partner.  
 
Cross-correlation Analysis 
To overcome the above described limitation of auto-correlation analysis for studying 
reaction kinetics between partners of equal size, dual-color cross-correlation spectroscopy 
(FCCS) has been developed 121. In dual-color FCCS, both reaction partners are labeled with 
spectrally different fluorophores (e.g. a green and red fluorophore). When both partners 
interact, a new double-labeled reaction product is formed. The two differently colored 
fluorophores are excited by independent laser lines. The light emitted in the common 
confocal detection volume is split onto two separate detectors. When both types of molecules 
are moving independently, there will be no correlation between the fluctuations of each color. 
However, when they interact and are moving together through the detection volume, (a 
fraction of) the fluctuations will occur synchronized in both detectors. From both the green 
and the red fluorescence fluctuation profiles, an auto-correlation curve can be derived, which 
gives information on the number of green (Ng + Ngr) or red-labeled (Nr + Ngr) molecules and 
their diffusion behavior, with Ng and Nr being the number of single-labeled green or red 
molecules and Ngr being the number of double-labeled green and red molecules. 
Alternatively, cross-correlation of the green and red detector signals gives rise to a cross-
correlation curve from which information on the diffusion behavior (τt) and number (Ngr) of the 
double-labeled molecules can be derived by fitting of the cross-correlation curve with 
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equation 4 121. Let it be noted that the amplitude of the cross-correlation curve is proportional 
to the number of double-labeled molecules Ngr.  
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A limitation of FCCS lies in the assumption that no fluorescence enhancement or 
quenching occurs upon interaction of the two fluorescently labeled molecules. Also, the 
experimental realization of a FCCS setup is more demanding, since the confocal volumes of 
both channels should be of equal size and perfectly overlapping. Calibration and alignment of 
the FCCS system can be done as described by Schwille et al. 121.  
 
FCS to Study the Behavior of Non-Viral Gene Delivery Systems 
Since FCS became a commercially available technique in the late nineties, FCS has 
been used to explore the barriers in the delivery process of nucleic acids 122. Auto-correlation 
analysis was used to examine the molecular movement of ONs and RNA in the nuclei of 
living cells 123;124, the self-assembling process of lipoplexes and polyplexes 125-127, the 
hydrolysis of DNA by several enzymes 128 and the intracellular fate of PEI and PEI/DNA 
complexes 129. Furthermore, cross-correlation analysis has been used to study the 
degradation of ONs in buffer 121;130 and the release of DNA from cationic lipid vesicles in 
buffer 131. In living cells, cross-correlation analysis is complicated due to experimental 
difficulties such as photobleaching, autofluorescence, light absorption and scattering leading 
to a low signal to noise ratio 120;132-134. Consequently, only limited studies can be found which 
applied cross-correlation analysis in the intracellular environment. Bacia et al. studied the 
endocytic pathway of the cholera toxin A and B subunits in live cells using FCCS 135 and 
reviewed the application of FCCS in living cells recently 136.  
Studying the complexation and dissociation behavior of non-viral gene delivery 
systems in living cells by auto- or cross-correlation analysis is a very difficult task. As the 
complexes usually consist of a large number of nucleic acid molecules and a large number of 
carrier molecules, each being fluorescently labeled, the complexes contain many 
fluorophores. Consequently, passage of the complexes through the detection volume of the 
FCS instrument causes very bright intensity peaks in the fluorescence fluctuation profiles that 
complicate classical auto- and cross-correlation analysis. Our group has come up with 
alternative means to examine the complexation and dissociation behavior of nucleic acid 
containing complexes by applying a statistical method to study the occurrence of such peaks 
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objectively 137;138. In this context, since correlation analysis is not performed anymore, the 
term FCS is usually replaced by FFS (fluorescence fluctuation spectroscopy). Our group has 
applied single-color FFS to study the association and dissociation of fluorescently labeled 
ONs with non-labeled cationic polymers in buffer 139-141 and demonstrated that dual-color 
FCS is a valuable tool to study the association and dissociation of fluorescently labeled ONs 
and fluorescently labeled cationic polymers and liposomes, both in buffer 142;143 and in living 
cells 144;145. 
Apart from FCS, the intracellular processing of nucleic acid containing complexes is 
often visualized by conventional fluorescence (confocal) microscopy. One can use 
fluorescent dyes of different colors simultaneously to differently stain the nucleic acids, their 
carriers, cellular compartments and so on. The intracellular behavior can then be evaluated 
by the absence or presence of co-localization of the different fluorescent dyes. The accuracy 
of co-localization studies is, however, limited by the resolution of the microscope setup, 
which is about ~170 nm. In some cases, this fundamental limit can be overcome by using 
fluorescence resonance energy transfer (FRET) 146. FRET can occur between two 
fluorescent molecules, termed a donor and acceptor, that are in very close proximity 
(typically < 10 nm) of each other. The acceptor fluorophore must have an excitation spectrum 
that is (partly) overlapping with the emission spectrum of the donor fluorophore. When the 
donor molecule is excited, it can transfer a part of its energy non-radiatively to the acceptor 
molecule 147. This leads to quenching of the donor fluorescence and, if the acceptor is a 
fluorophore, the emission of acceptor fluorescence. Since the FRET efficiency is inversely 
proportional to the 6th power of the intermolecular distance, it is a very sensitive marker to 
probe molecular interactions in the 1-10 nm range. FRET can be detected with (confocal) 
fluorescence microscopy by measuring the decrease in donor fluorescence and/or the 
increase in acceptor fluorescence 148. In the context of nucleic acid delivery, FRET (confocal) 
microscopy has been used to study the intracellular dissociation of lipoplexes 44 and 
polyplexes 69. In these studies, FRET occurred as long as the nucleic acids were compacted 
in the complexes, while it disappeared when the nucleic acids were released. FRET 
microscopy has also been used to study the hybridization 149 and degradation 110 of ONs. In 
the latter case, the ONs were double-labeled with a donor and an acceptor fluorophore and 
the degradation of the ONs was followed by an increase in donor fluorescence and a 
decrease in acceptor fluorescence. As will be described in the next chapters of this thesis, 
we evaluated the use of FRET and FCS as a sensitive method to study the (intracellular) 
degradation of double-labeled ONs. By following the ratio of acceptor to donor fluorescence 
as a function of time with the sensitive detectors of the FCS instrument, it was possible to 
determine the relative resistance against nucleases both in buffer and in living cells. 
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ABSTRACT 
 
In this chapter, we studied the use of a dual-color Fluorescence Correlation 
Spectroscopy (FCS) instrument to follow the intracellular degradation of single-stranded, 
double-labeled oligonucleotides (ONs). The degradatioan of the ONs was studied by 
following the disappearance of Fluorescence Resonance Energy Transfer (FRET) between 
the rhodamine green and Cy5 fluorophores attached to respectively the 3’ and 5’ end of the 
ONs. The green and red fluorescence intensities upon rhodamine green excitation were 
monitored using the ultrasensitive detectors of the FCS instrument. The ratio of the red to 
green fluorescence (R/G ratio) as obtained from such FRET-FCS measurements gave 
accurate information on the integrity of the ONs, without the need for additional auto- or 
cross-correlation analysis of the registered fluorescence intensity fluctuations. Intracellular 
measurements revealed that most of the 40 mer phosphodiester ONs were degraded before 
they entered the nucleus. For the 20 mer phosphodiester ONs, this degradation occurred 
more slowly, and both intact and degraded ONs entered the nucleus. For the 20 mer 
phosphothioate ONs, no intracellular degradation was observed during the measured time 
period. The sensitive detection of the intracellular fluorescence by the FCS setup will be 
particularly useful in situations where the expected fluorescence is too low to be detected by 
FRET-imaging as may occur after intracellular delivery of ONs by cationic carriers. 
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Chapter 2 
FRET-FCS as a Tool to Evaluate  
the Stability of Oligonucleotides  
after Intracellular Delivery 
 
 
INTRODUCTION 
 
Antisense oligonucleotides (ONs) are being widely investigated to down-regulate 
genes of interest. They have already been proved efficient in treating viral infections such as 
the human immunodeficiency virus type 1 1, the hepatitis B virus 2 and the human 
cytomegalovirus 3. Also, utilization of antisense ONs for the treatment of cancer is believed to 
be possible 4. Antisense drugs act by specifically binding to the target mRNA or DNA, which 
results in inhibition of the target translation or transcription. In spite of this simple action 
mechanism, different barriers still limit the antisense activity. Indeed, before the ONs can 
reach their target site, they first have to cross the cellular membrane, escape from the 
endosomal compartment, leave their pharmaceutical carriers (i.e. the delivery system) and 
hybridize to the target sequence. In all these processes, degradation of the antisense drug is 
highly undesirable. Regrettably, the intracellular fate of antisense ONs remains rather 
unknown, also because of the limited methods that allow characterization of these critical 
steps in living cells.  
An important tool to study interactions between molecules is Fluorescence 
Resonance Energy Transfer (FRET). In FRET, an excited donor fluorophore can lead to the 
emission signal from an acceptor fluorophore because of a distance-dependent energy 
transfer between the donor and the acceptor. Therefore, FRET can be used to monitor 
virtually any process that changes the distance between the donor and acceptor. Uchiyama 
et al. 5 used FRET-imaging to study the degradation of single-stranded ONs, double-labeled 
with a donor and acceptor fluorophore. Upon injection in sea urchin eggs, the decrease of 
the acceptor to donor fluorescence ratio showed that a phosphodiester ON was degraded 
within 60 minutes, whereas the phosphothioate ON remained intact. In FRET-imaging, the 
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amount of FRET is monitored using a conventional fluorescence or confocal microscope, 
followed by image analysis. However, when interacting molecules have to be studied at very 
low (e.g. nanomolar) concentrations, the (intracellular) fluorescence could become too low to 
allow FRET-imaging. Therefore, a more sensitive detection of the fluorescence could expand 
the possibilities of intracellular FRET measurements.  
A promising tool to measure intracellularly the fluorescence of lowly concentrated 
molecules is Fluorescence Correlation Spectroscopy (FCS) 6. Compared to a fluorescence 
microscope, a FCS setup makes use of much more sensitive avalanche photo diode 
detectors which can even register the fluorescence of single molecules. Basically, FCS 
monitors the fluorescence fluctuations as the fluorescent molecules move in and out the 
detection volume (typically some femtoliters) of a microscope. From the fluorescence 
intensity fluctuations information is obtained on the amount of molecules in the detection 
volume and their diffusion coefficient. In dual-color FCS, the fluorescence of two spectrally 
different fluorophores is measured by two (separate) detectors and also the amount of 
double-labeled molecules can be derived. Some studies were reported in which dual-color 
FCS was used to follow the hybridization of single-stranded ONs and the degradation of the 
double-labeled hybridization products 7-10. Our research group applied dual-color FCS to 
investigate the interactions between ONs and their pharmaceutical carriers 11;12. In cells 
however, the fluorescence fluctuation analysis is complicated 13;14 and using dual-color FCS, 
only one intracellular study has been reported so far 15.  
In this chapter we wondered whether the intracellular degradation of lowly 
concentrated ONs could be monitored by FRET using a dual-color FCS setup to measure the 
fluorescence. The degradation of single-stranded, double-labeled (Cy5 and rhodamine 
green) ONs, giving FRET between the two labels, was studied both in buffer, cytosolic cell 
extract and living cells. We found that the green and the red fluorescence intensities as 
registered by the detectors of the dual-color FCS instrument can provide us within seconds 
with information on the integrity of the ONs. Furthermore, these fluorescence intensities 
could be easily determined in living cells, giving us the possibility to follow the intracellular 
fate of ONs, without the need for additional auto- and cross-correlation analysis of the 
intracellular fluorescence intensity fluctuations. 
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MATERIALS AND METHODS 
 
Oligonucleotides  
Fluorescently labeled 20 mer phosphodiester (PO20-ONs), 20 mer phosphothioate 
(PS20-ONs) (5’-CCC-CCA-CCA-CTT-CCC-CTC-TC-3’) and 40 mer phosphodiester 
oligonucleotides (PO40-ONs) (5’-GCC-GTC-TCT-GAC-TGC-TGA-TGA-CTA-CTA-TCG-TAT-
AGT-GCG-G-3’) were purchased from Eurogentec (Seraing, Belgium). All ONs were double-
labeled with a rhodamine green fluorophore at the 3’ end and a Cy5 fluorophore at the 5’ 
end. Also, single-labeled (rhodamine green or Cy5) PO20-ONs were used. The ONs were 
PAGE-purified and the presence of both dyes was controlled by Maldi-Tof Mass 
Spectrometry by the supplier. The concentration of the ONs stock solutions as given by the 
supplier was verified by absorption measurements at 260 nm (1 OD260 = 33 µg ONs). 
Labeling efficiencies were calculated from absorption measurements at 500 nm (~ 
rhodamine green, ε = 54 000 l.mol-1.cm-1) and 647 nm (~ Cy5, ε = 250 000 l.mol-1.cm-1) and 
revealed that over 85% of the ONs bore the two labels. 
 
Fluorescence Emission Scans 
Fluorescence emission scans were taken on an Aminco Bowman Series 2 
Spectrofluorimeter to determine the FRET efficiency of the ONs. The excitation wavelengths 
used for rhodamine green and Cy5 were 488 nm and 647 nm, respectively. The emission 
wavelengths were 532 nm and 671 nm. The ONs were diluted in ‘degradation buffer’ (20 mM 
HEPES, 110 mM potassium acetate and 2 mM magnesium acetate, pH 7.4) to a final 
concentration of 100 nM. As a control sample, a mixture of 100 nM single-labeled 3’ 
rhodamine green and 100 nM single-labeled 5’ Cy5 PO20-ONs was used. Emission spectra 
were recorded from 510 to 750 nm with the excitation wavelength set to 488 nm, before and 
after addition of 1 unit DNase I solution (Pulmozyme®, 1 units/µL, Genentech) to 700 µL ON 
solution. In all experiments the background fluorescence of the degradation buffer used was 
negligible.  
The FRET efficiency of the ONs was determined as the extent of rhodamine green 
fluorescence quenching using eq. 1, with F1 being the fluorescence intensity at 532 nm of the 
double-labeled ONs upon excitation at 488 nm and F2 being the fluorescence intensity at 532 
nm of the control sample (in which no FRET occurs). 
 
( )( ) 100*1 21 FFQ −=   eq. 1 
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Fluorescence Correlation Spectroscopy (FCS) 
Theoretical Concept  
For details about the theoretical concept of FCS, we would like to refer to Chapter 1 
of this thesis and references 6 (single-color FCS) and 10 (dual-color FCS). Briefly, FCS 
makes use of ultrasensitive avalanche photodiode detectors to monitor fluorescence intensity 
fluctuations caused by the diffusion of fluorescently labeled molecules through the excitation 
volume of a microscope. From these fluorescence intensity fluctuations an auto-correlation 
curve can be derived which allows calculating the amount of fluorescent molecules in the  
detection volume and their diffusion coefficient. In dual-color FCS the interaction between 
two molecules labeled with spectrally different fluorophores is monitored (e.g. green and red 
fluorophore). Apart from an auto-correlation curve, a cross-correlation curve can be derived 
which gives information on the amount of double-labeled molecules and their diffusion 
coefficient. While the amplitude of the auto-correlation curve is inversely proportional to the 
amount of fluorescently labeled molecules in the detection volume (regardless of whether 
they are single or double-labeled), the amplitude of the cross-correlation curve is proportional 
to the amount of double-labeled molecules.  
Experimental Setup 
Dual-color FCS experiments were performed on a dual-color FCS setup installed on a 
MRC1024 Bio-Rad confocal laser scanning microscope. An inverted microscope (Eclipse 
TE300D, Nikon, Japan) was used, which was equipped with a water immersion objective 
lens (Plan Apo 60X, NA 1.2, collar rim correction, Nikon, Japan). The 488 nm and 647 nm 
lines of a krypton-argon laser (Biorad, Cheshire, UK) were used and fluorescence intensity 
fluctuations were recorded on a digital ALV 5000/E correlator. The system was calibrated as 
described by Schwille et al. 10 to optimize the overlap of the excitation and detection volumes 
and to determine the size of the detection volume. Briefly, a 20 nM rhodamine green solution 
was excited using 488 nm laser light. The fluorescence emission is mainly detected by the 
green detector but also partially reaches the red detector. Due to this ‘crosstalk’ an auto-
correlation curve can be generated from both the green and the red detector. If the detection 
volumes of the green and the red detector are of the same size, both auto-correlation curves 
should have the same amplitude. If additionally the green and red detection volume overlap, the 
generated cross-correlation curve should also have the same amplitude as the auto-correlation 
curves.  
Auto- and Cross-correlation analysis 
For determination of the diffusion behaviour, 50 µL of ONs solution was placed in a 
glass-bottomed 96 well plate (certified DNase/RNase free, Greiner Bio-one, lot 03170175, 
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Frickenhausen, Germany) and the laser beam (488 nm, 647 nm or a combination of both) 
was focused at 50 µm above the bottom of the wells. The ONs concentrations ranged 
between 5 and 10 nM. Fluorescence intensity fluctuations were recorded for 3 x 30 seconds 
with laser excitation set to 488 nm, 647 nm or both. The recorded auto- and/or cross-
correlation curves G(τ) were analyzed in OriginTM (Microcal software, Northampton, USA) 
using equation 1 or 4 as described in Chapter 1 of this thesis. From the diffusion time τt the 
diffusion coefficient D was calculated using equation 3 (see Chapter 1). 
R/G ratio as Obtained from FRET-FCS Measurements 
In FRET-FCS measurements, the green (rhodamine green) and red (Cy5) 
fluorescence intensities were recorded for 2 seconds with both detectors of the dual-color 
FCS instrument, with laser excitation set to 488 nm. From these fluorescence intensities, the 
ratio of the red to the green fluorescence (R/G ratio) was calculated. No additional auto- or 
cross-correlation analysis were performed.  
For FRET-FCS measurements on degrading ONs, the ONs were diluted to a 
concentration of 0.7 µM in degradation buffer (for DNase I) or an acidic buffer (for DNase II) 
(40 mM acetic acid and 60 mM potassium acetate, pH 4.7). Subsequently, 4 µL of 100x, 
500x or 2000x diluted DNase I or 4 µL DNase II (4.7 units/µL, Sigma) was added. The 
solutions with a total volume of 40 µL were incubated at 37°C. At different time points 2 µL 
was removed and diluted with 198 µL TBE buffer (10.8 g/L Tris base, 5.5 g/ L boric acid and 
0.58 g/L EDTA) to stop the degradation. On these solutions (final concentration of 7 nM), the 
R/G ratio was determined. For the FRET-FCS measurements in cytosolic cell extract, the 
ONs were incubated at 37°C with an equal volume of cell lysate and diluted with TBE to the 
appropriate concentration (between 5 and 10 nM).  
When performing intracellular FRET-FCS, first a confocal image of the microinjected 
cell was taken and the detection volume was positioned in the cytoplasm or the nucleus of 
the cell. Then, the green and red fluorescence intensities were recorded (for 2 seconds) with 
laser excitation set to 488 nm. Laser excitation was kept at a low level (1% of the maximum 
laser power (0.3 mW) at the focal plane) to prevent cell damaging and photobleaching. For 
real-time monitoring of the intracellular degradation, the green and red fluorescence 
intensities were recorded (for 2 seconds) in the nucleus at different time points. 
 
Cell Culture and Microinjection Experiments 
Vero cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) without 
phenol red (Gibco, Merelbeke, Belgium) containing 2 mM glutamine, 10% heat deactivated 
fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C in a humidified atmosphere 
containing 5% CO2. For intracellular FRET-FCS measurements, cells were seeded on petri 
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dishes with in the center a 150 µm thick glass bottomed circle (Part No. PG-1.5-14-F, Glass 
bottom No. 1.5, MatTek Corporation) at 104 cells/cm². The cells were incubated between 24 
and 48 hours before starting the microinjection experiments.   
Microinjection experiments were performed with a Femtojet® microinjector and an 
Injectman® NI 2 micromanipulator (Eppendorf). All injections were performed in the 
cytoplasm of the cells, using 2 µM ONs. Immediately after injection, FRET-FCS 
measurements were carried out as described earlier in the Fluorescence Correlation 
Spectroscopy section. 
 
Preparation of Cytosolic Cell Extract 
Cell extract was derived from Vero cells at 90% confluency following the Clontech 
Cytosolic Extraction Procedure. Briefly, cells were collected after centrifugation and 
suspended in a hypotonic lysis buffer containing protease inhibitors (10 mM HEPES pH 7.9, 
1.5 mM MgCl2 and 10 mM KCl + 1 µM Leupeptine, 0.5 mM Pefabloc SC, 1 mM DTT and 0.5 
mM EGTA). After 15 minutes swelling on ice, cells were centrifuged again and resuspended 
in 2 times the cell pellet volume of lysis buffer + protease inhibitors. This cell suspension was 
drawn into a narrow-gauge syringe and rapidly ejected. Lysis occurred by repeating the 
drawing and ejection procedure 10 times. The disrupted cell suspension was then 
centrifuged for 20 minutes at 11 000 g and the supernatant was stored at –80°C.  
The presence of lysosomal enzymes was determined by assessing the 
hexosaminidase activity. 10 µL of cytosolic extract was incubated overnight with 60 µL 
substrate solution (7.5 mM p-nitrophenyl-N-acetyl-β-D-glucosaminide and 0.1 mM citric acid, 
pH 5) at 37°C. After addition of 90 µL ‘stop solution’ (10 mM EDTA and 100 mM glycine, pH 
10.5) the absorbance was measured at 405 nm. As a control, the cytosolic cell extract was 
heated to 100°C to destroy all enzymatic activity. These tests revealed that the obtained 
cytosolic cell extract contained lysosomal enzymes (data not shown). 
 
 
RESULTS AND DISCUSSION  
 
Oligonucleotide Degradation as Revealed from Fluorescence Emission Scans 
Emission spectra were taken from 510 to 750 nm to determine the FRET efficiency of 
the double-labeled ONs (Figure 1A). All double-labeled ONs displayed FRET as can be seen 
by the decrease in the rhodamine green fluorescence (at 532 nm) and the increase in the 
Cy5 fluorescence (at 671 nm) when compared to the control sample. FRET efficiencies as 
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calculated from the rhodamine green quenching using eq. 1 equaled 84%, 66% and 44% for 
the PO40-ONs, PS20-ONs and PO20-ONs respectively. Clearly, the PO40-ONs give the 
best FRET efficiency. At first sight this may seem contradictory since one would expect the 
FRET efficiency to decrease when the distance between the fluorophores increases. 
However, probably the PO40-ONs are more flexible compared to the PO20-ONs and PS20-
ONs and take a shape that brings the two fluorophores closer together. 
 
 
Figure 1.   Fluorescence emission scans of the double-labeled ONs. The ‘control sample’ is a mixture of 100 nM 
single-labeled rhodamine green PO20-ONs and 100 nM single-labeled Cy5 PO20-ONs. Excitation wavelength 
was set to 488 nm. All ONs concentrations equaled 100 nM. (A) Before addition of DNase I. The FRET efficiency 
was calculated to be 66% (PS20-ONs), 84% (PO40-ONs) and 44% (PO20-ONs). The control showed no FRET 
(indicated by the arrow). (B) After addition of 1 unit DNase I to the ONs solutions. There is a 10-fold increase in 
the PO40-ONs’ rhodamine green emission and a corresponding decrease in the Cy5 emission (indicated by the 
arrows) showing the degradation of the PO40-ONs. The PS20-ONs and PO20-ONs emission scans remain 
unchanged.  
 
Emission scans were taken again after addition of 1 unit DNase I to the ONs solutions 
(Figure 1B). For the PO40-ONs, the rhodamine green emission increased 10-fold together 
with a corresponding decrease in the Cy5 fluorescence, demonstrating the degradation of 
the PO40-ONs. Indeed, when the ON-strand is degraded, the donor and acceptor 
fluorophore can move freely, the close proximity of the fluorophores is lost and FRET no 
longer occurs. Apparently, DNase I does not degrade the PS20-ONs and the PO20-ONs. As 
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for the PS20-ONs, this can be explained by the increased nuclease resistance due to the 
phosphothioate backbone. In the case of the PO20-ONs, however, this cannot be the 
reason. However, it has been reported that the DNase I endonuclease has the highest 
affinity for DNA with mixed-sequence regions 16. Cytidine and guanosine-rich regions or 
consecutive adenosines or thymidines seriously lower the cleavage probabilities. As the 
PO20-ONs contain two cytidine-rich regions, this probably explains the resistance towards 
DNase I.  
 
Oligonucleotide Degradation as Revealed from FRET-FCS Measurements 
We are interested to monitor the stability of ONs in living cells, even at low 
concentrations. As shown above, the elimination of FRET upon degradation of the ONs 
results in an increase in the rhodamine green fluorescence and a decrease in the Cy5 
fluorescence after excitation at 488 nm. Therefore, a major aim of this chapter is to evaluate 
whether the degradation of double-labeled, single-stranded ONs can be observed from the 
donor (green) and acceptor (red) fluorescence intensities as registered by the separate 
detectors of a dual-color FCS instrument.  
The ratio of the red to green fluorescence (R/G ratio) before and after addition of 
different desoxyribonucleases to the ON solutions are summarized in Figure 2. As already 
discussed above, each intact ON showed FRET, which can be seen by the high R/G ratio 
(black bars). From the initial R/G ratios, a FRET efficiency order of PO40-ONs > PS20-ONs > 
PO20-ONs appears, which is in agreement with the FRET efficiency order as determined 
from the fluorescence emission scans. Also in agreement with the results from the 
fluorimetric scans, addition of DNase I leads only to the degradation of the PO40-ONs (gray 
bars), which can be seen by the drop of the R/G ratio due to the disappearance of FRET. 
Upon incubation with DNase II (light gray bars), both the PO40-ONs and PO20-ONs 
degrade. So where the cytidine-rich regions of the PO20-ONs lower the splicing probability of 
the DNase I enzyme, this does not influence the DNase II enzyme which is indeed reported 
to cleave DNA without an apparent sequence specificity 17. After addition of cytosolic cell 
extract (white bars), again the PO40-ONs and PO20-ONs degrade. Probably this again 
results from DNase II or DNase II-like enzymes which are found intracellularly. With all 
desoxyribonucleases the PS20-ONs stay intact, which demonstrates the nuclease resistance 
of ONs with a phosphothioate backbone. The graphs insert in Figure 2 shows the 
degradation of the ONs visualized with PAGE gel electrophoresis. It can be seen that a drop 
in the R/G ratio corresponds to the disappearance of the ONs on gel, demonstrating the 
applicability of the R/G ratio to predict the degradation of the ONs.  
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Figure 2.  Degradation of the ONs in the presence of DNase I, DNase II or cytosolic cell extract. Ratio of the red 
(~ Cy5) to the green (~ rhodamine green) emission as obtained from the fluorescence intensity fluctuations 
registered by the FCS setup. Laser excitation was 488 nm. Measurements were performed in buffer (black bars), 
after addition of 1 unit DNase I (gray bars), 20 units DNase II (light gray bars) or cytosolic cell extract (white bars) 
to 200 µL of the ONs solutions. Values are the mean as obtained from four independent solutions. Graph insert: 
polyacrylamide gel electrophoresis on (A) PO40-ONs, (B) PO20-ONs and (C) PS20-ONs. The wells contain 100 
ng ON (lane 1), 100 ng ON + 1 unit DNase I (lane 2), 100 ng ON + 20 units DNase II (lane 3) or 100 ng ON + 
cytosolic cell extract (lane 4). The incubation times were 1 hour for the DNase I enzyme and cytosolic cell extract 
and 8 hours for the DNase II enzyme. 
 
Oligonucleotide Degradation as Revealed from the Auto- and Cross-correlation 
Analysis of the Fluorescence Fluctuations 
Based on theoretical considerations outlined below one can argue that auto-
correlation analysis can only be used to distinguish between fully intact and fully degraded 
ONs. Assuming D ~ ( ) 311 MG  7, a 8-fold change in molecular weight corresponds to a 2-fold 
change in diffusion coefficient, being the minimal change in mobility which is well-
distinguishable by FCS. With the molecular weight of for example the PO20-ONs being 6924 
g/mol, the molecular weight of the degradation products should be maximally 865 g/mol to 
double the diffusion coefficient. With the average molecular weight per nucleotide being 330 
g/mol, this corresponds to degradation products consisting of only 2 to 3 nucleotides before a 
distinguishable change in diffusion coefficient is obtained. Clearly, this makes auto-
correlation analysis less attractive to study the degradation when compared to the 
disappearance of the FRET signal, which is already achieved from the moment that both 
fluorophores are separated, regardless of the molecular weight of the degradation products 
formed.  
Cross-correlation analysis represents an alternative in reactions where the expected 
changes in diffusion coefficient are minimal. Nevertheless, the amplitude of the cross-
correlation curve is only proportional to the amount of double-labeled ONs if no fluorescence 
enhancement or quenching of the fluorophores occurs upon interaction. However, this was 
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not the case as FRET occurs. Although Kohl et al. 18 demonstrated that FRET efficiencies 
between 30-60% can be tolerated if properly corrected for in the data analysis, cross-
correlation analysis of the fluorescence fluctuations could also only be used to distinguish 
between fully intact or fully degraded ONs.  
 
Table 1.  Diffusion times of the PO20-ONs before and after addition of different desoxyribonucleases. Diffusion 
times τt (ms) were determined from the auto-correlation curves after excitation with respectively 488 nm (τg, 488) 
and 647 nm (τr, 647). When possible, τr, 488, being the diffusion time of the red labeled components upon excitation 
at 488 nm, was also determined. τcc represents the diffusion time determined from the cross-correlation curve. 
The diffusion time of rhodamine green was 0.21 ± 0.02 ms in our FCS setup and corresponds to a diffusion 
coefficient of 2.8 x 10 –10 m²/s. * ND: not determinable. 
 
  
 τg, 488 τr, 488 τr,647 τcc
Buffer 0.52 ± 0.05 0.57 ± 0.07 0.53 ± 0.02 0.56 ± 0.08 
DNase I 0.58 ± 0.08 0.57 ± 0.09 0.53 ± 0.02 0.50 ± 0.10 
DNase II 0.29 ± 0.02 ND* 0.29 ± 0.02 ND*
Cell lysate 0.30 ± 0.02 ND* 0.30 ± 0.02 ND*
 
As an example, the diffusion times for the PO20-ONs are depicted in Table 1. The 
auto- and cross-correlation curves from which these diffusion times were calculated are 
depicted in Figure 3. When the ONs are intact (in buffer and in the presence of DNase I), the 
auto-correlation curves from the green and red detector upon excitation with respectively 488 
nm (~ rhodamine green) and 647 nm (~ Cy5) are of good quality and almost completely 
overlap (Figure 3, green and red line). Also, due to FRET, it is possible to generate a proper 
auto-correlation curve for the Cy5 fluorophores upon excitation at 488 nm (Figure 3, gray 
line). Fitting of these auto-correlation curves with a single-species model is possible, leading 
to the diffusion times τg, 488 (~ rhodamine green), τr, 647 and τr, 488 (~ Cy5), which were all equal 
(Table 1). The diffusion time calculated from the cross-correlation curve (τcc ~ double-labeled 
ONs) equals the diffusion times from the auto-correlation curves, showing that the solutions 
consist of double-labeled ONs. However, calculating the amount of double-labeled ONs from 
the generated cross-correlation curve (Figure 3, blue line) was not possible, as FRET 
disturbed the cross-correlation analysis.  
When the ONs degrade (in the presence of DNase II and cytosolic cell extract), 
single-labeled degradation products are formed and a cross-correlation curve can no longer 
be recorded (Figure 3, graph insert, blue line). Hence, τcc cannot be determined. Also, the 
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auto-correlation curve generated from the red detector upon excitation at 488 nm has 
become very noisy (Figure 3, graph insert, gray line). Therefore, the diffusion time of the 
Cy5-labeled degradation products cannot be determined upon excitation at 488 nm (τr, 488) 
since FRET no longer occurs. Good quality auto-correlation curves can be generated from 
the green and red detector upon excitation at respectively 488 nm and 647 nm (Figure 3, 
graph insert, green and red line). From the calculated diffusion times τg, 488 (~ rhodamine 
green) and τr, 647 (~ Cy5) it can be seen that shorter degradation products were formed, 
which move more rapidly through the excitation volume of the FCS instrument (Table 1). 
 
 
Figure 3.  Auto- and cross-correlation curves of the PO20-ONs. Line 1 (green) is the auto-correlation curve 
obtained from the green detector upon excitation at 488 nm (~ rhodamine green), line 2 (gray) is the auto-
correlation curve obtained from the red detector upon excitation at 488 nm (~ Cy5, excitation due to FRET), line 3  
(red) is the auto-correlation curve obtained from the red detector upon excitation at 647 nm (~ Cy5, ‘direct’ 
excitation) and line 4 (blue) is the cross-correlation curve obtained from the fluorescence intensities registered by 
the green and the red detector upon excitation at 488 and 647 nm. The graph insert represents the auto-
correlation curves after degradation of the PO20-ONs. 
 
In Vitro Time Dependent Degradation of the ONs 
In the following experiments, we wondered whether the ratio of the red to the green 
fluorescence intensities as registered with the FCS setup upon excitation at 488 nm (R/G 
ratio) allows to monitor the time dependent degradation of the ONs. First, the change in the 
R/G ratio was evaluated upon mixing different amounts of intact and degraded PO40-ONs, 
mimicking the transition from fully intact to fully degraded ONs. Figure 4 shows that upon 
mixing a higher percentage of degraded PO40-ONs, the R/G ratio decreases and reaches a 
value of 8% of the initial value when the solution consists of only degraded PO40-ONs. 
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Figure 4.  Relation between the amount of intact ONs and the R/G ratio. Ratio of the red to green fluorescence 
intensities (R/G ratio) as measured by the dual-color FCS module of solutions prepared by mixing different 
amounts of intact and degraded PO40-ONs. The x-axis indicates the percentage of degraded PO40-ONs. Laser 
excitation was set to 488 nm. To normalize the R/G ratio we considered the R/G ratio for the intact PO40-ONs to 
be 1.   
 
Subsequently, the R/G ratios for the PS20-ONs, PO20-ONs and PO40-ONs were 
monitored when bringing them in contact with DNase I, DNase II or cytosolic cell extract 
(Figure 5). For incubation with 0.04 units DNase I (Figure 5A), the R/G ratio decreases 
rapidly for the PO40-ONs (triangle) and degradation is completed within the first 15 minutes. 
When comparing the R/G ratios with those in Figure 4, one can estimate the amount of intact 
and degraded ONs present. Already within 2 minutes, a R/G ratio of 0.35 is revealed, 
corresponding to approximately 50% degraded ONs. Additionally, the PO40-ONs solution 
was incubated with 0.008 units (diamond) and 0.002 units (cross) DNase I. As expected, the 
R/G ratio decreases more slowly when a lower enzyme concentration is used. For 0.008 
units DNase I, 50% degradation is reached after 30 minutes reaction time and for 0.002 units 
DNase I, still 80% of the ONs are intact after 90 minutes incubation. For the PO20-ONs 
(circle) and PS20-ONs (square), the R/G ratio remains within 90% of the initial value, again 
confirming the resistance of these ONs towards degradation by DNase I.  
The R/G ratios after incubation of the ONs with DNase II were followed for 8 hours 
(Figure 5B). Again, the R/G ratio for the PO40-ONs drops within the first 15 minutes and the 
stability of the PS20-ONs is demonstrated. For the PO20-ONs however, although rather 
slow, it is clear that the degradation occurs in the presence of DNase II.   
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Figure 5.  Time dependent degradation of the ONs in the presence of DNase I, DNase II and cytosolic cell 
extract. FRET-FCS measurements were performed with laser excitation set to 488 nm. To normalize the R/G 
ratio we considered the R/G ratio for the intact ONs to be 1. (A) PO20-ONs (circle), PS20-ONs (square) and 
PO40-ONs (triangle) incubated with 0.04 units DNase I and PO40-ONs incubated with 0.008 units (diamond) or 
0.002 units (cross) of DNase I. (B) PO20-ONs (circle), PS20-ONs (square) and PO40-ONs (triangle) incubated 
with 20 units DNase II. (C) PS20-ONs incubated with an equal volume of cytosolic cell extract. (D) PO40-ONs 
incubated with an equal volume of undiluted (down triangle) or 1/10 diluted (up triangle) cytosolic cell extract. 
 
Finally, the ONs were incubated in cytosolic cell extract. For the PS20-ONs, the R/G 
ratio did not decrease significantly during the 15 hours of incubation time (Figure 5C). This 
demonstrates the high resistance of the PS20-ONs towards degradation by cytosolic 
nucleases when compared to its phosphodiester analogue. Indeed, the R/G ratio for the 
PO20-ONs decreases immediately upon addition of cytosolic cell extract (data not shown). 
This is also the case for the PO40-ONs (Figure 5D). For the undiluted cytosolic cell extract 
(down triangle) the R/G ratio decreases very rapidly in the first two minutes of incubation 
while the degradation is slowed down when 1/10 diluted cytosolic cell extract is used (up 
triangle).  
Although not within the scope of this chapter, these results point out that monitoring 
the R/G ratio as a function of time shows potential to study the kinetics of enzymatic 
reactions that result in the splicing (or coupling) of a donor and an acceptor fluorophore on 
the molecules under investigation. 
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Real-time Monitoring of the ON Degradation in Living Cells 
The use of FRET-FCS in living cells was evaluated by injecting intact and degraded 
PO40-ONs into the cytoplasm of Vero cells (Figure 6). Both intact and degraded ONs 
accumulate in the nucleus, a behavior that has been reported previously 19. Due to FRET, the 
Cy5 fluorescence can be detected upon excitation at 488 nm for the intact PO40-ONs, but 
not for the degraded PO40-ONs (Figure 6A-B, picture 3). From FRET-FCS measurements, a 
R/G ratio > 1.5 was determined for the intact PO40-ONs both in the cytoplasm and the 
nucleus (Figure 6A), while for the degraded PO40-ONs the R/G ratios equaled 0.3 and 0.2 
respectively (Figure 6B). This demonstrates that the R/G ratios measured by the dual-color 
FCS setup appear to be a reliable parameter to distinguish intact from degraded ONs, even 
in living cells.  
 
 
Figure 6.  Intracellular applicability of the R/G ratio. R/G ratio measured in the cytoplasm or nucleus of Vero cells 
after microinjection of (A) intact or (B) degraded PO40-ONs in the cytoplasm of the cells. Laser excitation was set 
to 488 nm. The transmission image (1), rhodamine green (donor) fluorescence (2) and Cy5 (acceptor) 
fluorescence (3) are also shown. 
 
Subsequently, the intact ONs were injected in the cytoplasm of Vero cells and at 
different time points the rhodamine green and Cy5 fluorescence intensities were recorded in 
the nucleus after excitation at 488 nm. With these settings, only intact ONs can contribute to 
the measured red fluorescence. In contrast, the measured green fluorescence may come 
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from both intact and degraded ONs. The measured fluorescence intensities and the 
calculated R/G ratios of the injected ONs are summarized in Figure 7.  
 
 
Figure 7.  Time dependent intracellular degradation of the ONs. Fluorescence intensities measured by the green 
(square) and red (circle) detector of the dual-color FCS setup in the nucleus of Vero cells injected in the 
cytoplasm with (A) PS20-ONs, (B) PO20-ONs and (C) PO40-ONs. Laser excitation was set to 488 nm. (D) 
Normalized R/G ratios for the PS20-ONs (square), PO20-ONs (circle) and PO40-ONs (triangle).  
 
For the PS20-ONs, both the green and red fluorescence intensities increase during 
the first 15 minutes after injection, corresponding to the nuclear accumulation of the intact 
PS20-ONs (Figure 7A). Indeed, as long as intact ONs are entering the nucleus, FRET 
causes an equal increase in both the green and the red fluorescence. After this initial 
accumulation, the PS20-ONs seems to redistribute in the cell, as observed from a slow 
decay in both the green and red nuclear fluorescence intensities. This is in agreement with 
previously reported behavior of PS-ONs to continuously shuttle between the cytoplasm and 
the nucleus 20. It can be seen from the R/G ratios (Figure 7D, square) that there was no 
significant degradation of the PS20-ONs during the measured time period since the R/G ratio 
remains around its initial value. 
Also for the PO20-ONs, an increase in the green and red fluorescence intensities can 
be observed in the first 15 minutes (Figure 7B). Again this demonstrates that intact ONs are 
entering the nucleus. However, a decrease in the R/G ratio is observed starting from 10 
minutes after the injection, demonstrating the degradation of the PO20-ONs (Figure 7D, 
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circle). It should be noted that the degradation of the PO20-ONs as measured in living cells 
is much slower when compared to cytosolic cell extract. Since the hexosaminidase test 
revealed that the cytosolic cell extract contained lysosomal enzymes, it is most likely that 
DNase II-like enzymes present in the lysosomal compartment are responsible for this rapid 
degradation. Upon microinjection, the ONs are directly delivered to the cytosol which 
contains DNase I or DNase I-like enzymes but very little DNase II. This could explain why the 
degradation in the cytosol occurs much slower, since the buffer experiments mentioned 
above also showed that not DNase I but mostly DNase II is responsible for the degradation 
of the PO20-ONs.   
The green and red fluorescence intensities of a cell injected with the intact PO40-ONs 
are shown in Figure 7C. Interestingly, only the green fluorescence intensity increases during 
the first 20 minutes after injection. Apparently, the PO40-ONs undergo a very rapid 
cytoplasmic degradation: even within minutes after injection only degraded ONs accumulate 
in the nucleus. Also from the R/G ratios, the rapid degradation of the PO40-ONs is clear 
(Figure 7D, triangle). The R/G ratio indeed drops within the first 15 minutes and shows that 
the majority of the ONs are degraded within the first 15 minutes after injection. These results 
are consistent with the buffer measurements, which also showed that the PO40-ONs are 
very susceptible towards DNase I degradation. Interestingly, the red fluorescence intensity 
remains at its initial value during the first 20 minutes, indicating that the intact PO40-ONs that 
reached the nucleus are not degraded in the nucleus within this time. This observation was 
confirmed by direct microinjection of the PO40-ONs in the nucleus of the cells, where indeed 
no significant degradation of the PO40-ONs was observed (data not shown).  
These measurements show that monitoring the intracellular fluorescence intensities 
by the FCS instrument can be easily used to follow the fate of microinjected ONs. Where the 
fluorescence intensities give information on the amount and distribution of the ONs, the 
calculated R/G ratios can provide us with information on the integrity of the ONs. The short 
measurement times (2 seconds) and low laser excitation prevent photobleaching and cell 
photodamaging effects. Also, with these settings, the autofluorescence of the cells equaled 3 
kHz, being 10-40 fold lower than the fluorescence intensities coming from the ONs. 
Therefore the R/G ratios could be monitored over a long time period without introducing 
artifacts. This in contrast to conventional FCS measurements, where in general the 
fluorophores should generate high counts per molecule, preferentially at low laser excitation 
power. In cells, however, most fluorophores exhibit reduced counts per molecule when 
compared to buffer. Optimization of the intracellular counts per molecule can be achieved by 
using longer illumination times and/or higher laser power, but also increases the risk of 
disturbing photobleaching and cell photodamaging effects 21. Since in the FRET-FCS 
measurements used in this chapter auto- or cross-correlation analysis is not required, the 
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illumination time and laser power are less critical and can be minimized to reduce unwanted 
side effects. 
 
 
CONCLUSIONS AND OUTLOOK  
 
Because of the straightforward design and action mechanism, antisense ONs show 
great potential as therapeutic drugs, although intracellular barriers still limit the antisense 
activity. Many researchers focus on developing delivery systems to protect the ONs, while 
others try to improve the resistance of the antisense ONs towards nucleases by chemical 
modifications of the ON backbone. There are only few studies dealing with the turnover of 
antisense ONs in the cytoplasm and nucleus of cells, partially due to the limited methods 
applicable on living cells.   
In this chapter we evaluated the use of a dual-color FCS setup to study the 
intracellular degradation of single-stranded ONs labeled with rhodamine green at the 3’ end 
and Cy5 at the 5’ end. For the intact ONs, FRET occurred between the two labels: both 
green and red fluorescence was detected upon rhodamine green excitation. Upon 
degradation of the ONs, the rhodamine green fluorescence increased, while the Cy5 
fluorescence decreased. We showed that the ratio of the red to the green fluorescence (R/G 
ratio), as measured by the two detectors of the dual-color FCS setup, provides us within 
seconds with information on the integrity of the ONs. In vitro measurements showed that 
phosphothioate ONs were resistant to degradation with DNase I, DNase II and cytosolic cell 
extract. With regard to ONs with a phosphodiester backbone, DNase II (slowly) and cytosolic 
cell extract (rapidly) degraded both PO20-ONs and PO40-ONs, while the DNase I enzyme 
only degraded the PO40-ONs. The latter could be attributed to the sequence specific 
cleavage behavior of the DNase I enzyme, which prefers the mixed-region PO40-ONs over 
the cytidine-rich PO20-ONs.  
Especially, the potential of the dual-color FCS instrument to follow the intracellular 
degradation of the ONs was demonstrated. Based upon the R/G ratio, the cytoplasmic 
turnover of the PO40-ONs was estimated between 2-10 minutes. For the PS20-ONs, no 
degradation was observed during the 45 minutes measuring time. Interestingly, the 
degradation of the PO20-ONs in the microinjected cells occurred more slowly when 
compared to the degradation in cytosolic cell extract. Since the cytosolic cell extract 
contained lysosomal enzymes, this indicates that the DNase II-like enzymes present in the 
lysosomal compartment are most likely responsible for this rapid degradation. Therefore, 
avoiding the lysosomal compartment will be of great interest when delivering antisense ONs. 
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The role of DNase II in lowering the transfection efficiency of non-viral DNA delivery vectors 
has indeed been reported recently 22. It should be noted that the end-labeling of the ONs may 
interfere with the degradation by intracellular exonucleases. As a consequence, the 
measured degradation time of the double-labeled ONs could be an underestimation of the 
degradation time of their non-labeled analogues.     
Apart from the R/G ratios, the diffusion properties of the intact ONs and their 
degradation products could be determined, as a FCS setup was used to monitor the 
fluorescence intensity fluctuations. However, studying the degradation of the ONs based on 
a change in diffusion coefficient does not appear to be the most straightforward way. 
Especially in living cells an accurate determination of the diffusion coefficient is rather 
difficult. This highly recommends the use of the R/G ratios to follow the ONs degradation in 
living cells.  
    Using the FRET-FCS methodology described in this chapter, we aimed to study 
whether double-labeled ONs which are complexed to cationic liposomes and cationic 
polymers, frequently used to deliver antisense ONs, are adequately protected against 
degradation. Therefore, the double-labeled ONs were complexed to non-pegylated and 
pegylated cationic liposomes and non-pegylated and pegylated polyethyleneimine and the 
protection against enzymatic degradation was followed by the use of FRET-FCS, as 
described in Chapter 3 and Chapter 4, respectively.  
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ABSTRACT 
 
Antisense oligonucleotides (ONs), complexed to carriers such as cationic liposomes, 
inhibit the production of proteins. The biochemical and biophysical phenomena that govern 
the extent of this inhibition are still not fully understood. Major biological barriers limiting a 
pronounced antisense effect are the cellular entry and endosomal escape of the ONs 
containing liposomes, the release of the ONs from the liposomes and the extra- and 
intracellular degradation of the ONs. In this chapter we focus on the latter barrier and 
evaluate, by the FRET-FCS technique described in Chapter 2, to what extent phosphodiester 
ONs (PO-ONs) complexed to DOTAP/DOPE liposomes, are protected against degradation 
by nucleases. Liposomes studied were either with or without a polyethyleneglycol (PEG) 
moiety at the surface. Using non-pegylated liposomes the PO-ONs were initially adequately 
protected when exposed to DNase I. Indeed, in the mechanism for lipoplex formation as 
suggested by others, the ONs become trapped between lipid bilayers and are therefore 
shielded from the environment. However, after a few hours the PO-ONs no longer stayed 
intact. This was explained by a gradual fusion of the lipoplexes in time thereby 
spontaneously releasing PO-ONs. Using pegylated liposomes, a substantial fraction of the 
PO-ONs degraded immediately after exposing the complexes to DNase I. Based on 
experimental evidence we suggest that the presence of the PEG-chains influences lipoplex 
formation so that the ONs are not trapped between lipid bilayers and therefore remain 
accessible to the DNase I enzyme. 
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Chapter 3 
Protection of Oligonucleotides  
Against Nucleases by Pegylated and  
Non-Pegylated Liposomes 
 
 
INTRODUCTION 
 
Antisense oligonucleotides (ONs) are being widely investigated for the down- 
regulation of genes 1. To inhibit protein production, the ONs have to reach the cytoplasm or 
nucleus of the cells where they act by specific binding to the target mRNA or DNA. In spite of 
this simple action mechanism, different barriers still limit the antisense activity. Actually, 
before the ONs can reach their target site, they first have to cross the cellular membrane, 
escape from the endosomal compartment, leave their pharmaceutical carriers (i.e. the 
delivery system) and hybridize to the target sequence 2. 
Rapid degradation of phosphodiester ONs (PO-ONs) is known to be one of the 
factors limiting their success as therapeutics. One approach to improve antisense activity is 
to develop ONs with increased nuclease resistance so that intracellular degradation should 
not be an issue 3. However, modification of the ON backbone often induces undesirable 
features. The first generation of chemically modified ONs, namely phosphothioate ONs (PS-
ONs), are known to frequently exhibit non-specific, non-antisense effects, generally attributed 
to their increased non-specific protein binding when compared to their phosphodiester 
analogues 4. The second and third generation antisense compounds all work to some extent 
but have one or more problems such as solubility, delivery issues, lack of RNase H activation 
or simply the cost of synthesis 5. 
Another approach to improve the antisense activity of ONs is the development of 
suitable delivery systems 2;6. The delivery system, often composed of cationic lipids or 
cationic polymers, is designed to help the ONs to enter the cell and escape from the 
endosomes. Clearly, in cases where degradable PO-ONs are used, the protection of the 
ONs against nucleases, given by their carrier, becomes an important aspect. Ideally, the 
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delivery system should protect the complexed ONs during the different steps of the trafficking 
pathway. In general, cationic carriers are believed to protect the complexed ONs against 
degradation. However, we, among others, have observed that some carriers can establish an 
antisense effect with degradable PO-ONs, while other carriers fail 7;8. The lack of antisense 
activity has been attributed to insufficient ON protection against nucleases with the carriers 
used, although no direct proof of this hypothesis was given. 
There are few studies that relate the biophysical properties of carrier/ON complexes 
to the obtained antisense effect. In an attempt to better understand the intracellular behavior 
of carrier/ON complexes, our laboratory uses Fluorescence Correlation Spectroscopy 
(FCS) 9. We have already used FCS to monitor the complexation behavior 
(association/dissociation) between ONs and cationic polymers or lipids, both in buffer and in 
living cells 10-14. Also, in Chapter 2, we demonstrated that the FCS-setup allows following the 
intracellular degradation of fluorescently double-labeled ONs when Fluorescence Resonance 
Energy Transfer (FRET) occurs between the two fluorophores 15. In this approach, which we 
have termed FRET-FCS, the detectors of the dual-color FCS instrument register the acceptor 
and donor fluorescence upon donor excitation. The ratio of the acceptor to donor 
fluorescence (R/G ratio) gave accurate information on the integrity of the ONs, since the R/G 
ratio decreases when degradation proceeds. 
In this chapter, we aimed to determine the ON protection against nucleases when the 
ONs are complexed to either pegylated or non-pegylated cationic liposomes. Therefore, the 
ONs containing liposomes were dispersed in a DNase I solution and the degradation of the 
ONs was investigated by FRET-FCS. 
 
 
MATERIALS AND METHODS 
 
Materials  
A 40 mer phosphodiester oligonucleotide (PO40-ONs) (5’-GCC-GTC-TCT-GAC-TGC-
TGA-TGA-CTA-CTA-TCG-TAT-AGT-GCG-G-3’), double-labeled with a rhodamine green (λex 
= 488 nm, λem = 532 nm) fluorophore at the 3’ end and a Cy5 (λex = 647 nm, λem = 670 nm) 
fluorophore at the 5’ end was used. The ONs were purchased from Eurogentec (Seraing, 
Belgium) and were PAGE-purified by the supplier. The concentration of the ONs stock 
solutions as given by the supplier was additionally checked by absorption measurements at 
260 nm (1 OD260 = 33 µg ONs/mL). 
The cationic phospholipid DOTAP (N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethyl-
ammoniumchloride), the neutral phospholipid DOPE (dioleoylphosphatidylethanolamine) and 
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the pegylated, neutral phospholipid DSPE-PEG (distearoylphosphatidylethanolamine 
(polyethyleneglycol2000)) were purchased from Avanti® Polar Lipids (Alabaster, AL, USA). 
Sodium dodecylsulfate (SDS) was purchased from Sigma (St Louis, MO, USA). 
Human lung carcinoma cells (A549 cells, ATCC number: CCL-185) (DSMZ, 
Braunschweig, Germany) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
without phenol red (Gibco, Merelbeke, Belgium) containing 2 mM glutamine, 10% heat 
deactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin. Cells were 
prophylactically treated against mycoplasma with Plasmocin (Invivogen, Cayla, France). Any 
remaining contamination by mycoplasma was determined using a mycoplasma PCR 
detection kit (Venorgem, Minerva Biolabs GmbH, Berlin, Germany) and revealed that the 
cells were mycoplasma free. 
 
Preparation of Liposomes 
The non-pegylated liposomes contained DOTAP and DOPE in a 1:1 molar ratio. For 
the pegylated liposomes 5 mol % DSPE-PEG was incorporated. The lipids were dissolved in 
a 1:1 (volume) mixture of chloroform:methanol. Subsequently, the solution of lipids was 
placed in a round-bottomed flask and the solvents were evaporated under vacuum at 30°C. 
The resulting lipid film was further dried under a flow of nitrogen for 30 minutes. The lipid film 
was then resuspended in HEPES buffer (20 mM at pH 7.4) at a final concentration of 5 mM 
DOTAP and stored overnight at 4°C to allow liposome formation. The resulting liposomes 
were extruded at room temperature through a polycarbonate membrane with a pore size of 
0.1 µm, using the Avanti Polar Lipids mini-extruder. The hydrodynamic size and zeta 
potential of the resulting cationic liposomes was routinely checked by respectively dynamic 
light scattering (DLS, Malvern 4700, Malvern, Worcestershire, UK) and surface potential 
measurements (Zetasizer 2000, Malvern, Worcestershire, UK), as previously described 16. 
The hydrodynamic diameter and zeta potential of the non-pegylated liposomes equaled 
respectively 126 ± 7 nm and +45 ± 4 mV. The pegylated liposomes had a similar 
hydrodynamic diameter (128 ± 6 nm) and a lower zeta potential (+18 ± 3 mV) due to the 
presence of the PEG-chains. 
 
Preparation of Liposome/ONs Complexes 
Upon mixing positively charged liposomes with negatively charged ONs, 
spontaneously liposome/ONs complexes (lipoplexes) are formed. The lipoplexes were 
prepared by mixing equal volumes of a liposome dispersion and an ON solution. The 
resulting dispersion was vortexed for 10 seconds and the lipoplexes were allowed to 
equilibrate for 30 minutes at room temperature prior to use. The concentration of the 
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liposomes was dependent on the desired +/- ratio, being the ratio of the number of positive 
charges (originating from the liposomes) to the number of negative charges (originating from 
the ONs). Lipoplexes with +/- ratios of 2.5, 5 and 10 were used. The +/- ratio of the lipoplexes 
was calculated assuming that 1 µg of ONs contains 3.43 nmol negative charges. 
  
Fluorescence Correlation Spectroscopy (FCS) 
Experimental Setup 
Dual-color FCS experiments were performed on a dual-color FCS-setup installed on a 
MRC1024 Bio-Rad confocal laser scanning microscope. An inverted microscope (Eclipse 
TE300, Nikon, Japan) was used, which was equipped with a water immersion objective lens 
(Plan Apo 60X, NA 1.2, collar rim correction, Nikon, Japan). The laser beam was focused at 
about 50 µm above the bottom of the glass-bottom 96-well plate (Grainer Bio-one, 
Frickenhausen, Germany), which contained the samples. The 488 nm and the 647 nm laser 
beams of a krypton-argon laser (Bio-Rad, Cheshire, UK) were used and the fluorescence 
intensity fluctuations were recorded on a digital ALV 5000/E correlator. To verify whether the 
excitation volumes and the detection volumes optimally overlapped, the system was 
calibrated as described by Schwille et al. 17. 
Theoretical Background 
For details on the theoretical background of FCS, we would like to refer to Chapter 1 
of this thesis and Schwille et al. 18 and Hess et al. 19. Briefly, an FCS instrument registers 
fluorescence intensity fluctuations caused by the diffusion of fluorescently labeled molecules 
through the detection volume of a microscope. From these fluorescence intensity fluctuations 
an auto-correlation curve can be derived, which allows calculating the amount of fluorescent 
molecules in the detection volume and their diffusion coefficient. In dual-color FCS, two 
spectrally different fluorophores are used. The (green and red) fluorescence intensity 
fluctuations of the double-labeled (green and red) molecules can then be measured 
simultaneously using the green and red detector of the dual-color FCS instrument. 
Dual-color FCS measurements were done on lipoplexes composed of non-labeled 
cationic liposomes and double-labeled PO40-ONs. The green and red fluorescence 
fluctuations were recorded for 4 intervals of 50 seconds while exciting the lipoplexes at 488 
nm. When possible, auto-correlation analysis was done as described in Chapter 1. The auto-
correlation curves G(τ) were analyzed using a single-species fit (equation 1, see Chapter 1) 
or a dual-species fit (equation 2, see Chapter 1) to calculate the amount of molecules N in 
the detection volume and their diffusion time τt, being the average time the fluorescently 
labeled molecules need to migrate through the detection volume of the FCS instrument. The 
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auto-correlation curves were always analyzed using both equations and the non-sense 
analysis was disregarded based on the appearance of the residual of the fit (or if the dual-
species fit revealed that more than 95% of the species moved with a diffusion coefficient 
similar to the one obtained with eq.1). From the diffusion time τt the diffusion coefficient D 
was calculated using equation 3 (see Chapter 1). 
FCS on Liposomes/ON Complexes 
Figure 1A schematically illustrates on which type of samples FCS measurements 
were done.  
 
 
Figure 1.  A. Schematic representation of the conducted experiments. (A) Complexes were prepared from 
fluorescently double-labeled PO40-ONs with pegylated or non-pegylated liposomes. (B) These ON/liposome 
dispersions were incubated at 37°C with and without 0.2 Units DNase I enzyme. (C) After the appropriate 
incubation times (t1, t2, t3, …) a 50 µL aliquot was removed and the DNase I activity was inhibited by adding 50 
µL TBE buffer. On these dispersions, FCS measurements were performed with laser excitation set to 488 nm. (D) 
Then, PO40-ONs molecules were released from the lipoplexes by adding 2 µL 1% SDS. On those solutions, 
FRET-FCS measurements were performed to determine the R/G ratio, which is a measure for the amount of 
intact PO40-ONs, released from the complexes by SDS. Laser excitation was set to 488 nm. B. Schematic 
representation of the R/G ratio of the double-labeled ONs. In intact ONs, FRET occurs: upon excitation at 488 nm 
of the rhodamine green (donor, D, green) fluorophore, also the Cy5 (acceptor, A, red) fluorophore emits light. 
When degradation proceeds, FRET no longer occurs and only the rhodamine green fluorophore emits light. 
Hence, the R/G ratio decreases when the degradation proceeds. 
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500 µL of non-pegylated liposomes or pegylated liposomes (64, 32 or 16 µM for 
obtaining a +/- ratio of respectively 10, 5 or 2.5) was mixed with 500 µL of double-labeled 
PO40-ONs (160 nM) (Figure 1A, step A). The liposomes and ONs solutions were prepared in 
‘degradation buffer’ (20 mM HEPES, 110 mM potassium acetate and 2 mM magnesium 
acetate, pH 7.4) to ensure the activity of the DNase I enzyme. After 30 minutes, the lipoplex 
dispersion was incubated at 37°C both with and without 0.2 Units DNase I (Pulmozyme®, 1 
units/µL, Genentech) (Figure 1A, step B). At different time intervals, 50 µL of the lipoplex 
dispersion was removed and mixed with 50 µL EDTA-enriched TBE buffer (10.8 g/L tris 
base, 5.5 g/L boric acid and 3.7 g/L EDTA) to stop the DNase I activity. This 100 µL sample 
was transferred to a 96-well plate and FCS measurements were performed (Figure 1A, step 
C). After the FCS measurements, 2 µL 1% SDS solution was added to the well in order to 
induce the release of the ONs from the liposomes (Figure 1A, step D). On this solution, 
FRET-FCS measurements were performed: the rhodamine green and Cy5 fluorescence 
intensities were recorded with the dual-color FCS instrument upon excitation at 488 nm and 
the ratio of the red to green fluorescence (R/G ratio) was calculated. The R/G ratio is, as 
illustrated in Figure 1B, a measure for the amount of intact ONs 15. 
 
 
RESULTS AND DISCUSSION  
 
FCS on ONs Containing LPXs 
Upon mixing negatively charged ONs with positively charged liposomes, lipoplexes 
(LPXs) are spontaneously formed. As outlined below, using fluorescently double-labeled 
ONs, the LPXs could be detected by FCS. 
Figure 2A shows the fluorescence fluctuations measured on a solution of free double-
labeled ONs upon excitation of the rhodamine green fluorophore at 488 nm. FRET clearly 
occurs since the fluorescence of the Cy5 acceptor (red line) is higher than the fluorescence 
of the rhodamine green donor (green line). The calculated R/G ratio for the intact PO40-ONs 
equaled 6 ± 0.3. Figure 2B shows the auto-correlation curve as derived from the red 
fluorescence fluctuations together with the single-species fit (equation 1, see Chapter 1). 
From this auto-correlation curve, the presence of 195 ± 4 molecules with a diffusion 
coefficient of 1.12 ± 0.08 * 10-10 m²/s was calculated (Table 1). From the residuals of the fit 
(Figure 2C) it can be seen that a satisfactory fit was obtained using a single-species fit. A 
slight improvement of the fit was obtained by a dual-species fit (equation 2, see Chapter 1, 
residuals of the fit in Figure 2D), but more than 95% of the species moved with a diffusion 
coefficient similar to the one as calculated by a single-species fit. The latter together with the 
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fact that the solution of free PO40-ONs contains only 1 species, namely the ONs, made us 
disregard the dual-species fit.  
 
 
Figure 2.  (A) Fluorescence intensity fluctuations of free PO40-ONs as measured by the green (green line) and 
red (red line) detector of the FCS instrument. (B) From the red fluorescence fluctuations an auto-correlation curve 
was obtained that was best fitted with a single-species fit. (C) and (D) show the residuals of the fit after fitting the 
auto-correlation data with respectively a single-species fit or a dual-species fit. Laser excitation was set to 488 
nm. 
 
 Figure 3 shows the fluorescence fluctuations as obtained on a solution of double-
labeled ONs complexed with non-pegylated liposomes, upon excitation of the rhodamine 
green fluorophore at 488 nm. When compared to free ONs (Figure 2A), two observations can 
be made.  
 
 
 
Figure 3.  Fluorescence intensity fluctuations of non-pegylated lipoplexes as measured by the green (green line) 
and red (red line) detector of the FCS instrument. Lipoplexes were prepared with (A) a +/- ratio of 2.5, (B) a +/- 
ratio of 5 and (C) a +/- ratio of 10. Laser excitation was set to 488 nm. 
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First, highly intense fluorescence peaks occur in the fluorescence fluctuation profiles. 
When the +/- ratio is increased, the highly intense fluorescence peaks occur more frequently 
and the peak height increases. Second, the background fluorescence (i.e. the average 
fluorescence in between the peaks) decreases when the +/- ratio increases.  
For a +/- ratio of 2.5 and 5, auto-correlation analysis of the background fluorescence 
was feasible. The obtained auto-correlation curves together with the single-species fit are 
depicted in Figure 4A. Comparison of the residuals of the fit in Figure 4C (single-species fit) 
and Figure 4D (dual-species fit) shows that fitting to equation 2 gave only a slight 
improvement. Additionally, more than 95% of the species moved with a diffusion coefficient 
similar to the one obtained with a single-species fit. Also, the diffusion coefficient of the 
additional component was found to be poorly reproducible and thus the dual-species fit was 
disregarded. Fitting to equation 1 revealed a diffusion coefficient of respectively 
1.18 ± 0.15 * 10-10 m²/s and 1.09 ± 0.11 * 10-10 m²/s for LPXs with a +/- ratio of 2.5 and 5 
(Table 1). This is consistent with the diffusion of free PO40-ONs, indicating that the 
background fluorescence comes from free ONs. This can additionally be seen from the 
overlap of the normalized auto-correlation curves obtained on a solution of free ONs (blue 
line), LPXs with a +/- ratio of 2.5 (green line) and LPXs with a +/- ratio of 5 (red line) (Figure 
4B). The amount of free ONs in the detection volume (N in equation 1), as calculated from 
the background fluorescence, equaled 104 ± 3 and 32 ± 1 for a +/- ratio of 2.5 and 5, 
respectively (Table 1). Since the complexes were prepared with the same ON concentration 
as in Figure 2 for free PO40-ONs (where N equaled 195 ± 4), one can conclude that 
respectively about 47% and 84% of the ONs are complexed in the lipoplex dispersions of 
Figure 3A and 3B. For a +/- ratio of 10 (Figure 3C), the presence of successive highly intense 
fluorescence peaks disturbed the auto-correlation curve and auto-correlation analysis was 
impaired (graph insert in Figure 4A). However, from the auto-correlation amplitude of 0.3, the 
number of free ONs was estimated to be 3.5 ± 1, indicating that approximately 98% of the 
ONs are complexed using a +/- ratio of 10. 
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Figure 4.  (A) Auto-correlation curves and single-species fit as obtained from the red fluorescence fluctuations of 
non-pegylated lipoplexes with a +/- ratio of 2.5 (green line), a +/- ratio of 5 (red line) and a +/- ratio of 10 (graph 
insert, black line). As a comparison, the auto-correlation curve as obtained on a solution of free PO40-ONs is also 
depicted (blue line). (B) shows the same auto-correlation curves normalized to 1. (C) and (D) show the residuals 
of the fit after fitting the auto-correlation data of LPXs with a +/- ratio of 2.5 with respectively a single-species fit 
and a dual-species fit. The appearance of the residuals of the fit of LPXs with a +/- ratio of 5 was similar. Laser 
excitation was set to 488 nm.      
 
The obtained fluorescence fluctuation profiles for the LPXs are consistent with the 
diffusion of ‘multimolecular’ complexes bearing numerous ONs, each ON being labeled with 
the rhodamine green and Cy5 fluorophore. Indeed, large, multimolecular complexes give rise 
to highly intense fluorescence bursts each time such a complex passes the detection volume 
of the FCS instrument. In between the diffusion of complexes, free ONs move in and out of 
the detection volume and background fluorescence can be measured, which is clearly 
distinguishable from the fluorescence peaks. After increasing the +/- ratio, more ONs are 
complexed, indicated by a decrease in fluorescence background and an increase in the 
height and frequency of the fluorescence peaks. It should be noted that when SDS, which 
induces the disintegration of the LPXs, is added to the complexes, the background 
fluorescence returns to the level of free PO40-ONs as in Figure 2A. Also, fluorescence peaks 
are no longer detected, consistent with the induced release of the ONs from the LPXs (data 
not shown). After SDS release, the calculated R/G ratio for respectively a +/- ratio of 2.5, 5 
  79
CHAPTER 3 – PROTECTION OF OLIGONUCLEOTIDES AGAINST NUCLEASES BY PEGYLATED AND NON-PEGYLATED LIPOSOMES 
and 10 equaled 5.7 ± 0.2, 5.8 ± 0.3 and 5.8 ± 0.2, in agreement with the R/G ratio as 
determined from Figure 2A. It is important to notice that the R/G ratio can only be accurately 
determined after SDS release of the PO40-ONs from the LPXs. When the ONs are 
complexed, the background fluorescence becomes ill-defined with increasing +/- ratios. As a 
result, the calculated R/G ratios are associated with larger error bars and deviate from the 
actual R/G ratio of intact ONs after SDS release (Table 1). 
 
Table 1.  FCS measurements of free PO40-ONs and PO40-ONs complexed to non-pegylated (LPX) and 
pegylated (PEG-LPX) liposomes with a +/- ratio of 2.5, 5 and 10. All samples were excited at 488 nm. FG and FR 
represent the average background fluorescence intensity as measured by respectively the green and red detector 
of the dual-color FCS instrument. The R/G ratio, e.g. the ratio from the red to green fluorescence, was calculated 
from these fluorescence intensities. From auto-correlation analysis of the red fluorescence intensities, the amount 
of molecules N and their diffusion coefficient D was calculated. *single-species fit of the background fluorescence 
(fluorescence peaks omitted), #dual-species fit of the fluorescence fluctuations (fluorescence peaks included), 
N.D. not determinable. 
 
 FG (kHz) FR (kHz) R/G ratio N D (10-10 m²/s)  
free PO40-ONs* 42.7 ± 0.9 258.0 ± 10 6 ± 0.3 195 ± 4 1.12 ± 0.08  
LPX2.5* 23.7 ± 1.1 131.4 ± 6.0 5.5 ± 0.4 104 ± 3 1.18 ± 0.15  
LPX5* 8.4 ± 0.3 34.7 ± 1.1 4.1 ± 0.2 32 ± 1 1.09 ± 0.11  
LPX10* 5.0 ± 0.8 17.4 ± 5.0 2.9 ± 0.9 3.5 ± 1 N.D.  
PEG-LPX2.5# 38.4 ± 0.4 198.3 ± 2.9 5.2 ± 0.1 104 ± 5 1.06 ± 0.18 
0.022 ± 0.004 
50% 
50% 
PEG-LPX5# 28.6 ± 0.3 144.7 ± 3.1 5.1 ± 0.1 64 ± 2 1.20 ± 0.16 
0.018 ± 0.003 
53% 
47% 
PEG-LPX10# 16.1 ± 1.9 66.2 ± 7.7 4.1 ± 0.7 45 ± 1 1.12 ± 0.18 
0.025 ± 0.004 
64% 
36% 
 
 
FCS on ONs Containing PEG-LPXs 
Next, we measured the fluorescence fluctuations of double-labeled PO40-ONs 
complexed with pegylated liposomes upon excitation at 488 nm (Figure 5). Again two 
observations were made. First, the green and the red detector of the FCS instrument 
detected fluorescence peaks. In contrast to the LPXs (Figure 3), the peaks in the 
fluorescence fluctuation profiles appeared more frequently, were narrower and showed a 
more uniform height. A second observation in Figure 5 was that the average fluorescence 
decreases with an increasing +/- ratio. This again reflects that at a higher +/- ratio more ONs 
become complexed. In contrast to LPXs, it was, however, not possible to accurately 
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determine the background fluorescence since the fluorescence peaks appeared too 
frequently, indicating the continuous presence of PEG-LPXs in the detection volume of the 
FCS instrument. It should be noted that also for PEG-LPXs, the addition of SDS restored the 
red and green fluorescence to the level of free PO40-ONs as in Figure 2A. Also, 
fluorescence peaks were no longer detected, consistent with the induced release of the ONs 
from the PEG-LPXs (data not shown). 
  
 
Figure 5.  Fluorescence intensity fluctuations of pegylated lipoplexes as measured by the green (green line) and 
red (red line) detector of the FCS instrument. Pegylated lipoplexes were prepared with (A) a +/- ratio of 2.5, (B) a 
+/- ratio of 5 and (C) a +/- ratio of 10. Laser excitation was set to 488 nm. 
 
In contrast to LPXs, the more uniform fluorescence peaks originating from the PEG-
LPXs did not disturb the auto-correlation analysis. Therefore, auto-correlation analysis was 
performed on the fluorescence fluctuations with the fluorescence peaks included. The 
obtained auto-correlation curves together with the dual-species fit are depicted in Figure 6A. 
Comparison of the residuals of the fit using equation 1 (Figure 6B) versus equation 2 
(Figure 6C) shows that fitting of the auto-correlation curves was best performed with the 
dual-species fit, indicating the presence of two species with a distinct diffusion coefficient 
(Table 1). For a +/- ratio of 2.5, 104 ± 5 particles were calculated from which 50% (N1 = 
52 ± 2.5) had a diffusion coefficient D1 of 1.06 ± 0.18 * 10-10 m²/s, consistent with diffusion of 
free ONs. The second species (N2 = 52 ± 2.5) diffused more slowly (D2 = 0.022 ± 0.004 * 10-
10 m²/s) reflecting the diffusion of the PEG-LPXs through the detection volume of the FCS 
instrument. This value agreed well with the diffusion coefficient of 0.018 * 10-10 m²/s found for 
DOTAP/ONs vesicles by Merkle et al., using two photon FCS 20. Again, the ON concentration 
used in the preparation of the PEG-LPXs equaled the ON concentration as used in Figure 
2A. When compared to free PO40-ONs (N3 = 195 ± 4), 143 ± 6.5 (N3-N1) ONs were 
complexed in 52 ± 2.5 (N2) complexes, being an average of 2.8 ± 0.2 ONs per complex. 
Using the same approach as for a +/- ratio of 2.5, an average of 5.4 ± 0.2 and 10.3 ± 0.7 
ONs per complex was calculated for the PEG-LPXs with a +/- ratio of 5 and 10, respectively. 
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Figure 6.  (A) Auto-correlation curves and dual-species fit as obtained from the red fluorescence fluctuations of 
pegylated lipoplexes with a +/- ratio of 2.5 (green line), a +/- ratio of 5 (red line) and a +/- ratio of 10 (black line). 
As a comparison, the auto-correlation curve and single-species fit as obtained on a solution of free PO40-ONs is 
also depicted (blue line). (B) and (C) show the residuals of the fit after fitting the auto-correlation data of PEG-
LPXs with a +/- ratio of 2.5 with respectively a single-species fit and a dual-species fit. The appearance of the 
residuals of the fit of PEG-LPXs with a +/- ratio of 5 and 10 was similar. Laser excitation was set to 488 nm. 
 
Once again, the obtained fluorescence fluctuation profiles for the PEG-LPXs are 
consistent with the diffusion of ‘multimolecular’ complexes bearing numerous ONs through 
the detection volume. However, when compared to LPXs (Figure 3), where the free ONs 
(~ background fluorescence) could be well separated from the lipoplexes which occasionally 
diffuse through the detection volume of the FCS instrument (~ dissimilar fluorescence 
peaks), the fluorescence fluctuation profile of PEG-LPXs suggests a more frequent presence 
of PEG-LPXs in the detection volume (~ successive fluorescence peaks) which appear to 
contain an equal amount of ONs (~ uniform peak height).  
The question now raised is how best to explain the difference in fluorescence 
fluctuation profiles of LPXs and PEG-LPXs. It is well known that pegylation of lipoplexes 
prevents their aggregation, whereas non-pegylated lipoplexes can fuse to form large 
aggregates 21. Due to the aggregation of LPXs, large multimolecular complexes are formed, 
bearing various amounts of ONs. The passage of such a complex through the detection 
volume of the FCS instrument results in highly intense fluorescence bursts, as seen from the 
non-uniform broad peaks. Also, the largest aggregates will sediment and will therefore no 
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longer pass through the detection volume of the FCS instrument, which could explain the 
lower amount of fluorescence peaks in Figure 3. For PEG-LPXs, the PEG-chains prevent 
complex aggregation. Consequently, the complexes do not sediment and remain 
homogeneously distributed. This causes complexes to be present in the detection volume of 
the FCS instrument most of the time, explaining the regular appearance of fluorescence 
peaks in Figure 5. The lack of aggregation could also explain why PEG-LPXs seem to 
contain a more consistent amount of ONs as suggested from the uniform peak height in the 
fluctuation profile.  
 
ON Protection Against Nucleases by LPXs 
In general it is believed that cationic liposomes protect complexed ONs against 
degradation by nucleases. We examined to what extent ONs complexed to liposomes are 
actually protected against degradation by nucleases. Although PAGE could be used for this 
purpose, the concentration of ONs needed to detect degraded ONs could be quite extensive 
(and expensive). Therefore we preferred to use FRET-FCS to determine the extent of ON 
degradation in LPXs and PEG-LPXs incubated with DNase I, as illustrated schematically in 
Figure 1B. 
Figure 7A shows the R/G ratio as obtained for PO40-ONs released by SDS from non-
pegylated lipoplexes after they were exposed to DNase I for various times (i.e. after step D in 
Figure 1A). The R/G ratio obtained from LPXs incubated in a solution without DNase I does 
not decrease, which was expected since no degradation can occur. When the LPXs were 
incubated in a solution containing DNase I, the R/G ratio decreases: the longer the exposure 
of the LPXs to DNase I, the lower the R/G ratio of PO40-ONs released by SDS. In the LPXs 
with a +/- ratio of 2.5 and 5, the ONs seem to be completely degraded when the LPXs are 
exposed to DNase I for about 12 hours. The LPXs with a +/- ratio of 10 offer better ON 
protection during the first 12 hours of incubation, however, the ONs become almost 
completely degraded after 18 hours incubation time. These results suggest that over time, 
the DNase I enzyme has access to and degrades the PO40-ONs. 
One question is whether or not the ON degradation occurs inside the complexes, i.e. 
when the ONs are associated to the liposomes. To address this question we took a closer 
look at the amount of free ONs in the lipoplex dispersions, spontaneously released as a 
function of time. As we used an FCS instrument, which can detect single molecules, the 
number of free ONs in the LPX dispersions as obtained in Figure 1A, step C, (i.e. before 
PO40-ONs release induced by SDS) could be easily calculated from the amplitude of the 
auto-correlation curves or by fitting to equation 1 (auto-correlation data not shown, but similar 
as in Figure 4). 
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Figure 7B shows the amount of spontaneously released ONs in the dispersion of non-
pegylated lipoplexes. For all +/- ratios studied, the amount of spontaneously released ONs 
starts to increase after 4 hours incubation time. For a +/- ratio of 2.5 and 5, all ONs seem to 
be released upon 12 hours incubation time, exactly the time in Figure 7A at which all PO40-
ONs are degraded. Similarly, for a +/- ratio of 10, maximum release is obtained after 18 
hours incubation time, again being the time after which Figure 7A shows that all ONs are 
degraded. Combining Figure 7A and 7B, one comes to the conclusion that not the 
complexed ONs, but rather the spontaneously released ONs become degraded by the 
DNase I enzyme.  
 
 
Figure 7.  (A) R/G ratio of PO40-ONs released by SDS from non-pegylated lipoplexes with a +/- ratio of 2.5 
(circle), 5 (square) and 10 (up triangle). The x-axis represents the time during which the LPXs were incubated 
with 0.2 Units DNase I. As a control, LPXs to which no DNase I was added were used (down triangle). Laser 
excitation was set to 488 nm and the green and red detector of the dual-color FCS instrument recorded the 
fluorescence intensities. (B) Number of free PO40-ONs as spontaneously released from non-pegylated lipoplexes 
with a +/- ratio of 2.5 (circle), 5 (square) and 10 (triangle). The x-axis represents the time during which the LPXs 
were incubated with 0.2 Units DNase I. The amount of free PO40-ONs was calculated from the background 
fluorescence intensities as measured by the red detector upon excitation at 647 nm (~ Cy5). In this way, the 
amount of calculated free ONs is independent from the possible degradation of the ONs. A line is drawn at the 
level of full PO40-ONs release. It should be noted that the same amount of spontaneously released PO40-ONs 
was observed when the LPXs were incubated without the DNase I enzyme. 
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One should then wonder why a gradual release of ONs from the LPXs occurs. It has 
been observed previously that lipid contact and membrane mixing in a lipoplex dispersion 
can trigger lipoplex aggregation and contents leakage 22;23. So each time fusion between 
lipoplexes occurs, part of the ONs are released. As can be seen in Figure 7B, the amount of 
spontaneously released ONs reaches the level of free ONs before complexation with the 
liposomes. This means that full release of the complexed ONs may occur when using 
DOTAP/DOPE liposomes if the LPxs are able to aggregate during a prolonged period of 
time. The disassembly of the LPXs as a function of time could also be observed from the fact 
that the release of ONs was accompanied by a decrease in the amount of highly intense 
fluorescence peaks (~ lipoplexes) in the fluorescence fluctuation profiles and an increase in 
the average fluorescence background (~ free ONs). As an example, this phenomenon is 
depicted in Figure 8 for LPXs with a +/- ratio of 10, respectively 4, 8 and 18 hours after 
incubation with the DNase I enzyme. Note that after 18 hours the released ONs are 
degraded, since the green fluorescence is now higher than the red fluorescence due to the 
disappearance of FRET. This gradual release of ONs was also observed for LPXs that were 
incubated without DNase I. In this case, however, the released ONs remained intact.  
 
 
Figure 8.  Fluorescence intensity fluctuations of non-pegylated lipoplexes with a +/- ratio of 10 as measured by 
the green (green line) and red (red line) detector of the FCS instrument. The LPXs were incubated with 0.2 units 
DNase I for (A) 4 hours, (B) 8 hours and (C) 18 hours. Laser excitation was set to 488 nm. 
 
ON Protection Against Nucleases by PEG-LPXs 
Figure 9A shows the R/G ratio as obtained on PO40-ONs released by SDS from 
pegylated lipoplexes after being exposed to DNase I for various lengths of time. Again, the 
R/G ratio obtained for PEG-LPXs that were incubated in a solution without DNase I remained 
rather constant, indicating that in this control experiment the ONs were not degraded. In the 
presence of DNase I, for all +/- ratios, there is a significant drop in the R/G ratio during the 
first 2 hours of incubation. This indicates that, initially, there is a substantial fraction of the 
ONs that is accessible to the DNase I enzyme. After this initial degradation the R/G ratio 
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remains rather constant (as in the control sample without DNase I). Apparently, no significant 
further degradation of the remaining intact PO40-ONs occurs, even not after 24 hours 
incubation time. 
 
 
Figure 9.  (A) R/G ratio of PO40-ONs released by SDS from pegylated lipoplexes with a +/- ratio of 2.5 (circle), 5 
(square) and 10 (up triangle). The x-axis represents the time during which the PEG-LPXs were incubated with 0.2 
Units DNase I. As a control, PEG-LPXs to which no DNase I was added were used (down triangle). Laser 
excitation was set to 488 nm and the green and red detector of the dual-color FCS instrument recorded the 
fluorescence intensities. (B) Number of free PO40-ONs as spontaneously released from pegylated lipoplexes with 
a +/- ratio of 2.5 (circle), 5 (square) and 10 (triangle). The x-axis represents the time during which the PEG-LPXs 
were incubated with 0.2 Units DNase I. The amount of free PO40-ONs was calculated from the fluorescence 
intensities as measured by the red detector upon excitation at 647 nm (~ Cy5). In this way, the amount of 
calculated free ONs is independent from the possible degradation of the ONs. A line is drawn at the level of full 
PO40-ONs release. It should be noted that the same amount of spontaneously released PO40-ONs was 
observed when the PEG-LPXs were incubated without the DNase I enzyme. 
 
As for the LPXs, we took a closer look at the amount of spontaneously released ONs 
in the PEG-LPX dispersions as a function of the incubation time (Figure 9B). The number of 
free ONs in the PEG-LPX dispersions as obtained in Figure 1A, step C, (i.e. before 
PO40-ONs release induced by SDS) was calculated by fitting the obtained auto-correlation 
curves to equation 2 and determination of the number of species 1 (N*y) that had a diffusion 
coefficient 1 that corresponds to the diffusion of free ONs (auto-correlation data not shown, 
but similar as in Figure 6). Interestingly, a longer incubation of the PEG-LPXs did not result in 
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a spontaneous release of the ONs. Apparently, the ONs remain attached to the PEG-LPXs. It 
can be expected that the presence of the PEG-chains provides a steric hindrance and 
prevents lipid contact between the different PEG-LPXs. Consequently, PEG-LPX 
aggregation and contents leakage do not take place. This was also clearly reflected in the 
FCS measurements, where consecutive similar fluorescence peaks remained to exist even 
after 24 hours incubation time, independent on the +/- ratio of the PEG-LPXs (Figure 10). 
From the green and red fluorescence intensities it can also be seen that the R/G ratio upon 
24 hours incubation time is only slightly increased upon increasing the +/- ratio from 2.5 over 
5 to 10.   
 
 
Figure 10.  Fluorescence intensity fluctuations of pegylated lipoplexes as measured by the green (green line) and 
red (red line) detector of the FCS instrument upon incubation with 0.2 units DNase I for 24 hours. The PEG-LPXs 
were prepared with (A) a +/- ratio of 2.5, (B) a +/- ratio of 5 and (C) a +/- ratio of 10. Laser excitation was set to 
488 nm. 
 
Explanation of the Protective Properties of LPXs and PEG-LPXs Based upon 
their Structural Properties 
It should be noted that the initial decrease in the R/G ratio for PEG-LPXs in Figure 9A 
is more pronounced than observed for LPXs in Figure 7A. Since this reflects the immediate 
degradation of uncomplexed ONs, one could argue that more free (uncomplexed) ONs are 
present in the PEG-LPX dispersion than in the LPX dispersion. However, the initial amount of 
free, uncomplexed ONs did not differ significantly between LPXs and PEG-LPXs as can be 
seen when the first data points in Figure 7B and Figure 9B are compared. This indicates that 
for PEG-LPXs, apparently also a large fraction of the complexed ONs are accessible to the 
DNase I enzyme. A possible explanation can be found in the mechanism for lipoplex 
formation as proposed by others 24-26 (Figure 11A). When mixing negatively charged ONs 
with positively charged non-pegylated liposomes, the ONs bind to the surface of the 
liposomes due to electrostatic interactions. In the case of non-pegylated liposomes, these 
‘ON coated’ liposomes subsequently ‘bridge’ neighbouring cationic liposomes. Thereby the 
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liposomes fuse and the ONs become entrapped between lipid bilayers originating from the 
individual cationic non-pegylated liposomes (Figure 11A, step 1 and 2). This process may 
repeat several times, resulting in the formation of multilamellar liposomes/ON particles 
(lipoplexes) that contain the ONs on the inside (Figure 11A, step 3). The ONs are thus 
shielded from the environment and expected to be protected against enzymatic degradation. 
This hypothesis is in agreement with our observation that when using non-pegylated 
liposomes, not the complexed, but rather the spontaneously released ONs are accessible to 
the DNase I enzyme.  
 
 
 
Figure 11.  Mechanism proposed for the formation of (A) non-pegylated lipoplexes and (B) pegylated lipoplexes. 
The gray band represents the lipid bilayer from the liposomes, while the black band represent the ONs. 
 
In contrast to non-pegylated lipoplexes rather few studies, if any, describe the 
mechanism behind the formation of pegylated lipoplexes. The initial degradation of the 
complexed ONs, however, suggests that in the PEG-LPXs the ONs are present on the 
outside, rather than on the inside. In Figure 11B we propose a mechanism for the formation 
of PEG-LPXs that can account for these observations. As occurs in the formation of LPXs, 
first the anionic ONs will bind to the cationic surface of the pegylated liposomes due to 
electrostatic interactions (Figure 11B, step 1). However, the presence of the PEG-chains on 
the surface of the pegylated liposomes is expected to prevent close contact between 
different ‘ON coated’ PEG-LPXs, hindering the fusion of pegylated liposomes and thus the 
formation of multilamellar particles. Hence, the ONs are not entrapped between lipid bilayers 
originating from the individual pegylated liposomes, but remain unprotected at the surface of 
the pegylated liposomes, still susceptible towards enzymatic degradation (Figure 11B, step 
2). This could explain why not only the free ONs, but also part of the ONs associated to the 
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outer surface of the PEG-LPXs, can be degraded by the DNase I enzyme. To verify this 
hypothesis, the surface charge of the non-pegylated and pegylated liposomes was 
measured, before and after complexation with negatively charged ONs at a +/- ratio of 2.5, 5 
and 10. 
 
Zeta Potential and Hydrodynamic Diameter of LPXs and PEG-LPXs 
Figure 12A shows the zeta potential and hydrodynamic diameter of non-pegylated 
liposomes before and after complexation with negatively charged ONs. At a +/- ratio of 5 and 
10 the zeta potential equaled the value of the cationic liposomes without ONs. This indicates 
that the surface of the LPXs consists of cationic liposomes, with most of the negatively 
charged ONs inside the LPXs. This agrees with the mechanism of lipoplex formation as 
proposed in Figure 11A, where the negatively charged ONs become sandwiched between 
lipid bilayers from the positively charged DOTAP/DOPE liposomes. At a +/- ratio of 2.5, the 
zeta potential decreased when compared to the cationic liposomes. This indicates that the 
amount of cationic liposomes with this +/- ratio is not sufficient to capture all negatively 
charged ONs inside the LPXs. Also, the lower surface charge and thus the lower electrical 
repulsion between the lipoplexes at a +/- ratio of 2.5 encourages aggregate formation, which 
can be seen by the larger hydrodynamic diameter when compared to lipoplexes with a +/- 
ratio of 5 and 10. 
 
Figure 12.  The zeta potential (bars) and hydrodynamic diameter (line) of liposome/ONs complexes prepared 
with (A) non-pegylated and (B) pegylated liposomes with a +/- ratio of 2.5, 5 and 10. The first data point 
represents the zeta potential and hydrodynamic diameter of respectively non-pegylated (LP) and pegylated 
(PEG-LP) liposomes before complexation. 
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Figure 12B shows the zeta potential and hydrodynamic diameter of pegylated 
liposomes before and after complexation with negatively charged ONs. Independent on the 
+/- ratio, the positively charged liposomes turn neutral to slightly negative when ONs are 
added to the solution. This indicates that the negatively charged ONs are attached to the 
surface of the pegylated liposomes without being covered by a second layer of positively 
charged pegylated liposomes, what agrees with the proposed mechanism for the formation 
of PEG-LPXs as depicted in Figure 11B. With this zeta potential, normally, aggregate 
formation would be expected due to the rather low electrical repulsion between different 
PEG-LPXs. However, from the hydrodynamic diameter it can be seen that the PEG-LPXs all 
display equal small sizes. This, again, can be explained by the presence of the PEG-chains 
at the surface of the pegylated liposomes, which prevent aggregate formation.  
 
 
CONCLUSIONS AND OUTLOOK  
 
In this chapter, we used the FRET-FCS technique as described in Chapter 2 to 
contribute to a better understanding of the protection of antisense ONs against nucleases by 
pegylated and non-pegylated DOTAP/DOPE liposomes.  
Both pegylated and non-pegylated liposomes were able to complex an increasing 
number of ONs when a higher +/- ratio was used. When exposed to DNase I, initially, the 
non-pegylated lipoplexes offered a good protection of ONs against enzymatic degradation. 
However, due to lipoplex aggregation and subsequent ON release, the protection against 
enzymatic degradation was overcome during longer incubation times. We suggest that not 
the complexed, but rather the spontaneously released ONs are accessible to the DNase I 
enzyme, which agrees with the mechanism of lipoplex formation as proposed by others 24-26. 
One way to prolong the protection of ONs against enzymatic degradation would therefore be 
to prevent the aggregation between different LPXs, e.g. by the incorporation of PEG-chains 
at the liposomes’ surface. Complexes prepared from pegylated liposomes indeed remained 
stable over a prolonged period of time, without aggregate formation or spontaneous release 
of the ONs (e.g. even after 24 hours the FCS profile had not changed). However, when the 
PEG-LPXs were exposed to nucleases, initially a significant amount of the complexed ONs 
was degraded. We obtained experimental evidence that the presence of the PEG-chains 
influences lipoplex formation so that the ONs are not sandwiched between different lipid 
bilayers, but remain unprotected at the surface of the PEG-LPXs. To circumvent this rapid 
degradation, ‘post-pegylation’ should be considered, in which the incorporation of PEG-
chains takes place after the initial lipoplex formation. In that way, the good complexation 
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properties of non-pegylated liposomes, in which the ONs are shielded from the environment, 
would be combined with the prolonged stability of the pegylated lipoplexes. This chapter 
showed that FCS and FRET-FCS are capable tools to investigate characteristics such as 
complexation behavior and ON protection against nucleases of cationic lipid-based carriers 
used in antisense delivery. In the next chapter, we evaluated whether the FRET-FCS 
technique could also be used to determine the protective properties of cationic polymer-
based carriers used in gene delivery, such as polyethyleneimine (PEI). Also, as FRET-FCS 
is readily applicable on living cells, we evaluated in Chapter 5 and Chapter 6 respectively, 
whether FRET-FCS could be used to give further insight into the relationship between the 
intracellular fate and degradation of ONs when delivered by the LPXs and PEG-LPXs as 
used in this chapter and the observed antisense activity. 
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ABSTRACT 
 
In the previous chapter we demonstrated that FRET-FCS could be used to investigate 
characteristics such as the complexation behavior and protection of oligonucleotides (ONs) 
against nucleases by cationic lipid-based carriers frequently used in antisense delivery. 
Besides cationic lipids, also cationic polymers can be used in gene delivery. Among the 
cationic polymers, polyethyleneimine (PEI) is a promising candidate for delivery of ONs. In 
this chapter we aimed to investigate whether ONs are differently protected against enzymatic 
degradation in respectively PEI and polyethyleneglycol-polyethyleneimine (PEG-PEI) 
polyplexes. Using the FRET-FCS technique as described in Chapter 2, we found that 
PEI/ON polyplexes remain to protect the ONs they carry over a prolonged period of time, 
while in PEG-PEI/ON polyplexes the degradation of the ONs slowly proceeds. We attribute 
this to the observation that PEI appears to compact the ONs more firmly in the polyplexes’ 
core when compared to PEG-PEI, which apparently also results in a better protection against 
enzymatic degradation. These observations may also influence the efficiency of PEI-based 
ON delivery in vivo, where pegylation is an attractive strategy to enhance the stability of the 
polyplexes in the bloodstream. 
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Chapter 4 
Protection of Oligonucleotides Against 
Nucleases by Pegylated and  
Non-Pegylated Polyethyleneimine 
 
 
INTRODUCTION 
 
Currently a variety of carriers are under investigation for the delivery of nucleic acids 
such as plasmid DNA (pDNA). Viral vectors provide high transfection efficiencies for pDNA 
but suffer from the limited size of the pDNA they can carry. Also, they can induce severe 
immune responses. Non-viral vectors, such as cationic polymers 1 and cationic liposomes 2 
are advantageous over viral vectors in that they are less expensive, easier and safer to make 
and more suitable for long time storage. They can also deliver much larger pieces of pDNA 
when compared to viral methods 3. Cationic lipids as well as cationic polymers spontaneously 
form interpolyelectrolyte complexes with the negatively charged nucleic acids. These DNA 
complexes are respectively called lipoplexes and polyplexes. The current transfection 
efficiencies of non-viral vectors are, however, far from optimal. Despite their low efficiency, 
non-viral vectors retain high interest due to their favorable safety profile and ease of 
manufacturing.  
Non-viral carriers are, besides for the delivery of pDNA, also investigated for the 
delivery of antisense oligonucleotides (ONs). Antisense ONs show potential in the treatment 
of a wide variety of genetic and viral disorders. The principle of antisense is based on the 
specific inhibition of unwanted gene expression by blocking mRNA activity. This is achieved 
by a sequence-specific binding of the ONs to their complementary target mRNA, which 
results in blocking or degradation of the target sequence. Before the ONs can down-regulate 
a targeted gene expression, they have to reach the intracellular environment. The non-viral 
carriers should help the ONs to enter the cells and to escape from the endosomal 
compartment. Generally speaking, the ON/carrier complexes should exhibit a net positive 
charge to enhance the binding to the negatively charged cell membrane, which can be 
  97
CHAPTER 4 – PROTECTION OF OLIGONUCLEOTIDES AGAINST NUCLEASES BY PEGYLATED AND NON-PEGYLATED POLYETHYLENEIMINE 
accomplished by varying the ratio of the cationic carrier to the negatively charged ONs 4. 
Also, the complexes should preferably have a small, uniform size distribution (< 200 nm) to 
facilitate endocytosis 5. For successful ONs delivery, the carriers should also protect the ONs 
against enzymatic degradation by the nucleases in the blood and the cells.  
Among the cationic polymers, polyethyleneimine (PEI) is a promising candidate for 
non-viral gene delivery 6;7. The repeating unit of PEI consists of two carbon atoms followed 
by one nitrogen atom (Figure 1). Because of the amine groups, PEI carries a positive surface 
charge which allows binding and condensing the negatively charged DNA. Both the molar 
mass and the backbone structure of PEI (being linear or branched) influence the transfection 
efficiency and cytotoxicity of the PEI/DNA polyplexes 8;9. Conflicting information is available 
regarding the structural requirements and the molecular weight of PEI necessary for efficient 
gene delivery. Kunath et al. reported that low molecular weight PEI is better for transfection 
when compared to PEI with a high molecular weight 10. In contrast, Godbey et al. found a 
higher transfection efficiency with increasing molecular weight 11. Von Harpe et al. studied 
the transfection efficiency of a wide variety of commercially available PEIs and although he 
found vast differences in transfection efficiencies, he found no correlation between the 
physicochemical properties of the PEIs and their transfection efficiency 12.  
  In vitro, the use of unmodified PEI-based polyplexes comes with problems of 
cytotoxicity, biocompatibility and solubility. In vivo, non-specific protein adsorption, 
aggregation and rapid blood clearance can be added to the list. Approaches for improving 
the solubility of PEI-based polyplexes include grafting of PEI with nonionic water-soluble 
polymers such as polyethyleneglycol (PEG). Furthermore, this pegylation reduces the 
cytotoxicity and prolongs the stability and circulation of the polyplexes in the 
bloodstream 13;14. Also for cationic lipids, pegylation is an attractive strategy to prevent 
aggregation of the lipoplexes and opsonization by the reticulo endothelial system. In the 
previous chapter, we indeed found that the pegylated lipoplexes were stable over a 
prolonged period of time, whereas the non-pegylated lipoplexes were liable to aggregation. 
However, we also investigated the protection of ONs while being complexed to the non-
pegylated and pegylated liposomes and found that pegylation influenced the lipoplex 
formation so that the ONs remain unprotected at the surface of the lipoplexes, prone to 
enzymatic degradation. On the contrary, non-pegylated lipoplexes contained the ONs on the 
inside, inaccessible to nuclease attack 15. 
In this chapter, we wondered whether pegylation of PEI influences the complexation 
with ONs. To truly investigate the influence of pegylation, PEI and PEG-PEI with an identical 
PEI segment (branched, 2 kDa) were used (Figure 1). We especially aimed to investigate 
whether ONs are differently protected against enzymatic degradation in respectively PEI and 
PEG-PEI polyplexes. Following our previous work, in which we used Fluorescence 
  98
CHAPTER 4 – PROTECTION OF OLIGONUCLEOTIDES AGAINST NUCLEASES BY PEGYLATED AND NON-PEGYLATED POLYETHYLENEIMINE 
Correlation Spectroscopy (FCS) to monitor the association and dissociation between ONs 
and cationic polymers and cationic liposomes 16-20, we used FCS to study the PEI/ON and 
PEG-PEI/ON polyplexes. We demonstrated in Chapter 2 and Chapter 3 respectively, that the 
FCS-setup allows to follow the enzymatic degradation of fluorescently double-labeled ONs, 
both naked and complexed to cationic lipids 15;21. In this chapter, fluorescently double-labeled 
ONs were complexed to PEI and PEG-PEI polymers and their protection against enzymatic 
degradation was followed by FCS. 
 
 
 
Figure 1.  Schematic representation of (A) branched PEI and (B) PEG-PEI as used in this chapter. The molar 
mass of the branched PEI was 2 kDa. The PEG-PEI (12 kDa) consists of one branched PEI segment (2 kDa) and 
one PEG segment (10 kDa).  
 
 
MATERIALS AND METHODS 
 
Materials  
Double-labeled 40 mer phosphodiester oligonucleotides (ONs) (5’ GCC-GTC-TCT-
GAC-TGC-TGA-TGA-CTA-CTA-TCG-TAT-AGT-GCG-G 3’; 13388,1 g/mol) were purchased 
from Eurogentec (Seraing, Belgium) and were purified by polyacrylamide gel electrophoresis 
(PAGE) by the supplier. The ONs were double-labeled with a rhodamine green fluorophore 
at the 3’ end (λex = 488 nm, λem = 532 nm) and a Cy5 fluorophore at the 5’ end (λex = 647 
nm, λem = 670 nm).  
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Non-pegylated branched polyethyleneimine (PEI, 2 kDa) was purchased from Sigma 
(St. Louis, USA) (Figure 1A). Polyethyleneglycol-polyethyleneimine (PEG-PEI) was 
synthesized by the University of Nebraska Medical Center as described by Vinogradov et al., 
by coupling an activated PEG to the branched PEI of 2 kDa that was purchased from Sigma 
(Figure 1B) 22. The total content of nitrogen of the PEI and PEG-PEI was respectively 23.3 
and 3.75 µmol/mg polymer. The weight average molecular weight Mw of the PEG-PEI was 
determined to be 12 kDa by static light scattering (e.g. one PEG-segment of 10 kDa and one 
branched PEI segment of 2 kDa per PEG-PEI). 
DNase I (Pulmozyme®, 1 unit/µL) was kindly provided by NV Roche, Brussels, 
Belgium. Dextran sulfate was purchased from Sigma (St Louis, USA). The molar mass and 
sulfate content, as provided by the supplier, equaled respectively 500 kDa and 2.3 sulfate 
groups per glucosyl residue. A stock solution of 10 µg/µL was prepared in 20 mM HEPES 
buffer, pH 7.4. 
 
Preparation of PEI/ON and PEG-PEI/ON Polyplexes 
 The N/P ratio of the polyplexes is defined as the molar ratio of the total number of 
nitrogen atoms in the PEI-segment of the polymer to the number of DNA phosphates. 
Polyplexes with different N/P ratios were prepared by adding a cationic polymer solution to 
an equal volume of an ON solution, followed by vortexing the dispersion for 10 seconds. 
Every polymer and ON solution was prepared in the so called ‘degradation buffer’ (2 mM 
magnesium acetate, 110 mM potassium acetate and 20 mM HEPES, pH 7.4). In this buffer it 
is known that the enzyme DNase I is active 23. The polyplexes were allowed to equilibrate at 
room temperature for 30 minutes prior to use. The hydrodynamic size and zeta potential of 
the polyplexes was routinely checked by respectively dynamic light scattering (DLS, Malvern 
4700, Malvern, Worcestershire, UK) and surface potential measurements (Zetasizer 2000, 
Malvern, Worcestershire, UK), as previously described 16. 
 
Gel Electrophoresis Measurements on the Polyplex Dispersions and ONs 
Degradation 
 To study the complexation between ONs and respectively PEI and PEG-PEI by 
agarose gel electrophoresis, 5 µL of the ON solution (60 µg/mL) was mixed with 5 µL of a 
PEI respectively PEG-PEI solution (the concentration of PEI respectively PEG-PEI being 
dependent on the desired N/P ratio). The polyplexes were allowed to equilibrate for 30 
minutes at room temperature before further use. To study the displacement of the ONs from 
the polyplexes an increasing amount of dextran sulfate was added to the dispersions. All 
samples were diluted with degradation buffer to a total volume of 30 µL. Also, 5 µL was taken 
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from each sample and diluted with degradation buffer to a total volume of 50 µL to perform 
FCS measurements. Before loading the remaining samples on the agarose gel, 5 µL of 50% 
sucrose was added.   
 The degradation of the ONs, upon exposure of the polyplexes to DNase I, was 
studied by polyacrylamide gel electrophoresis (PAGE) as follows. 2 µL of the ON solution 
(150 µg/mL) was mixed with 2 µL of the PEI respectively PEG-PEI solution (resulting in 
polyplexes with a N/P ratio of 10). After equilibration, the samples were diluted with 
degradation buffer to a total volume of 12 µL. Then, the samples were incubated, 
respectively with or without 0.2 units of DNase I for 30 hours. After the desired incubation 
time, 5 µL 10x EDTA-enriched TBE buffer was added (10.8 g/L tris base, 5.5 g/L boric acid 
and 3.7 g/L EDTA) to inhibit DNase I. Subsequently, 5 µL of dextran sulfate (10 µg/µL) was 
added to release the ONs from the polyplexes before loading the samples on the 
polyacrylamide gel. Also, from these dispersions 5 µL was removed and diluted with 
degradation buffer to a total volume of 50 µL to perform FCS measurements. Before loading 
the remaining samples on the polyacrylamide gel, 5 µL of 50% sucrose was added.   
 
FCS Measurements on the Polyplex Dispersions and ONs Degradation 
Dual-color FCS measurements were performed on polyplexes composed of non-
labeled cationic PEI or PEG-PEI polymers and fluorescently double-labeled ONs. A dual-
color FCS-setup installed on a MRC1024 Bio-Rad confocal laser scanning microscope was 
used. An inverted microscope (Eclipse TE300, Nikon, Japan) was used, which was equipped 
with a water immersion objective lens (Plan Apo 60X, NA 1.2, collar rim correction, Nikon, 
Japan). To verify whether the excitation volumes and the detection volumes optimally 
overlapped, the system was calibrated as described by Schwille et al. 24. The laser beam was 
focused at about 50 µm above the bottom of the glass-bottom 96-well plate (Grainer Bio-one, 
Frickenhausen, Germany), which contained the samples. The 488 nm and the 647 nm laser 
beams of a krypton-argon laser (Bio-Rad, Cheshire, UK) were used and the green and red 
fluorescence intensity fluctuations were recorded on a digital ALV 5000/E correlator while 
exciting the polyplexes at 488 or 647 nm for 5 intervals of 50 seconds. To evaluate the 
integrity of the ONs, the ratio of the red to the green fluorescence (R/G ratio) was calculated 
after release of the ONs from the polyplexes by dextran sulfate upon excitation at 488 nm.
 For FCS measurements in Figure 2, 100 µL of 200 nM ONs in degradation buffer was 
incubated respectively with and without 1 unit DNase I at 37°C for 4 hours. Then, 100 µL 2x 
EDTA-enriched TBE buffer was added to the Eppendorf tubes to inhibit the DNase I. 
Mixtures of intact and degraded ONs were prepared by mixing 50/0, 40/10, 30/20, 20/30, 
10/40 and 0/50 µL of intact/degraded ONs. For FCS measurements in Figure 6 and 7, 50 µL 
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samples were obtained from the gel electrophoresis experiments as described above. To 
follow the degradation of the complexed ONs as a function of time (Figure 8), polyplexes 
were prepared by mixing 200 µL 1 µM ONs with 200 µL polymer solution (respectively 
0.0087 or 0.0174 µg/µL PEI and 0.054 or 0.107 µg/µL PEG-PEI to obtain a N/P ratio of 5 or 
10). After 30 minutes equilibration, the polyplex dispersions were diluted with degradation 
buffer to a total volume of 1000 µL and subsequently divided into two aliquots of  500 µL. To 
one 500 µL aliquot 1 µL (1 unit) DNase I was added. The two aliquots were further divided 
into Eppendorf tubes containing each 50 µL polyplex dispersion and incubated at 37°C. After 
the desired incubation time, 50 µL 2x EDTA-enriched TBE buffer was added to the 
Eppendorf tubes to inhibit the DNase I. On these samples, FCS measurements were 
performed respectively before and after addition of 20 or 10 µL dextran sulfate (10 µg/µL) to 
release the ONs from respectively the PEI and PEG-PEI polyplexes. 
 
 
RESULTS  
 
FRET to Study the Degradation of Fluorescently Double-Labeled ONs 
As reported in Chapter 2, in the intact ONs used in this chapter Fluorescence 
Resonance Energy Transfer (FRET) occurs between the rhodamine green fluorophore at the 
3’ end and the Cy5 fluorophore at the 5’ end 21. Upon excitation at 488 nm laser light, the 
energy is transferred from the rhodamine green (donor fluorophore) to the Cy5 (acceptor 
fluorophore). This turns the ONs more red fluorescent while they become less green 
fluorescent. Figure 2 shows the green and red fluorescence intensities (as measured by the 
detectors of the FCS instrument upon excitation at 488 nm laser light) of solutions containing 
a mixture of intact and degraded ONs. At higher amounts of degraded ONs, the solutions 
become less red fluorescent but more green fluorescent. Hence, the ratio of the red to green 
fluorescence (R/G ratio) decreases as a function of the amount of degraded ONs. Indeed, 
degradation of the ONs by endonucleases increases the distance between the fluorophores 
so that FRET no longer occurs 21. Therefore, the R/G ratio can be used to monitor the 
integrity of the double-labeled ONs.   
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Figure 2.  Green (green bars) and red (red bars) fluorescence of solutions composed of intact and degraded 
double-labeled ONs. The total (intact + degraded) ON concentration of all solutions was equivalent to 100 nM of 
intact ON. The red and green fluorescence was measured by the detectors of the FCS instrument with laser 
excitation set to 488 nm. The R/G ratio is also depicted (triangle). Values represent the average ± standard 
deviation of three independent experiments.      
 
Association of ONs with PEI and PEG-PEI 
 The association of ONs with PEI and PEG-PEI as a function of the N/P ratio, was first 
studied by agarose gel electrophoresis. As Figure 3 shows, up to a N/P ratio of 1, free 
(uncomplexed) ONs migrate in the agarose gel thus indicating that the amount of cationic 
polymer is not sufficient to bind all the negatively charged ONs. At a N/P ratio of 2.5 a large 
amount of the ONs appears to be bound to the PEI and PEG-PEI, indicating that the amount 
of PEI and PEG-PEI is sufficient to bind all the ONs.  
 
 
Figure 3.  Gel electrophoresis on (A) PEI/ON and (B) PEG-PEI/ON dispersions. Lane 1: free ONs. Lane 2-12: 
PEI or PEG-PEI/ON polyplexes with the N/P ratio as depicted above each lane. The amount of ONs in each lane 
was 300 ng. This experiment was repeated three times with newly prepared samples, showing the same results 
as depicted.   
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 Figure 4 shows the fluorescence fluctuation profiles of respectively free and 
complexed double-labeled ONs as measured by FCS upon excitation at 488 nm. FRET 
clearly occurs in the free ONs (Figure 4A) since the red fluorescence (acceptor fluorophore) 
is much higher than the green fluorescence (donor fluorophore). From the fluorescence 
intensities, a R/G ratio of 11.3 ± 0.6 was obtained. When PEI, respectively PEG-PEI, is 
added to the ONs the red fluorescence decreases significantly (Figure 4B and C). Also, 
‘fluorescence peaks’ are visible in the red fluorescence fluctuations of the PEG-PEI/ON 
dispersions (Figure 4C) but not in the fluorescence fluctuations of the PEI/ON dispersions 
(Figure 4B). Both observations will be interpreted and explained in the Discussion section.  
  
 
Figure 4.  Representative FCS measurements on (A) free ONs, (B) PEI/ON dispersions and (C) PEG-PEI/ON 
dispersions. The green (green line) and red (red line) fluorescence intensity fluctuations were recorded by the 
FCS instrument with laser excitation set to 488 nm. The N/P ratio of the polyplexes was 10.  
 
Dissociation of PEI/ON and PEG-PEI/ON Polyplexes  
When negatively charged dextran sulfate is added to the polyplex dispersions, it is 
expected that it will compete with the ONs for binding to the PEI and PEG-PEI polymers, 
thereby possibly displacing the ONs from the polyplexes. As Figure 5 shows, this was indeed 
observed by gel electrophoresis. Release of the ONs from both PEI (Figure 5A) and PEG-
PEI (Figure 5B) starts from lane 5, containing 1 µg dextran sulfate. It can be seen, however, 
that a greater amount of dextran sulfate is required for complete release of the ONs from PEI 
versus PEG-PEI based polyplexes. Indeed, while 3 µg dextran sulfate seems to be sufficient 
to fully displace the ONs from the PEG-PEI based polyplexes, complete release of the ONs 
from the PEI based polyplexes only occurs as from lane 9-10, containing 30-60 µg dextran 
sulfate.   
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Figure 5.  Gel electrophoresis on (A) PEI/ON and (B) PEG-PEI/ON dispersions. Lane 1: free ONs. Lane 2-12: 
PEI or PEG-PEI/ON polyplexes (N/P ratio of 10) to which increasing amounts of dextran sulfate were added as 
depicted above each lane in µg. The amount of ONs in each lane was 300 ng. This experiment was repeated 
three times with newly prepared samples, showing the same results as depicted.    
 
The dextran sulfate containing dispersions, as analyzed by gel electrophoresis in 
Figure 5, were further measured by FCS as described in the Materials and Methods section. 
The average fluorescence intensities upon excitation of the polyplex/dextran sulfate 
dispersions at 488 nm, and the corresponding R/G ratio, are depicted in Figure 6. Free ONs 
show higher red than green fluorescence due to FRET, which results in a R/G ratio of around 
11 (Figure 6 A and B, sample 1). Upon complexation, the ONs significantly loose their green 
and red fluorescence which is due to the quenching of the fluorophores (see Discussion 
section). Accordingly, the R/G ratio of the complexed ONs dropped to 0.2 ± 0.1 (Figure 6 A 
and B, sample 2).  
Figure 6A, samples 3-12 show the outcome of the FCS measurements on PEI/ON 
dispersions containing increasing amounts of dextran sulfate. We can clearly see that the 
green and red fluorescence increases as a function of the amount of dextran sulfate, which 
indicates the gradual release of the ONs from the polyplexes. In agreement with the gel 
electrophoresis experiment in Figure 5A, the release starts from sample 5 containing 1 µg 
dextran sulfate. It takes however up to 150 µg dextran sulfate to fully release the ONs from 
the PEI/ON polyplexes (Figure 6A, sample 12). Importantly, upon adding increasing amounts 
of dextran sulfate to the PEI/ON dispersions not only the fluorescence intensities, but also 
the R/G ratio gradually recovers until the value as measured for free ONs (Figure 6A, sample 
1).  
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As Figure 6B shows, adding dextran sulfate to PEG-PEI/ON dispersions also 
increases the green and red fluorescence. Although not visible on the agarose gel in Figure 
5B, FCS measurements point out that the release of ONs from the polyplexes starts from 
sample 4, containing 0.5 µg dextran sulfate. The addition of 1 µg dextran sulfate releases all 
the ONs, accompanied by a full recovery of the R/G ratio (Figure 6B, sample 5). This is in 
clear contrast to the PEI/ON dispersions in Figure 6A, where the ONs were only gradually 
released upon adding increasing amounts of dextran sulfate. Apparently, the ONs become 
more easily displaced from the PEG-PEI/ON polyplexes than from the PEI/ON polyplexes.  
 
 
Figure 6.  FCS measurements on (A) PEI/ON and (B) PEG-PEI/ON dispersions. The green (green bar) and red 
(red bar) fluorescence intensity fluctuations were recorded by the FCS instrument with laser excitation set to 488 
nm. The samples as measured by FCS were composed of a fraction of the samples 1-12 used in Figure 5 as 
described in the Materials and Methods section. Accordingly, lane 1 contains free ONs and lane 2-12 contain PEI 
or PEG-PEI/ON polyplexes (N/P ratio of 10) to which respectively 0, 0.25, 0.5, 1, 3, 5, 10, 30, 60, 100, and 150 
µg dextran sulfate was added. The R/G ratio is also depicted (triangle). Values represent the average ± standard 
deviation of three FCS measurements per sample. 
 
Protection of ONs Against Enzymatic Degradation by PEI and PEG-PEI   
Figure 7 shows the result of polyacrylamide gel electrophoresis on respectively free 
and complexed ONs that were incubated with or without 0.2 units of DNase I. Comparing 
lanes 2 and 3 shows that the degradation products run further on the gel. Lanes 4 and 6 
contain respectively PEI and PEG-PEI based polyplexes that were incubated at 37°C for 30 
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hours without DNase I. After the 30 hours of incubation, dextran sulfate was added to release 
the ONs from the polyplexes. It seems that only intact ONs are released from both types of 
polyplexes. Lanes 5 and 7 contain respectively PEI and PEG-PEI based polyplexes that 
were incubated for 30 hours with DNase I. After inhibition of the DNase I and release of the 
ONs by adding dextran sulfate, it can be seen that the ONs that were complexed to PEI 
predominantly stayed intact, while a large fraction of the ONs that were complexed to PEG-
PEI were degraded.     
 
 
 
Figure 7.  Gel electrophoresis on free ONs, PEI/ON and PEG-PEI/ON dispersions. (Lane 1) bromophenolblue 
marker, (lanes 2-3) free ONs respectively without and with 0.2 units DNase I, (lanes 4-5) PEI polyplexes 
respectively without and with 0.2 units DNase I and (lanes 6-7) PEG-PEI polyplexes respectively without and with 
0.2 units DNase I. The N/P ratio of the polyplexes was 10. The samples were incubated at 37°C for 30 hours. 
Before loading the samples on the gel, the DNase I activity was inhibited with EDTA-enriched TBE buffer and the 
ONs were released from the polyplexes by adding dextran sulfate. For lanes 2-7, the R/G ratio (as determined by 
FCS on a fraction of the samples) is also depicted. Each lane (except for lane 1) contained 300 ng ONs. This 
experiment was repeated three times with newly prepared samples, showing the same results as depicted.  
         
 The samples as analyzed by gel electrophoresis in Figure 7 were also measured by 
FCS. From the R/G ratio, as depicted at the bottom of Figure 7, the amount of degraded ONs 
could be calculated using the equation y = 1.0437e-0.035x in which y is the normalized R/G 
ratio and x is the percentage of degraded ONs. This equation was determined from an 
exponential fit (R² = 0.9901) of the normalized R/G ratio as a function of the percentage of 
degraded ONs as depicted in Figure 2. For the samples in lanes 2, 4 and 6, 98 ± 2% of the 
ONs remained intact. From the free ONs in lane 3, only 0.5 ± 0.1% remained intact upon 
incubation with the DNase I enzyme. When the ONs were complexed to PEI or PEG-PEI 
(lanes 5 and 7), respectively 82 ± 5% and 38 ± 4% of the ONs survived the incubation with 
the DNase I enzyme.  
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We examined the degradation kinetics of the ONs complexed to PEI and PEG-PEI in 
more detail with the FCS instrument (Figure 8). Therefore, as described in the Materials and 
Methods section, we measured the R/G ratio of the ONs (upon excitation at 488 nm) after 
release of the ONs by dextran sulfate from the polyplexes that were incubated with DNase I 
for a certain period of time. Again, from the R/G ratio, the amount of degraded ONs was 
calculated using the equation y = 1.0437e-0.035x in which y is the normalized R/G ratio and x is 
the percentage of degraded ONs.  
 
 
 
Figure 8.  Percentage of ONs remaining intact after incubating (A) PEI/ON polyplexes and (B) PEG-PEI/ON 
polyplexes with DNase I, as measured by FCS. The percentage of intact ONs was calculated from the R/G ratio, 
after inhibition of the DNase I with EDTA-enriched TBE buffer and subsequent release of the ONs from the 
polyplexes using dextran sulfate. Laser excitation was set to 488 nm. (squares) polyplexes incubated without 
DNase I (average ± standard deviation of the N/P ratio 5 and 10), (open circles) polyplexes with a N/P ratio of 5 
incubated with 1 unit of DNase I, (closed circles) polyplexes with a N/P ratio of 10 incubated with 1 unit of 
DNase I and (crosses) naked ONs incubated with 1 unit of DNase I. Values represent the average ± standard 
deviation of two samples per time point. When no error bars appear, they were smaller than the symbol. 
 
When PEI/ON and PEG-PEI/ON polyplexes were incubated without DNase I, the 
amount of intact ONs only slightly decreased to respectively 96 ± 3% and 93 ± 1% after 30 
hours of incubation, indicating that almost no degradation occurred (Figure 8, squares). For 
PEI/ON polyplexes with a N/P ratio of 5, 26 ± 2% of the ONs were degraded after a couple of 
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hours. Upon longer incubation times the degradation slowly proceeded: 33 ± 5% of the ONs 
were degraded after 30 hours (Figure 8A, open circles). For PEI/ON polyplexes with a N/P 
ratio of 10 initially only 15 ± 1% of the ONs became degraded while a longer incubation with 
DNase I did not further degrade the ONs (Figure 8A, closed circles).   
For PEG-PEI/ON polyplexes the protection of the ONs seemed independent on the 
N/P ratio of the polyplexes (Figure 8B, open and closed circles). Initially, also 14 ± 3% of the 
ONs become degraded. In contrast to PEI/ON polyplexes, more ONs become degraded 
upon longer incubation with DNase I. Indeed, after 30 hours 66 ± 2% of the ONs are 
degraded. It should be noted that when free ONs were incubated with DNase I under the 
same circumstances, complete degradation was already achieved within 30 minutes (Figure 
8 A and B, crosses). 
 
Hydrodynamic Size and Zeta Potential of PEI/ON and PEG-PEI/ON Polyplexes 
Figure 9 shows the hydrodynamic size and zeta potential of PEI/ON and PEG-
PEI/ON polyplexes with a N/P ratio of 5 and 10. PEG-PEI polyplexes are respectively 
170 ± 13 nm and 203 ± 9 nm for a N/P ratio of 5 and 10. PEI polyplexes are about three 
times larger, with respectively 570 ± 33 nm and 627 ± 34 nm for a N/P ratio of 5 and 10. 
Depending on the N/P ratio, the PEI polyplexes are neutral to slightly positive, while the 
PEG-PEI polyplexes are neutral to slightly negative. 
 
 
Figure  9.  Hydrodynamic size and zeta potential measurements (graph insert) on PEI/ON and PEG-PEI/ON 
dispersions. (Black bars) N/P ratio of 5 and (gray bars) N/P ratio of 10. Values represent the average ± standard 
deviation of three independent experiments. 
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DISCUSSION 
 
A better understanding of the physicochemical properties and biological behavior of 
cationic polymers is expected to provide valuable knowledge for the future design of highly  
efficient nucleic acid delivery systems. The in vitro transfection efficiency of cationic 
polymer/nucleic acid polyplexes depends, however, on a large variety of factors such as cell 
type, confluency of cells, the way the complexes are formed as well as their composition, the 
composition of the incubation medium, the time of incubation and so on 25. This complicates 
the search for optimal nucleic acid delivery systems and necessitates screening of new 
candidates under various experimental conditions. Physicochemical properties such as the 
size and charge of carrier/DNA complexes are routinely checked by respectively dynamic 
light scattering and zeta potential measurements. To what extent the carriers protect the 
nucleic acids against enzymatic degradation is mostly investigated by agarose (in the case of 
pDNA) and polyacrylamide (in the case of ONs) gel electrophoresis. This requires, however, 
a sufficient amount of complexes and thus a sufficient amount of cationic carriers to be able 
to visualize the degradation of the nucleic acids, which may be an issue for cationic carriers 
that are expensive or difficult to synthesize. In this chapter, we used FCS as a tool to gain 
insight in the protection of ONs against enzymatic degradation when complexed to cationic 
polymers. FCS is advantageous in that it can be done in very small sample volumes 
(microliters) in the nanomolar concentration range. The low concentrations used are a major 
advantage when studying scarce DNA and polymer material. Also, the small sample volume 
required makes the technique suitable for measurements in rare media (e.g. cytosolic 
lysates) and living cells.  
First, we studied the association and dissociation behavior of PEI/ON and PEG-
PEI/ON polyplexes. From a gel retardation assay (Figure 3), we observed that both PEI and 
PEG-PEI upon mixing with ONs spontaneously form complexes at a N/P ratio of 2.5 and 
higher. From gel electrophoresis, one would thus conclude that the PEG-chains in PEG-PEI 
did not influence the complexation behavior when compared to PEI, an observation that has 
been reported before in the complex formation with plasmid DNA 13. This could result from 
the fact that for the PEG-PEI, as used in this chapter, there is only about one PEG-chain per 
cationic PEI segment (Figure 1B), thus lowering the chance that the PEG-chains would 
shield the cationic charges on the PEI backbone. 
FCS measurements, however, did reveal some differences between PEI and PEG-
PEI with regard to the complexation of ONs (compare Figures 4B and 4C). Both with PEI and 
PEG-PEI, a drastic decrease in the green and red fluorescence of the ONs occurred upon 
complexation, which we attribute to the quenching of the fluorophores due to the compaction 
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of the ONs in the polyplexes. Probably, PEI and PEG-PEI interfere with the emitted photons 
through scattering or blockage (absorption) when the ONs are present in the polyplexes’ 
core. Clearly, electrostatic interactions between the anionic ONs and the cationic PEI 
segment of PEI and PEG-PEI drive the complex formation. The polyplexes consist of a core 
of cationic segments (partially) neutralized by ON strands, additionally surrounded by a shell 
of neutral PEG-chains in the case of PEG-PEI. In the core, the ONs are tightly packed so 
that the fluorophores they are carrying are quenched. The compaction of the ONs in the core 
of the PEG-PEI based polyplexes appears, however, different from that in the PEI based 
polyplexes. Indeed, highly intense fluorescence peaks are visible in the red fluorescence 
fluctuation profiles of the PEG-PEI polyplexes (Figure 4C). Such a high peak is due to the 
movement of a PEG-PEI/ON complex containing multiple ONs (and thus multiple 
fluorophores) through the detection volume of the FCS instrument. In other words, it 
indicates the presence of multiple ONs in a PEG-PEI/ON complex. It is very likely that 
PEI/ON complexes also contain multiple ONs. Such highly intense fluorescence peaks could, 
however, not be observed with PEI/ON polyplexes (Figure 4B). We attribute this to a stronger 
quenching of the fluorophores in the PEI based polyplexes when compared to the PEG-PEI 
based polyplexes. Assuming that the quenching of the fluorophores on the ONs is related to 
the compaction of the ONs in the polyplexes’ core, PEI would thus compact the ONs more 
firmly than PEG-PEI. In Figures 5 and 6 we determined the amount of dextran sulfate 
needed to displace the ONs from the polyplexes. Both gel electrophoresis and FCS 
measurements pointed out that the ONs were more easily released from the PEG-PEI 
polyplexes than from the PEI polyplexes. This observation, together with the different 
quenching of the fluorophores, supports the hypothesis that the ONs are compacted more 
tightly by PEI than by PEG-PEI.   
In a next set of experiments we studied the degradation of the ONs complexed to PEI 
and PEG-PEI upon dispersion of the polyplexes in a DNase I solution. The fluorescently 
double-labeled ONs used in this thesis show FRET: degradation of the ONs increases the 
green fluorescence and lowers the red fluorescence. Consequently, a high R/G ratio 
indicates intact ONs while a low one points out degradation of the ONs 21. On the one hand, 
for a solution of free ONs the R/G ratio is representative for the amount of intact free ONs 
(e.g. Figure 2). On the other hand, upon complexation of the ONs with PEI and PEG-PEI, the 
fluorescence drops to nearly zero (e.g. Figure 4). Due to this severe quenching, the R/G ratio 
of the complexed ONs is no longer representative for the amount of intact ONs in the 
polyplexes. Figure 6 showed that the R/G ratio of the ONs, released from the polyplexes by 
the addition of dextran sulfate, is restored to its original level. Also, when the ONs are free in 
solution, it is known that FRET can only occur between the labeled ends of a single ON. With 
greater compaction of the ONs in the polyplexes, however, it is possible that FRET occurs 
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between fluorophores of different ONs. Therefore, the R/G ratio of the ONs was only 
interpreted upon release of the ONs from the polyplexes. In this case, the R/G ratio reflects 
to what extent the ONs were protected against enzymatic degradation while they were 
present in the polyplexes. The ONs were released from the polyplexes by adding the 
negatively charged dextran sulfate. It should be noted that at high amounts of dextran sulfate 
the green and red fluorescence of the ONs released from the polyplexes (samples 12 in 
Figure 6A and 6B) are higher than the green and red fluorescence of the ON solution before 
complexation (samples 1 in Figure 6A and 6B). This increase in fluorescence could not be 
attributed to the non-fluorescing dextran sulfate, nor were the fluorescence properties of the 
ONs altered upon the presence of dextran sulfate. Instead, we found that the amount of ONs 
in the solutions containing dextran sulfate had increased, indicating that dextran sulfate also 
displaced the ONs that sticked to the bottom of the wells. The R/G ratio is, however, not 
dependent on the concentration of the ONs in solution, explaining why the R/G ratio before 
and after complexation is similar. Therefore, the increased fluorescence does not impede the 
use of the R/G ratio to monitor the degradation of the ONs as a function of time. 
Let us now focus on the outcome of the FCS measurements on polyplexes with a N/P 
ratio of 10 that were incubated with DNase I (Figure 8, closed circles). Initially, PEI and 
PEG-PEI equally protect the ONs they carry against enzymatic degradation: 15 ± 3% of the 
ONs degrade during the first 2 hours. One could wonder whether these degraded ONs 
originate from free (uncomplexed) ONs present in the dispersions, indicating that 15 ± 3% of 
the ONs remained free in solution. However, Figure 3 clearly shows that no free ONs appear 
at a N/P ratio of 5 or 10. Therefore, the initial degradation as observed in Figure 8 is highly 
likely attributed to the enzymatic degradation of ONs while being complexed to the PEI and 
PEG-PEI polymers. We mentioned before that the complexed ONs are present in the 
polyionic core of the polyplexes. It seems that for the polyplexes with a N/P ratio of 10, 15 ± 
3% of the ONs is still accessible to nucleases, probably as a result of being located at the 
edge of the polyplexes’ core. By analogy, free regions of plasmid DNA strands have been 
observed to dangle from the polyplexes’ core of PEI/DNA polyplexes 26.  
Figure 8 clearly shows that pegylation of the PEI based polyplexes has an influence 
on the protection of the ONs: PEI/ON polyplexes remain to protect the ONs they carry over a 
prolonged period of time while in PEG-PEI/ON polyplexes the degradation of the ONs slowly 
proceeds, reaching 66 ± 2% of degraded ONs after 30 hours of incubation. As reported 
above, PEI appears to compact the ONs more firmly in the polyplexes’ core than PEG-PEI. 
This firm compaction apparently also results in a better protection against enzymatic 
degradation. Alternatively, PEG-PEI polyplexes exhibit a core-shell structure in which the 
polyplexes’ core is shielded from the environment by a shell of hydrophilic PEG-chains 27. 
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This PEG-shield may provide an additional (steric) barrier for nuclease attack and may thus 
contribute to the protection of the ONs. The latter is, however, not supported by the results 
presented in this chapter. A possible explanation for the worse protection of ONs in PEG-PEI 
polyplexes is the following. In essence, polyplexes are oppositely charged polyion strands 
held together by electrostatic interactions. It is expected that polyplexes are subjected to 
dynamic processes of binding and dissociation of the involved polyelectrolytes. During these 
‘rearrangements’, ONs from the inner part of the polyplexes’ core could relocate to the edge 
of the polyplexes’ core, becoming accessible to enzymatic degradation. Since weaker 
polyelectrolyte interactions seem to exist in the PEG-PEI polyplexes (as indicated from the 
lesser quenching of the ONs’ fluorescence and the easier displacement of the ONs by 
dextran sulfate), the rearrangements of the ONs in the PEG-PEI/ON polyplexes may be more 
pronounced when compared to those in PEI/ON polyplexes, leading to more opportunities for 
DNase I attack. Since the ONs are about 13.3 kDa and the PEI polymers are about 2 kDa, 
one would expect that 6-7 PEI polymers can bind to a single ON. The ON-binding PEI 
segment of the PEG-PEI polymers is also 2 kDa, but the PEG-chains (10 kDa) could make it 
more difficult for 6-7 PEG-PEI polymers to bind to a single ON. This could explain why the 
ONs more easily ‘rearrange’ in the PEG-PEI based polyplexes. Another difference between 
the PEI and PEG-PEI based polyplexes is the size of the particles, with PEG-PEI polyplexes 
being about 3 times smaller than the PEI polyplexes. This implies that the effective surface 
area for DNase I attack is larger for the smaller PEG-PEI polyplexes when compared to the 
larger PEI polyplexes, which could contribute to the more pronounced degradation of the 
ONs in the PEG-PEI polyplexes. It should be noted that free ONs were fully degraded within 
the first 30 minutes of incubation with the DNase I enzyme. From this point of view, both PEI 
and PEG-PEI offer a drastic improvement in the life time of the complexed ONs.  
The degradation of the ONs was also followed by PAGE (Figure 7). When analyzed 
by gel electrophoresis (using Image J) 12% and 72% of the ONs were degraded in 
respectively PEI and PEG-PEI polyplexes after incubation for 30 hours with DNase I. When 
the degradation was calculated from the R/G ratio of the same samples that were analyzed 
by FCS, these values were respectively 18 ± 5% and 62 ± 4% at the 30 hours time point. 
These values agree very well with the degradation that was observed in Figure 8: 
respectively 15 ± 3% and 66 ± 2% of the ONs were degraded after incubation of PEI and 
PEG-PEI polyplexes with DNase I for 30 hours. This points out that FCS is a valuable 
alternative for gel electrophoresis to follow the degradation of ONs complexed to cationic 
carriers.      
In literature, there is only one report comparing the stability of ONs complexed to 
respectively PEI and PEG-PEI. By densitometric analysis of PAGE gels, Brus et al. found 
that PEI and PEG-PEI with molecular weight ranging from 0.8 to 2 kDa equally protected the 
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complexed ONs with a recovery of 90% of intact ONs 28. The shorter incubation time (2 
hours), lower DNase I concentration (e.g. for free ONs, only 50% degraded under these 
circumstances) and different N/P ratio (N/P of 20) most likely explain why the degradation 
was less pronounced when compared to our observations. They also found that PEG-PEI 
polyplexes with more, but shorter PEG chains protected more efficiently when compared to 
polyplexes containing fewer PEG chains of a higher molecular weight. Godbey et al. found, 
using gel electrophoresis, that plasmid DNA that was complexed with branched PEI (25 kDa) 
was not degraded when exposed to at least 25 units of DNase I for 24 hours 29. With regard 
to other polymers, Harada et al. used capillary gel electrophoresis to determine the protective 
properties of PEG-PLL (pegylated poly-l-lysine) polyplexes and found that after 2 hours of 
incubation with DNase I respectively 60% and 85% of the ONs were still intact, dependent on 
the density of the PEG shell 30. Clearly, these studies demonstrate that the stability of the 
complexed ONs depends on the polyplexes’ characteristics such as the density of the PEG 
shell. Nevertheless, Fisher et al. found that in vivo, pegylation of PEI worsened the protection 
of the ONs after intravenous injection of the polyplexes 14. Also, the pegylated PEI polyplexes 
used in this chapter did not offer a better protection when compared to the unpegylated PEI 
polyplexes, which may suggest that the PEG-PEI did not result in a sufficiently dense PEG-
shield to prevent nuclease attack.    
The complexation between ONs 17 and plasmid DNA 31;32 with PEI and PEG-PEI has 
been studied by FCS before, both in buffer and in living cells. This is, however, the first time 
that FCS was used to obtain more information on the protection that PEI and PEG-PEI 
polymers offer to complexed ONs. Since PEI and PEG-PEI with an identical PEI segment 
(branched, 2 kDa) were used, we could truly investigate the effect of pegylation. In 
conclusion, pegylation lowered the protective properties of the PEI/ON polyplexes, especially 
at longer incubation times, an observation which may be related to the weaker compaction of 
the ONs with the PEG-PEI polymers. These observations may also influence the efficiency of 
PEI-based ON delivery in vivo, where pegylation is an attractive strategy to enhance the 
stability of the polyplexes in the bloodstream. 
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ABSTRACT 
 
Delivering phosphodiester ONs (PO-ONs) remains an attractive but challenging goal 
in antisense therapy. In Chapter 3, we found that PO-ONs complexed to DOTAP/DOPE 
liposomes were adequately protected against enzymatic degradation. In this chapter, 
however, we found that the liposomes fail in generating an antisense effect with PO-ONs, 
while they succeed with chemically modified ONs like phosphothioate ONs (PS-ONs). 
Therefore, we aimed to explain the biological activity of PO- and PS-ONs delivered by 
DOTAP/DOPE liposomes based on a detailed understanding of their cell biological behavior 
by means of Fluorescence Correlation Spectroscopy and Confocal Laser Scanning 
Microscopy. We conclude that DOTAP/DOPE liposomes are not suited to deliver PO-ONs 
due to the release of naked PO-ONs in the cytosol at the time of the endosomal escape of 
the liposomes and the subsequent rapid degradation of the naked PO-ONs. In the case of 
PS-ONs, the ONs are not degraded upon release at the time of the endosomal escape of the 
liposomes, creating a pool of intact, biologically active PS-ONs. This indicates that 
DOTAP/DOPE liposomes are mainly suitable to deliver nuclease resistant ONs. However, 
the cells seemed to display an export pathway to remove intact PS-ONs from the cells, 
limiting the presence of naked PS-ONs in the nucleus to about 8 hours following the delivery. 
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Chapter 5 
Intracellular Fate and Biological Activity 
of Antisense Oligonucleotides 
Delivered by  
Non-pegylated Liposomes 
 
 
INTRODUCTION 
 
Antisense ONs show potential as therapeutics in the treatment of viral infections and 
cancer 1. Oligonucleotide-based therapeutics act by a sequence specific binding to their 
target mRNA, which results in blocking or degradation of the target sequence. This on its turn 
results in the down-regulation of the targeted protein expression. Despite this simple 
mechanism of action and many identified potential targets, only a few oligonucleotide-based 
therapeutics are actually on the market 2;3.  
To improve the efficacy of ONs, chemically modified ONs are explored to minimize 
the degradation in the body 4. The synthesis of modified ONs can, however, introduce 
unwanted side effects 4;5. Therefore, finding optimal delivery systems (‘carriers’) for 
unmodified phospodiester ONs (PO-ONs) remains attractive but very challenging. Generally 
speaking, optimal carriers for PO-ONs should protect the ONs against enzymatic 
degradation, enhance their cellular entry and facilitate endosomal escape. The ONs should 
also be released into the cytoplasm of the cells or should be able to exert an antisense effect 
while being encapsulated by the carriers. Clearly, the carriers should be sufficiently 
‘intelligent’ to overcome extra- and intracellular barriers to be able to deliver sufficient 
amounts of intact PO-ONs at their target. 
Cationic liposomes are among the most widely investigated carriers for delivery of 
nucleic acids 6. Upon mixing cationic liposomes with the negatively charged ONs, 
spontaneously cationic liposome/ONs complexes (lipoplexes) are formed. In literature as well 
as in our experiments, cationic liposomes fail in generating an antisense effect with PO-ONs, 
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while they succeed with the chemically modified phosphothioate ONs (PS-ONs) 7-9. It is well 
known that PS-ONs are more resistant towards enzymatic degradation than ONs with a 
phosphodiester backbone. Therefore a major hypothesis to explain the difference in 
biological activity is that PS-ONs remain intact while PO-ONs degrade. However, to find 
better carriers for PO-ONs, one should know when and where in the cells the PO-ONs begin 
to degrade. Importantly, we should also know whether, besides degradation of the PO-ONs, 
other intracellular mechanisms are involved in limiting the biological activity. In this chapter 
we aimed to explain the biological activity of PO- and PS-ONs delivered by liposomes 
composed of the cationic lipid DOTAP and the neutral helper lipid DOPE, based on a 
detailed understanding of their intracellular fate. Especially, we focused on the time and 
place of degradation of the delivered PO- and PS-ONs. Therefore, fluorescently double-
labeled ONs, giving FRET between the two labels, were complexed to non-pegylated 
cationic liposomes and their intracellular distribution and degradation was followed by FCS 
and CLSM.  
 
 
MATERIALS AND METHODS 
 
Materials  
Anti-intracellular adhesion molecule-1 (Anti-ICAM-1) 20 mer ONs with a 
phosphodiester backbone (PO20-ONs) or a phosphothioate backbone (PS20-ONs) were 
used (Isis1939: 5’ CCC-CCA-CCA-CTT-CCC-CTC-TC 3’). As a control ON, an ON without 
anti-ICAM-1 activity was used (5’GAG-ACT-TTC-ACT-TTT-CTC-TA 3’). For the 
Fluorescence Correlation Spectroscopy (FCS) experiments and confocal imaging, 
fluorescently double-labeled PO20-ONs and PS20-ONs were used as well as 40 mer 
phosphodiester ONs without anti-ICAM-1 activity (PO40-ONs; 5’-GCC-GTC-TCT-GAC-TGC-
TGA-TGA-CTA-CTA-TCG-TAT-AGT-GCG-G-3’). The ONs were double-labeled with a 
rhodamine green fluorophore at the 3’ end (λex = 488 nm, λem = 532 nm) and a Cy5 
fluorophore at the 5’ end (λex = 647 nm, λem = 670 nm). All ONs were purchased from 
Eurogentec (Seraing, Belgium) and were PAGE-purified by the supplier.  
The cationic phospholipid DOTAP (N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethyl-
ammoniumchloride) and the neutral phospholipid DOPE (dioleoylphosphatidylethanolamine) 
were purchased from Avanti® Polar Lipids (Alabaster, AL, USA).  
Human lung carcinoma cells (A549 cells, ATCC number: CCL-185) (DSMZ, 
Braunschweig, Germany) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
without phenol red (Gibco, Merelbeke, Belgium) containing 2 mM glutamine, 10% heat 
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deactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C in a humidified 
atmosphere containing 5% CO2. 
 
Preparation of Liposome/ONs Complexes 
The liposomes contained DOTAP and DOPE in a 1:1 molar ratio and were prepared 
as described in Chapter 3. The hydrodynamic size and zeta potential of the resulting cationic 
liposomes was routinely checked by respectively dynamic light scattering (DLS, Malvern 
4700, Malvern, Worcestershire, UK) and surface potential measurements (Zetasizer 2000, 
Malvern, Worcestershire, UK), as previously described 10 and equaled respectively 126 ± 7 
nm and +45 ± 4 mV. 
  
Confocal Imaging and Fluorescence Correlation Spectroscopy (FCS) 
Confocal imaging and dual-color FCS experiments were performed on a Confocor2 
installed on a LSM510 confocal laser scanning microscope (Carl Zeiss, Jena, Germany). The 
excitation light of an argon ion laser (488 nm, 30 mW) and/or a helium-neon laser (633 nm, 5 
mW) was reflected by a dichroic mirror (HFT 488/633) and focused through a Zeiss C-
apochromat 40x, NA 1.2 water immersion objective into the sample. The fluorescence 
emission was recollected by the same objective and split by another dichroic mirror (NFT 
635) into the green detector (after passing a 505-550 bandpass filter) or into the red detector 
(after passing a 650 longpass filter). Detection of the emission light was obtained with 
photonmultipliers (in the case of confocal imaging) or much more sensitive avalanche 
photodiodes (in the case of FCS). Confocal detection was ensured by excluding out-of-plane 
fluorescence with pinholes in front of the detectors (70 µm or 90 µm for respectively the 
green or the red detector). For FCS measurements, the apparatus was calibrated by 
measuring the diffusion time of rhodamine green in solution, which equaled 40 ± 5 µs in this 
FCS setup and corresponds to a diffusion coefficient of 2.8 x 10-10 m²/s.   
When performing intracellular FCS measurements, first a LSM510 confocal image of 
the cell was taken. Then, Confocor2 measuring points were selected on the confocal image 
in the cytoplasm or the nucleus of the cell and the green and red fluorescence intensities 
were recorded with laser excitation set to 488 nm (or 633 nm). From these fluorescence 
intensities, the R/G ratio was calculated. When possible, the calculated auto-correlation 
curves G(τ) were analyzed with the Confocor2 software using a single-species (eq. 1) or 
dual-species (eq. 2) fit according to the Marquardt nonlinear least-squares fit algorithm. Note 
that these equations are very similar to the ones used for our FCS setup (eq. 1 and eq. 2 in 
Chapter 1), except that with the commercially available Confocor2 as used in this chapter, 
the auto-correlation curves decay to 1 instead of 0. Fitting to equation 1 gives information on 
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the amount of molecules N in the detection volume and their diffusion time τt, being the 
average time the fluorescently labeled molecules need to migrate through the detection 
volume of the FCS instrument. 
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ω1 and 2ω2 represent the radius and the height of the detection volume. T represents the 
percentage of molecules in triplet state and τT represents the triplet relaxation time. For dual-
species fit (eq. 2), there are N*y molecules with diffusion time τt1 and N*(1-y) molecules with 
diffusion time τt2.  
 
Transfection of A549 Cells with ONs Containing DOTAP/DOPE Liposomes 
Lipoplexes (LPXs) were prepared by mixing 15 µL of a liposome dispersion (200 µM) 
and 15 µL of fluorescently double-labeled ONs (2 µM), resulting in a +/- ratio of 5 (being the 
ratio of the number of positive charges originating from the liposomes, to the number of 
negative charges originating from the ONs). The resulting dispersion was vortexed for 10 
seconds and the lipoplexes were allowed to equilibrate for 30 minutes at room temperature 
prior to use. Then, 120 µL DMEM was added before transferring the lipoplex dispersion to 
A549 cells grown to 90% confluency on glass-bottomed cover slips (Part No. PG-1.5-14-F, 
Glass bottom No. 1.5, MatTek Corporation). After 4 hours incubation at 37°C and 5% CO2, 
the cells were washed and incubated further in DMEM containing 2 mM glutamine, 10% heat 
deactivated FBS and 1% penicillin-streptomycin. Confocal imaging and FCS measurements 
were performed at 1, 2, 4, 8, and 12 hours after applying the lipoplex dispersion to the A549 
cells.  
 
Microinjection 
  Microinjection experiments were performed with a Femtojet® microinjector and an 
Injectman® NI 2 micromanipulator (Eppendorf, Hamburg, Germany) coupled to the LSM510 
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confocal laser scanning microscope. All injections were performed in the cytoplasm of A549 
cells. Immediately after injection, FCS measurements were carried out as described above in 
the Fluorescence Correlation Spectroscopy section. Naked fluorescently double-labeled 
PO20-ONs (2 µM) or a mixture of fluorescently double-labeled PO20-ONs (2 µM) and non-
labeled PO20-ONs (20 µM) were injected. Upon microinjection, the concentration of the 
injected ONs is expected to be diluted about 30 times, yielding intracellular concentrations of 
respectively 66 nM and 733 nM.    
 
Antisense Activity of PO20-ONs and PS20-ONs Containing DOTAP/DOPE 
Liposomes 
The antisense activity of non-labeled phosphodiester (PO20-ONs) and 
phosphothioate (PS20-ONs) anti-ICAM-1 ONs was determined by detecting the ICAM-1 
expression on the surface of A549 cells using ELISA. Mycoplasma free A549 cells were 
plated onto 96-well microtiter plates at 104 cells/well. At 90% confluency, the cells were 
washed three times with phosphate buffered saline (PBS) (Gibco, Merelbeke, Belgium) and 
free or complexed ONs were added to the cells (0.7 µg ON/well), followed by 4 hours of 
incubation. Lipoplexes with a +/- ratio of 2.5, 5 and 10 were used, containing non-labeled 
ONs. Subsequently, the free or complexed ONs were removed and after washing of the cells 
with PBS, 100 µL culture medium supplemented with 10 ng/mL TNF-α was added to induce 
overexpression of ICAM-1. After 18 hours of incubation, the ICAM-1 expression was 
determined as described below. To determine the basal ICAM-1 expression, the cells were 
incubated for 18 hours with 100 µL culture medium without TNF-α.   
 
ICAM-1 Assay 
The cells were fixed for 15 minutes at room temperature with PBS containing 20 
mg/mL paraformaldehyde. After washing with PBS, aspecific binding places were blocked by 
incubating the cells for 1 hour with 2% normal goat serum (NGS) in a 1% bovine serum 
albumin/PBS (BSA/PBS) solution. The cells were washed with PBS and incubated for 90 
minutes at 37°C with mouse anti-human ICAM-1 antibody (ImmunoSource, Zoersel, 
Belgium) (0.5 µg/mL in 1% BSA/PBS). After washing the cells with PBS, antibody bound to 
the cell surface was determined by incubating the cells for 1 hour at 37°C with sheep anti-
mouse antibody-alkaline phosphatase conjugate (1:1000 dilution in 1% BSA/PBS). After 3 
washes, the alkaline phosphatase activity was determined using 100 µL of p-
nitrophenylphosphate (10 mg/mL in 0.1 M TRIS pH 8.4). After 30 minutes incubation at 37°C, 
the absorbance was determined using an ELISA plate reader at 405 nm (Wallac Victor2 
multilabel reader, Perkin-Elmer Life Sciences, Boston, MA, USA).  
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The antisense activity of the anti-ICAM-1 PO20- or PS20-ONs was calculated as the 
percentage of the ICAM-1 expression when compared to A549 cells that were treated with a 
control ON using equation 3. In this way, the level of the basal and induced expression of the 
ICAM-1 protein in A549 cells treated with the control ONs is set to respectively 0% and 
100%. As the level of the basal or induced expression can be influenced by the conditions 
that are applied on the cells, the basal and induced ICAM-1 expression was determined on 
cells that were treated with the control ONs in the same conditions as were applied for the 
antisense PO20- or PS20-ONs (e.g. naked or complexed to DOTAP/DOPE liposomes at a 
+/- ratio of 2.5, 5 or 10).  
 
( )
( ) 100,,
,, ×−
−
CMControlTNFControl
CMControlTNFON
AA
AA
α
α    eq.3 
 
AControl,CM is the absorption of cells treated with naked or complexed control ONs and 
without TNF-α induction (the basal ICAM-1 expression). AControl,TNFα is the absorption of cells 
treated with naked or complexed control ONs upon induction with TNF-α (the control TNF-α-
induced ICAM-1 expression) and AON,TNFα is the absorption of cells treated with naked or 
complexed anti-ICAM-1 ONs upon induction with TNF-α (the ON-treated TNF-α-induced 
ICAM-1 expression).  
 
 
RESULTS  
 
Anti-ICAM-1 Activity of Phosphodiester and Phosphothioate ONs Delivered by 
DOTAP/DOPE Liposomes  
Figure 1 shows the antisense activity obtained with DOTAP/DOPE liposomes 
containing 20 mer anti-ICAM-1 ONs with either a nuclease sensitive phosphodiester 
backbone (PO20-ONs) or a nuclease resistant phosphothioate backbone (PS20-ONs). 
Naked PO20- and PS20-ONs did not show antisense activity. It is indeed well known that 
naked ONs do not adequately enter cells, which is often attributed to their negative charge. 
The antisense effect of LPXs with a +/- ratio of 2.5 does not differ significantly from the 
antisense effect established by naked ONs. In Chapter 3 we showed experimentally that at a 
+/- ratio of 2.5, only 45% of the ONs were complexed to the cationic liposomes, the other part 
of the ONs remained free 11. Apparently, this inadequate complexation resulted in a low 
biological activity of the LPXs at this +/- ratio, both for PO20- and PS20-ONs. At a +/- ratio of 
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5 or 10, we showed that the amount of complexed ONs increased to respectively 84% and 
98% (see Chapter 3) 11. In the case of PS20-ONs, increasing the +/- ratio to 5 or 10 resulted 
in a significant antisense effect. PO20-ONs, however, were not able to down-regulate the 
targeted protein expression. A major difference between PO-ONs and PS-ONs is the 
nuclease sensitivity of the backbone. Therefore, intracellular degradation could well be one 
of the factors limiting the antisense activity of the PO20-ONs. In the following experiments we 
aimed to figure out whether intracellular degradation is indeed the major barrier towards 
DOTAP/DOPE liposome-mediated PO-ONs delivery, or whether also other intracellular 
barriers contribute to the lack of antisense activity. Therefore, the intracellular pathway of 
fluorescently double-labeled ONs complexed to DOTAP/DOPE liposomes was followed by 
FCS and confocal imaging.  
 
 
Figure 1.  Antisense activity of PO20-ONs (triangle) or PS20-ONs (circle) administered to A549 cells naked or 
complexed to DOTAP/DOPE liposomes (LPX) at a +/- ratio of  2.5, 5 or 10. The antisense activity was calculated 
as the percentage of induced ICAM-1 expression when compared to A549 cells that were treated with the 
corresponding formulation containing the control ONs (e.g. respectively naked or complexed to DOTAP/DOPE 
liposomes at a +/- ratio of 2.5, 5 or 10) as described in the Materials and Methods section. 
 
Detection of Intact and Degraded ONs by FRET-FCS 
In the intact fluorescently double-labeled ONs, Fluorescence Resonance Energy 
Transfer (FRET) occurs between the rhodamine green (donor) and the Cy5 (acceptor) 
fluorophore 12. Consequently, excitation of rhodamine green gives rise to emission by both 
rhodamine green and Cy5 (Figure 2A). A prerequisite for energy transfer is the close 
proximity of the donor and acceptor fluorophore. When the ONs degrade, the distance 
between both fluorophores increases and FRET no longer occurs. In this case, excitation of 
the rhodamine green does not result anymore in emission by the Cy5 (Figure 2B). As 
outlined below, FRET can be used to distinguish between intact and degraded ONs.  
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Figure 2.  Schematic representation of FCS experiments on (A) intact and (B) degraded double-labeled ONs. In 
the intact ONs, FRET occurs between rhodamine green (donor, D, green) and Cy5 (acceptor, A, red) upon 
excitation at 488 nm laser light.  (C, D) Fluorescence fluctuations as registered by the green (green line) and red 
(red line) detector of the FCS instrument in a solution of respectively intact and degraded PO20-ONs. (E, F) Auto-
correlation curves as obtained from the fluorescence fluctuations of respectively intact and degraded PO20-ONs. 
The concentration of the ONs in solution ranged between 5 and 10 nM. PO20-ONs hydrolysis was accomplished 
by incubating the intact PO20-ONs with 20 units of the DNase II enzyme (4.7 units/µL, Sigma) for 8 hours at 
37°C in an acidic buffer (40 mM acetic acid and 60 mM K-acetate, pH 4.7). 
 
Figure 2C shows the fluorescence fluctuations as registered by the green and red 
detector of the FCS instrument upon excitation of a solution of intact double-labeled PO20-
ONs at 488 nm light. Clearly, the fluorescence intensity fluctuates as fluorescently labeled 
molecules move in and out of the detection volume of the FCS instrument. Due to FRET the 
ONs are, besides green fluorescent, also red fluorescent. Table 1 shows the ‘R/G ratio’ 
which is defined as the ratio of the red to the green fluorescence as measured by the FCS 
detectors. For the intact double-labeled PO20-ONs used in this thesis, the R/G ratio is higher 
than 1. Figure 2E shows that proper auto-correlation curves can be derived from both the 
green and red fluorescence fluctuations. The diffusion time, which is the average time the 
ONs need to migrate through the detection volume of the FCS instrument, can be calculated 
by fitting the auto-correlation curves to equation 1 (Table 1).  
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Figure 2D shows the fluorescence fluctuations as registered by the green and red 
detector upon excitation of a solution of degraded PO20-ONs at 488 nm. Due to the 
disappearance of FRET, the Cy5 fluorophores are no longer excitable at 488 nm. This is 
reflected in a decrease in the red fluorescence intensity in combination with an increase in 
the green fluorescence intensity, which lowers the R/G ratio (Table 1). Figure 2F shows that 
a proper auto-correlation curve can be obtained from the green fluorescence fluctuations and 
a diffusion time can be calculated by fitting to equation 1 (Table 1). In contrast, the red 
fluorescence fluctuations can no longer be auto-correlated.  
 
Table 1.  The fluorescence intensities as measured by the green (FG) and the red (FR) detector of the FCS 
instrument on solutions of intact PS20-ONs, intact and degraded PO20-ONs and intact and degraded PO40-ONs 
(laser excitation set to 488 nm light). The R/G ratio represents the ratio of the red to green fluorescence. The 
diffusion times τt calculated from the auto-correlation curves obtained from these fluorescence fluctuations are 
depicted as well (N.D. = not determinable). The concentration of the ONs in solution ranged between 5 and 10 
nM. PO20-ONs hydrolysis was accomplished by incubating the intact PO20-ONs with 20 units of the DNase II 
enzyme (4.7 units/µL, Sigma) for 8 hours at 37°C in an acidic buffer (40 mM acetic acid and 60 mM K-acetate, 
pH 4.7). PO40-ONs hydrolysis was accomplished by incubating the intact PO40-ONs with 1 unit of the DNase I 
enzyme (1 unit/µL, Genentech) for 1 hour at 37°C in ‘degradation buffer’ (20 mM HEPES, 110 mM potassium 
acetate and 2 mM magnesium acetate, pH 7.4).   
 
 Intact PS-ON 
Intact 
PO20-ON 
Degraded 
PO20-ON 
Intact 
PO40-ON 
Degraded 
PO40-ON 
FR (kHz) 3.4 3.5 1.2 3.7 0.7 
FG (kHz) 1.4 2 8.8 0.7 6.3 
R/G ratio 2.4 1.8 0.1 5.2 0.1 
Diffusion time τt (µs) as 
calculated from FR
131 ± 6 125 ± 14 N.D. 207 ± 4 N.D. 
Diffusion time τt (µs) as 
calculated from FG
105 ± 12 110 ± 5 60 ± 5 43 ± 2 60 ± 6 
 
In the case of PO40-ONs, the diffusion time calculated from the green fluorescence 
fluctuations increases upon degradation of the ONs (Table 1). This may seem contradictory 
as shorter degradation products are expexted to be formed. However, due to the high FRET 
efficiency of the PO40-ONs, there remains only little donor fluorescence originating from the 
intact PO40-ONs. Instead, fluorescence originating from a small fraction of free rhodamine 
green fluorophores may reach the green detector. Consequently, the diffusion time lies within 
the range of that of free rhodamine green fluorophores. When the PO40-ONs degrade, the 
donor fluorescence increases and a diffusion time can be calculated, corresponding to the 
green labeled degradation products that were formed. As for the PO20-ONs, the red 
fluorescence fluctuations (upon excitation at 488 nm) can be auto-correlated as long as the 
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ONs remain intact. The latter together with the R/G ratio allows distinguishing between intact 
and degraded ONs with the FCS instrument.   
  
Intracellular Fate of PS20-ONs Delivered by Non-pegylated Liposomes 
 A549 cells were transfected with DOTAP/DOPE liposomes containing fluorescently 
double-labeled PS20-ONs (PS20-LPXs). At certain time points confocal images were taken 
and FCS measurements were performed in the nucleus and cytoplasm of the cells with laser 
excitation set to 488 nm (Figure 3). In that case excitation of the Cy5 fluorophores only 
occurs if the ONs are still intact.   
 
Figure 3.  Green (A), red (B) and merged (C) confocal images of A549 cells respectively 1, 4, 8 and 12 hours 
after transfection with PS20-LPXs. As excitation light of 488 nm was used, the red fluorescence in B comes from 
Cy5 excitation due to FRET. In the transmission images (D) a circle was drawn around the nucleus (as also 
around the non-fluorescent nuclei in A, B and C). The arrows point to PS20-LPXs aggregates. 
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 Within 1 hour after adding PS20-LPXs to A549 cells, confocal images showed green 
fluorescence in the nuclei of most cells (Figure 3A-1h). As the PS20-LPXs themselves are by 
far too large (~150 nm) to cross the pores of the nuclear membrane, the nuclear 
fluorescence indicates the entry of free PS20-ONs after being released from the LPXs. 
Figure 3B-1h shows that also red fluorescence can be detected in the nuclei of most cells, 
indicating that FRET occurs and thus that the PS20-ONs are intact. From the red and green 
fluorescence fluctuations in the nucleus, as measured by the FCS detectors (upon excitation 
at 488 nm), an average R/G ratio of 2.2 ± 0.4 was calculated, which agreed well with the R/G 
ratio of intact PS20-ONs in buffer (Table 1). Also, proper auto-correlation curves could be 
generated from both the green and red fluorescence fluctuations (Figure 4). As discussed in 
Chapter 2 12, the diffusion time itself (as obtained from the auto-correlation curves) can only 
be used to distinguish between fully intact and fully degraded double-labeled ONs. 
Nevertheless, the fact that a proper auto-correlation curve can be derived for the Cy5 
fluorophores upon 488 nm excitation points out that FRET still occurs. Therefore, we chose 
to depict the auto-correlation curves, which were best fitted with a dual-species fit 
(equation 2), without further discussing the obtained diffusion times. Taken together, the 
above-mentioned observations clearly show that 1 hour after transfection PS20-ONs were 
released from the LPXs and stayed intact in the intracellular environment. 
 
Figure 4.  FCS measurements performed in the nucleus of A549 cells 1 hour after transfection with PS20-LPXs 
with laser excitation set to 488 nm. The graph shows the auto-correlation curves (dotted line) as derived from the 
green (rhodamine green, donor, green line) and red (Cy5, acceptor, red line) detector of the FCS instrument. The 
auto-correlation curves were best fitted with a dual-species fit (eq. 2) (solid line). The graph insert shows the 
green (green line) and red (red line) fluorescence fluctuations from which the auto-correlation curves were 
derived. 
 
More PS20-LPXs were able to enter the cells and release their ONs upon 4 hours 
incubation time, as was concluded from the increased nuclear fluorescence intensity 
(Figure 3-4h). Also, as pointed by the arrows, aggregates of PS20-LPXs became visible in 
the medium surrounding the cells. It is indeed known that lipoplexes have the tendency to 
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aggregate into large multimolecular complexes at longer contact times 13. Figure 3B-4h 
indicates the presence of FRET in the PS20-LPX aggregates outside the cells as well as in 
the free PS20-ONs in the nuclei of the cells. Also here, the average R/G ratio of 2.3 ± 0.4 in 
the nuclei revealed that the PS20-ONs were still intact. 
At longer incubation times, the formation of nuclear bodies could be seen in some 
cells as bright fluorescent spots in the nucleus (Figure 3-8h). This phenomenon has been 
reported previously for PS-ONs, especially at higher concentrations 14-16. The nuclear bodies 
contained intact PS20-ONs, as they were both green and red colored. Also, the R/G ratio of 
1.8 ± 0.2 as measured in the nucleus demonstrates that the PS20-ONs were still intact upon 
8 hours residence time.   
 After 12 hours, the nuclear fluorescence largely disappeared (Figure 3-12h). The 
average fluorescence intensities in the nuclei, as measured by the FCS detectors, equaled 
the autofluorescence of the nuclei (~ 5 kHz). Since the FCS detectors are much more 
sensitive than the CLSM detectors and can detect single molecules, this confirms that no 
PS20-ONs are left in the nuclei of most cells. Importantly, the disappearance of PS20-ONs 
out of the nuclei correlated with the appearance of punctated structures in the cytoplasm of 
the cells (Figure 3A-12h). As seen from the red fluorescence in Figure 3B-12h these 
cytoplasmic granules contain intact PS20-ONs. Now and then highly intense green and red 
fluorescence peaks simultaneously occurred in the fluorescence fluctuation profiles as 
measured by the FCS instrument in the cytoplasm of these cells (Figure 5). The fluorescence 
peaks had an average R/G ratio of 1.6 ± 0.3 and indicate the simultaneous movement of a 
number of intact PS20-ONs through the detection volume of the FCS instrument. As 
deduced from the broadness of the peaks in Figure 5, the PS20-ONs containing structures 
need about 5 to 10 seconds to pass through the detection volume of the FCS instrument, 
indicating a slow movement in the cytosol. 
 
Figure 5.  Fluorescence fluctuations as measured by the green (green line) and red (red line) detector of the FCS 
instrument in the cytoplasm of A549 cells transfected with PS20-LPXs. Laser excitation was set to 488 nm. The 
average R/G ratio of the fluorescence peaks was 1.6 ± 0.3, indicating intact PS20-ONs.   
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 Intracellular Fate of PO20-ONs Delivered by Non-pegylated Liposomes 
 A549 cells were transfected with DOTAP/DOPE liposomes containing fluorescently 
double-labeled PO20-ONs (PO20-LPXs). As for the PS20-LPXs, confocal images of the cells 
were taken and FCS measurements were performed in the nucleus and cytoplasm of the 
cells with laser excitation set to 488 nm (Figure 6).  
 
 
Figure 6.  Green (A), red (B) and merged (C) confocal image of A549 cells respectively 1, 2 and 4 hours after 
transfection with PO20-LPXs. As excitation light of 488 nm was used, the red fluorescence comes from Cy5 
excitation due to FRET. In the transmission images (D) a circle was drawn around the nucleus (as also around 
the non-fluorescent nuclei in A, B and C). 
 
 Green fluorescent nuclei were observed in the first hour after transfection (Figure 6A-
1h). This demonstrates the entry of PO20-LPXs in the cells and the release of the PO20-ONs 
from the LPXs, as only free ONs can diffuse through the pores of the nuclear membrane. In 
contrast to PS20-ONs (Figure 3), no red fluorescence was found in the nuclei upon excitation 
at 488 nm light (Figure 6B-1h). This suggests that FRET does not occur and indicates that 
the PO20-ONs present in the nuclei are degraded. FCS measurements in the nuclei revealed 
an average R/G ratio of 0.3 ± 0.1, showing that the released PO20-ONs that had entered the 
nuclei were indeed degraded. Also, upon excitation at 488 nm light, the auto-correlation 
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curve obtained from the nuclear green fluorescence fluctuations (~ rhodamine green) was of 
good quality (Figure 7, green line) while the red fluorescence fluctuations (~ Cy5) could not 
be correlated (Figure 7, red line). Nevertheless, red fluorescence could be detected in the 
PO20-LPXs outside the cells (Figure 6B-1h, region 1) as well as in some PO20-LPXs in the 
cytoplasm of the cells (Figure 6B-1h, region 2). By positioning the measuring points of the 
FCS instrument on the fluorescent dots, the R/G ratio of the PO20-LPXs could be 
determined. The average R/G ratio of the fluorescent dots in region 2 was 1.7 ± 0.2 and 
confirmed that the DOTAP/DOPE liposomes in the cytosol still contained intact PO20-ONs. 
This indicates that the degradation of the PO20-ONs occurs after release of the ONs from 
the LPXs.  
 
Figure 7.  FCS measurements performed in the nucleus of A549 cells 1 hour after transfection with PO20-LPXs 
with laser excitation set to 488 nm. The graph shows the auto-correlation curves (dotted line) as derived from the 
green (rhodamine green, donor, green line) and red (Cy5, acceptor, red line) detector of the FCS instrument. The 
auto-correlation curves were best fitted with a dual-species fit (eq. 2) (solid line). The graph insert shows the 
green (green line) and red (red line) fluorescence fluctuations from which the auto-correlation curves were 
derived 
 
The nuclear green fluorescence faded already after 2 hours incubation (Figure 6A-2h) 
and disappeared upon incubation times longer than 4 hours (Figure 6A-4h). Most likely, as 
previously observed by Fisher et al. 16, the small fluorescent degradation products easily 
diffuse out of the cells and are therefore no longer detected. However, the red dots in Figure 
6B-2h and Figure 6B-4h show that most of the PO20-LPXs in and around the cells still 
contain intact PO20-ONs, again confirming that degradation mainly occurs after release of 
the ONs from the LPXs.    
. 
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Intracellular Fate of PO40-ONs Delivered by Non-pegylated Liposomes 
Figure 8 shows confocal and transmission images of A549 cells after being 
transfected with non-pegylated liposomes containing fluorescently double-labeled PO40-ONs 
(PO40-LPXs). As for the PS20-LPXs and PO20-LPXs, the cells were excited at 488 nm. In 
that case, the red fluorescence comes from the excitation of the Cy5 fluorophores due to 
FRET, what can only occur if the ONs are still intact.  
 
 
 
Figure 8.  Green (A), red (B) and merged (C) confocal images of A549 cells respectively 2, 4, 8 and 12 hours 
after transfection with P040-LPXs. As excitation light of 488 nm was used, the red fluorescence in B comes from 
Cy5 excitation due to FRET. In the transmission images (D) a circle was drawn around the nuclei (as also around 
the non-fluorescent nuclei in A, B and C). The arrows point to PO40-LPXs that are located outside the cells. 
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In the first two hours following transfection, green fluorescent nuclei were observed 
(Figure 8A-2h). As the P040-LPXs themselves are too large to cross the pores of the nuclear 
membrane, this demonstrates the nuclear accumulation of the free PO40-ONs, released 
from the DOTAP/DOPE liposomes. Figure 8B-2h shows that red fluorescence could not be 
detected in the nuclei of the cells, suggesting that FRET does not occur and that the ONs in 
the nuclei were thus degraded. The average R/G ratio in the nuclei of the transfected cells, 
as measured by the FCS setup, equaled 0.2 ± 0.1 and confirmed that the PO40-ONs were 
degraded. 
As Figure 8A-4h shows, the green fluorescence in the nuclei faded upon 4 hours 
incubation time. Also, fluorescence measurements with the very sensitive detectors of the 
FCS setup pointed out that the nuclear fluorescence intensity did not differ significantly 
anymore from the autofluorescence of the nuclei (~ 5 – 10 kHz). However, some green and 
red fluorescent dots could be detected in the cytoplasm of the cells. Also at 8 hours 
incubation time, nuclear fluorescence could no longer be detected. However, the amount of 
green fluorescent spots in the cytoplasm of the cells clearly increased (Figure 8A-8h). From 
the color of the fluorescent spots in Figure 8C-8h it could be deduced that most of the 
punctated structures in the cytoplasm contained degraded PO40-ONs (green fluorescent 
spots) while other ones contained intact PO40-ONs (red fluorescent spots) or a mixture of 
intact and degraded PO40-ONs (yellow fluorescent spots). Similar information was obtained 
from measurements with the FCS setup: the R/G ratio as measured in the cytoplasm of the 
cells varied between 0.5 and 4 confirming that some of the cytoplasmic structures contained 
mostly degraded ONs while other ones were composed of mostly intact ONs.  
At 12 hours incubation time (Figure 8A-12h), a large number of green fluorescent 
spots were still present in the cytoplasm of the cells. However, there were less red 
fluorescent spots when compared to 8 hours incubation time, indicating that degradation of 
the PO40-ONs proceeded in these cytoplasmic structures (Figure 8B-12h). It should be 
noted that the PO40-LPXs located outside the cells (as pointed out by the arrows in the C- 
and D-images of Figure 8) remained red fluorescent and thus remained to contain intact 
ONs, irrespective of the incubation time. When FCS measurements were performed on these 
not endocytosed lipoplexes, the R/G ratio of 5.1 ± 0.6 clearly confirmed that they contained 
intact PO40-ONs. These observations suggest that the degradation of the complexed ONs 
only occurred after entry of the PO40-LPXs in the A549 cells. 
 
Degradation of Naked PO20-ONs upon Microinjection in A549 Cells 
As described above, FCS measurements and confocal images of A549 cells 
transfected with DOTAP/DOPE liposomes revealed that PO-ONs were degraded in the 
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intracellular environment within the first hour following transfection. Also, the data suggested 
that the degradation occurred after being released from the liposomes. To see whether 
PO-ONs indeed degrade that rapidly, naked PO-ONs were injected in the cytoplasm of A549 
cells and FCS measurements were performed to monitor the degradation. We chose to inject 
the PO20-ONs, as they contain the sequence for the anti-ICAM-1 activity, while the 
PO40-ONs are not biologically active.   
  As observed previously by others, PO20-ONs accumulated in the nuclei of the 
injected cells within a few minutes following the injection (data not shown) 17;18. Despite this 
rapid nuclear accumulation, intact PO20-ONs could not be detected in the nuclei of the 
injected cells. This could be concluded from the R/G ratio of 0.3 ± 0.1. Also, a proper 
auto-correlation curve could not be registered from the red (acceptor) fluorescence 
fluctuations upon 488 nm excitation (Figure 9A, red line) while a good auto-correlation curve 
was obtained from the green (donor) fluorescence fluctuations (Figure 9A, green line). 
Subsequently, the concentration of the injected PO20-ONs was increased 11-fold by 
injecting a mixture of fluorescently labeled (2 µM) and non-labeled (20 µM) PO20-ONs in the 
cells. In that way the amount of fluorescent PO20-ONs was kept low enough to allow for 
proper auto-correlation analysis. As shown in Figure 9B, proper auto-correlation curves from 
both the green and red fluorescence fluctuations were obtained upon excitation at 488 nm, 
indicating that FRET occurred and thus intact PO20-ONs were present in the nuclei of the 
cells. Also, the R/G ratio of 1.1 ± 0.1 confirmed that intact PO20-ONs entered the nuclei 
when a larger amount of PO20-ONs was injected in the cytosol. 
 
 
Figure 9.  FCS measurements performed in the nucleus of A549 cells immediately after injection of (A) 2 µM 
fluorescently labeled PO20-ONs and (B) a mixture of 2 µM fluorescently labeled and 20 µM non-labeled 
PO20-ONs. Injections were performed in the cytoplasm of A459 cells. The graph shows the auto-correlation 
curves (dotted line) as derived from the green (rhodamine green, donor, green line) and red (Cy5, acceptor, red 
line) detector of the FCS instrument. The auto-correlation curves were best fitted with a dual-species fit (eq. 2) 
(solid line). The graph insert shows the green (green line) and red (red line) fluorescence fluctuations from which 
the auto-correlation curves were derived. 
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DISCUSSION 
 
For some years now, antisense ONs are being investigated for the selective inhibition 
of various genes 1. Regretfully, the therapeutic potential remains largely unrealized. Attempts 
to fundamentally explain the biological activity of nucleic acids loaded carriers, by studying 
their biophysical properties and cell biological behavior, are scarce although these studies 
are highly needed to allow the design of better delivery systems for nucleic acids. For that 
purpose, our laboratory uses advanced microscopy techniques like Fluorescence Correlation 
Spectroscopy 19-21. In Chapter 3, we observed that PO-ONs in non-pegylated lipoplexes 
(LPXs) were well protected against enzymatic degradation when the LPXs were incubated in 
a DNase I solution. Although being protected against enzymatic degradation, we observed in 
this chapter that the nuclease sensitive PO-ONs delivered by non-pegylated liposomes did 
not show a biological effect, while the nuclease resistant PS-ONs did down-regulate the 
ICAM-1 protein expression (Figure 1). Subsequently, we followed the intracellular distribution 
and degradation of fluorescently double-labeled PO-ONs or PS-ONs delivered by 
DOTAP/DOPE liposomes by means of FCS and confocal imaging in order to explain the 
observed biological activity.  
 
Explanation of the Biological Activity of Non-pegylated Lipoplexes Based on 
their Intracellular Fate and Structural Properties 
Based on the mechanism of lipoplex formation as proposed in Chapter 3 and the 
intracellular fate and distribution of antisense ONs delivered by these lipoplexes as observed 
in this chapter, we propose below the intracellular pathway of non-pegylated liposomes 
containing PO- or PS-ONs in A549 cells, that can account for the obtainied antisense activity 
(Figure 10).   
In a first step, the cationic LPXs settle on and electrostatically bind to the negatively 
charged cell membranes (Figure 10, step 1). It is widely accepted that liposomes 
predominantly enter cells by endocytosis 22-25. Upon endocytosis of the DOTAP/DOPE 
liposomes loaded with fluorescent ONs, one would expect to see the endosomal vesicles as 
fluorescent dots in the cytoplasm of the transfected cells (Figure 10, step 2). Surprisingly, 
rather few cytoplasmic fluorescent dots were detected in the first hour following transfection. 
On the contrary, fluorescent nuclei were observed within the first hour after applying the 
LPXs to the A549 cells (Figure 3, 6 and 8). As the LPXs are too large to cross the pores of 
the nuclear membrane, the fluorescent nuclei suggest that the endosomal escape of the 
DOTAP/DOPE liposomes and release of the ONs in the cytosol of the A549 cells is a very 
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efficient process (Figure 10, step 3). A possible mechanism for endosomal escape of ON 
containing LPXs has been proposed by Zelphati and Szoka 26. According to these authors, 
lipid contact occurs between cationic lipids from the LPXs and anionic lipids from the inner 
face of the endosomal membrane resulting in flip-flop of anionic lipids from the cytoplasmic 
face of the endosomal membrane. These anionic lipids laterally diffuse into the LPXs and 
form a charge neutralized ion-pair with the cationic lipids from the LPXs, which results in 
destabilization of the LPXs and displacement of the negatively charged ONs with their 
release into the cytoplasm of the cells. Recently, Gordon et al. demonstrated that anionic 
lipids in the endosomal membrane are not a primary prerequisite to trigger ON release 27. On 
the contrary, neutral helper lipids in the delivery system, such as DOPE, seem to play a 
crucial role in improving the endosomal escape by adopting a hexagonal phase in the lumen 
of the endosomes that destabilizes the endosomal membrane 28;29. Therefore, the presence 
of DOPE in the LPXs used in this chapter most likely explains the rapid endosomal escape 
that results in release of the ONs in the cytoplasm of the transfected cells. 
 
 
Figure 10.  Proposed intracellular pathway of non-pegylated lipoplexes. (1) binding to the cell membrane, (2) 
internalization by endocytosis, (3) endosomal escape with release of the ONs in the cytoplasm, (3a) nuclear 
accumulation of intact ONs, (4) intracellular degradation of ONs, (4a) nuclear accumulation of degraded ONs and 
(5) degradation of the ONs in the endosomal compartment. 
 
Several studies have reported that, once in the cytosol, free ONs readily accumulate 
in the nucleus 15;17;18. By FCS, we observed that the ONs present in the nuclei were intact in 
the case of PS-ONs (Figure 10, step 3a), but degraded in the case of PO-ONs (Figure 10, 
step 4a). It is well known that PS-ONs are more resistant to degradation by nucleases. 
However, life times of PO-ONs in cells reported in literature vary from minutes to some 
hours 16;17;30;31. In this chapter, we found that injected PO20-ONs were degraded within 
minutes when injected at low concentrations (2 µM), while intact PO20-ONs could be 
detected when the injected concentration was 11-fold higher. The fact that intact PO20-ONs 
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were not observed in the nuclei of the transfected cells, together with the observation that 
intact PO20-ONs were detected in the PO20-LPXs outside as well as inside the transfected 
cells, suggests that degradation occurs after release of the PO20-ONs from the 
DOTAP/DOPE liposomes (Figure 10, step 4). We indeed demonstrated in Chapter 3 that 
DOTAP/DOPE liposomes offer a good protection against enzymatic degradation to the 
PO-ONs they are carrying, as long as the PO-ONs remain complexed to their carrier 11. 
Nevertheless, this chapter demonstrates that this protection against enzymatic degradation 
does not translate into a biological effect of the PO20-ONs due to the too efficient release 
and subsequent degradation of the PO20-ONs at the step of endosomal escape. We 
additionally observed that the nuclear fluorescence of PO20-ONs and PO40-ONs faded 
respectively within the first 2 hours and 4 hours after exposing PO20-LPXs and PO40-LPXs 
to the A549 cells (Figure 6-2h and Figure 8-4h). This probably reflects the diffusion of the 
shorter fluorescent degradation products out of the cells, as was already observed previously 
by Fisher et al. 16. It should be noted that the fluorescent labels at the 3’ and 5’ end of the 
double-labeled ONs could interfere with the splicing activity of exonucleases. Therefore, the 
actual degradation of unlabeled PO-ONs is expected to occur even more rapidly.   
In the case of phosphothioate ONs, intact PS20-ONs could be observed in the nuclei 
of the cells for at least 8 hours (Figure 3). This was no surprise as the more nuclease 
resistant PS20-ONs are not expected to degrade upon their release at the time of endosomal 
escape, thus creating a pool of intact PS20-ONs. This on its turn results in a longer time for 
PS20-ONs to bind to the target mRNA and to inhibit the targeted protein expression, which 
most likely explains why the nuclease resistant PS20-ONs could indeed establish an 
antisense effect. Although PS20-ONs did not degrade in the intracellular environment and 
are therefore not expected to spontaneously diffuse out of the cells, the fluorescence in the 
nuclei disappeared after more than 8 hours. Interestingly, there seemed to be a fluorescence 
shift from the nucleus to the cytoplasm of the cells (Figure 3-12h): the nuclear fluorescence 
faded while fluorescent dots (as seen by confocal imaging) and simultaneous green and red 
fluorescence peaks (as seen by FCS) appeared in the cytoplasm of the cells. The identity of 
the cytoplasmic granules is currently unknown, however, their appearance directly correlates 
with the dissipation of fluorescent PS20-ONs from the nucleus. This phenomenon has been 
observed previously by Fisher et al., who suggested that intracellular PS-ONs could be 
exported from the cells by exocytosis 16. In agreement with Fisher et al. we believe that the 
formation of these cytoplasmic granules, which apparently contain the fluorescent PS20-ONs 
that were previously present in the nucleus, could indicate that the cells display an export 
pathway to remove intact PS20-ONs out of the cells. It should be noted that nuclear bodies 
occurred in the nucleus before the apparent removal of the intact PS20-ONs from the nuclei 
of the cells. Since the formation of nuclear bodies is reported to mainly occur at higher 
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concentrations of PS-ONs 14-16, this could be the first step in exporting intact PS-ONs from 
the nuclei of the cells. Indeed, high PS-ONs concentrations could trigger ordening of PS-ONs 
in nuclear bodies that are then exported via the cytoplasm to the cellular membrane. 
Whether or not the formation of nuclear bodies is correlated with the export of PS-ONs from 
the cells is an important question that remains to be elucidated. 
To our surprise, an increasing amount of fluorescent spots, which most likely 
represent endosomal vesicles, were detected in the cytoplasm of the cells transfected with 
PO40-LPXs at longer incubation times (see Figure 8-8h and 12h). The fluorescent spots 
persisted in the cytoplasm of the cells without the appearance of fluorescent nuclei, which 
indicates that endosomal escape of the LPXs with release of the PO40-ONs in the cytoplasm 
of the cells did not occur. Furthermore, upon increasing the incubation time from 8 till 12 
hours, less (red colored) endosomal vesicles containing intact PO40-ONs were observed 
(compare the amount of intracellular red fluorescent dots in Figure 8B-8h and 
Figure 8B-12h), showing that degradation of the PO40-ONs took place. The question now 
raised is why DOPE appears to be unable to destabilize the endosomal membrane with 
release of the PO40-ONs in the cytoplasm of the cells. We have observed in Chapter 3 that 
PO40-ON containing DOTAP/DOPE liposomes, after being 4 hours in a buffer solution, 
spontaneously start to release their ONs in the surrounding environment, which we attributed 
to the fusion of neighbouring LPXs. It could well be that this lipoplex fusion also occurs in the 
endosomal compartment upon longer incubation times, thereby releasing PO40-ONs in the 
endosomes rather than in the cytoplasm of the cells (Figure 10, step 5). Consequently, the 
released PO40-ONs are entrapped and degraded in the endosomal compartment. In 
conclusion, DOPE is now apparently responsible for the destabilization of the lipids 
originating from the neighbouring LPXs, rather than the destabilization of the lipids originating 
from the endosomal membrane. Apart from LPXs fusion, the increasing amount of green 
fluorescent spots containing degraded PO40-ONs could also reflect the degradation of the 
LPXs by lysosomal enzymes.    
 
Is there Potential in the Delivery of Nuclease Sensitive PO-ONs? 
As described in the introduction, one approach to improve antisense activity of nucleic 
acids is to synthesize ONs with increased nuclease stability so that intracellular degradation 
should not be an issue 4. However, modification of the ON backbone can introduce 
undesirable features such as solubility problems, delivery issues, lack of RNase H activation 
or simply the cost of synthesis 32. Therefore, the development of cationic carriers that can 
efficiently deliver unmodified PO-ONs remains important and challenging. However, as 
observed in this chapter, cationic lipids are mainly useful in the delivery of nuclease resistant 
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ONs such as PS-ONs. Indeed, the efficient delivery of ONs at the time of endosomal escape 
does create a barrier for nuclease sensitive PO-ONs due to the rapid intracellular 
degradation of the naked PO-ONs, while the nuclease resistant PS-ONs remain intact. 
Therefore, carriers that could bring the PO-ONs as close as possible to the target mRNA or 
that allow the PO-ONs to establish an antisense effect while being encapsulated could be 
more suitable to deliver unmodified PO-ONs. One such carrier that could do the trick is the 
cationic polymer polyethyleneimine (PEI). In general it is believed that PEI escapes from the 
endosomes via a proton sponge mechanism 33;34. The buffering capacity of PEI causes 
protons to be pumped in the endosomes, accompanied with an influx of Cl- ions. This builds 
up the osmotic pressure which eventually causes the endosomes to rupture. The ON/PEI 
complexes are thus released in the cytosol of the cells as such, without release of the ONs at 
the step of the endosomal escape. In contrast to liposome/DNA complexes, PEI/DNA 
complexes can enter the nucleus as an associated complex 35. Also, Pollard et al. found that, 
in contrast to cationic lipids, the dissociation of plasmid DNA from PEI was not necessary to 
establish a therapeutic effect 36. This was again observed recently by Honoré et al. 37. In a 
study employing oligonucleotides, Dheur et al. observed that PEI was able to improve the 
antisense activity of nuclease sensitive PO-ONs while cationic lipids were not 8. We also 
observed that PO-ONs complexed with the cationic polymer graft-pDMAEMA (poly(2-
dimethylamino)ethylmethacrylate bearing polyethyleneglycol chains) showed the same 
antisense effect as PS-ONs complexed with graft-pDMAEMA 7. These results support the 
idea that cationic polymers could show more potential as non-viral gene delivery systems for 
unmodified PO-ONs when compared to cationic lipids.  
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ABSTRACT 
 
Liposomal vesicles have been widely investigated as carriers for the intracellular 
delivery of oligonucleotides (ONs). To avoid aspecific uptake by the reticulo endothelial 
system, ‘pegylation’ of the liposomes, by incorporating polyethyleneglycol (PEG) at the 
surface, has been an attractive strategy. While pegylation has a clear benefit on the 
systemic level, one could wonder whether pegylation also benefits the delivery efficacy of 
liposomes at the intracellular level. In this chapter, we followed the intracellular distribution of 
pegylated liposomes, with special attention to the integrity of the ONs they were carrying. 
We found that pegylated liposomes failed in protecting the phosphodiester ONs (PO-ONs) 
they carried, leading to rapid degradation of the PO-ONs in the endosomal compartment. 
Nuclease resistant phosphothioate ONs (PS-ONs) stayed intact in the intracellular 
environment. However, both for PO-ONs and PS-ONs, the PEG-chains at the surface of the 
pegylated liposomes inhibited the endosomal escape of the ONs. These intracellular findings 
explain why pegylated liposomes failed in establishing an antisense effect, both with 
nuclease sensitive PO-ONs and nuclease resistant PS-ONs.  
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Chapter 6 
Intracellular Fate and Biological Activity 
of Antisense Oligonucleotides 
Delivered by Pegylated Liposomes 
 
 
INTRODUCTION 
 
The potential of antisense therapeutics lies in the simple mechanism where one 
needs only to know the sequence of the mRNA of interest to design the appropriate 
complementary oligonucleotide (ON) that can down-regulate the production of the 
corresponding protein. The antisense approach shows clear potential in the treatment of 
cancer and viral infections 1. However, to adequately deliver antisense ONs into cells, the 
search for suitable delivery systems continues. Cationic liposomes are widely investigated as 
antisense ONs carriers. There is currently a fair idea on which parameters are crucial in the 
delivery of ONs by cationic liposomes 2. First, the positive charge on the polar head group of 
the cationic lipids is important for binding the negatively charged ONs. Also, the liposome/ON 
complexes (‘lipoplexes’) ideally exhibit a net positive charge both to prevent their rapid 
aggregation and to promote their binding to the negatively charged cell membranes. Second, 
the features of the alkyl chains play an important role in the organization of the lipoplexes. To 
promote the endosomal escape of the lipoplexes, a cone-like lipid (with a small head group 
and expanding alkyl chains) should be incorporated in the liposomes. Cone-like lipids, such 
as dioleoylphosphatidylethanolamine (DOPE) can adopt a hexagonal phase that disturbs the 
endosomal membrane thereby provoking endosomal escape 3.  
While a net positive charge may enhance cell membrane binding of the lipoplexes, it 
is well known that in vivo positively charged lipoplexes may bind to negatively charged serum 
components. This eventually leads to aggregation of the lipoplexes and opsonization by the 
reticulo endothelial system 4. To overcome the rapid clearance of lipoplexes, 
polyethyleneglycol (PEG) bearing lipids have been incorporated in the liposomes to provide 
the lipoplexes with a PEG-shield at the surface. The so-called ‘stealth’ lipoplexes indeed 
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show a prolonged stability and circulation in the bloodstream 5. Interestingly, our research 
group recently demonstrated that the pegylation of lipoplexes also positively influences their 
behavior in extracellular matrices like vitreous and sputum 6;7. The pegylated lipoplexes 
retained their mobility in the vitreous, while the non-pegylated lipoplexes aggregate and get 
stuck in the collagen fiber network of the vitreous 6. Also upon exposure to Cystic Fibrosis 
sputum the non-pegylated lipoplexes aggregate, which significantly decreases their gene 
transfection activity. On the contrary, pegylated lipoplexes retain their gene transfection 
activity after exposure to Cystic Fibrosis sputum 7.  
Clearly, pegylation ‘guides’ lipoplexes in a more effective way through the 
extracellular compartments of the body. On the contrary, pegylation appears to decrease the 
transfection efficiency of lipoplexes once they go on to the intracellular level. Deshpande et 
al. reported that pegylation lowers the cellular interaction and uptake of the lipoplexes 8. 
Song et al., however, found that the cellular uptake of pegylated lipoplexes was unaltered 
and suggested that the inhibitory effect of pegylation is situated at the step of the endosomal 
escape 9. Also in this chapter, we observed that pegylation lowers the transfection efficiency 
of DOTAP/DOPE liposomes carrying nuclease resistant phosphothioate ONs (PS-ONs) or 
nuclease sensitive phosphodiester ONs (PO-ONs).  
For successful antisense delivery, the carriers should protect the ONs against extra- 
and intracellular nucleases. In Chapter 3, we found that PO-ONs complexed to non-
pegylated liposomes were adequately protected against enzymatic degradation 10. In 
Chapter 5, however, we observed that this protection against enzymatic degradation was not 
translated into a biological effect of the PO-ONs. This was attributed to the fact that the 
PO-ONs were rapidly degraded in the intracellular environment upon release of the non-
pegylated liposomes 11. Also in Chapter 3, we demonstrated that PO-ONs complexed to 
pegylated lipoplexes could still be degraded, demonstrating their accessibility to 
nucleases 10. A major aim of this chapter was to elucidate how pegylation of lipoplexes 
influences their intracellular behavior and biological activity, with the focus on the intracellular 
degradation of the ONs they are carrying. Therefore, A549 cells were transfected with 
pegylated liposomes containing fluorescently double-labeled PO-ONs or PS-ONs and the 
intracellular distribution and degradation of the complexed ONs was followed by means of 
Fluorescence Correlation Spectroscopy (FCS) and confocal imaging.  
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MATERIALS AND METHODS 
 
Materials  
For the ICAM-1 antisense assay a non-labeled 20 mer phosphodiester 
oligonucleotide (PO20-ON; Isis1939: 5’-CCC-CCA-CCA-CTT-CCC-CTC-TC-3’) and its 
phosphothioate analogue (PS20-ON) were used. As a control, a 20 mer phosphothioate ON 
without anti-ICAM-1 activity was used (5’GAG-ACT-TTC-ACT-TTT-CTC-TA 3’). In the FCS 
experiments and confocal imaging a fluorescent 40 mer phosphodiester ON (PO40-ON; 5’-
GCC-GTC-TCT-GAC-TGC-TGA-TGA-CTA-CTA-TCG-TAT-AGT-GCG-G-3’) and the 
fluorescent equivalent of PS20-ON were used. The fluorescent ONs were double-labeled 
with a rhodamine green fluorophore at the 3’ end (λex = 488 nm, λem = 532 nm) and a Cy5 
fluorophore at the 5’ end (λex = 647 nm, λem = 670 nm). All ONs were purchased from 
Eurogentec (Seraing, Belgium) and were PAGE-purified by the supplier.  
The cationic phospholipid DOTAP (N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethyl-
ammoniumchloride), the neutral phospholipid DOPE (dioleoylphosphatidylethanolamine) and 
the pegylated (neutral) phospholipid DSPE-PEG (distearoylphosphatidylethanolamine 
(polyethyleneglycol 2000)) were purchased from Avanti® Polar Lipids (Alabaster, AL, USA). 
Human lung carcinoma cells (A549 cells, ATCC number: CCL-185) (DSMZ, 
Braunschweig, Germany) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
without phenol red (Gibco, Merelbeke, Belgium) containing 2 mM glutamine, 10% heat 
deactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C in a humidified 
atmosphere containing 5% CO2. 
 
Preparation of Liposomes and Lipoplexes 
The pegylated and non-pegylated liposomes were prepared as described in 
Chapter 3. The hydrodynamic size and zeta potential of the pegylated and non-pegylated 
liposomes was routinely checked in 20 mM HEPES buffer (pH 7.4) by respectively dynamic 
light scattering (DLS, Malvern 4700, Malvern, Worcestershire, UK) and surface potential 
measurements (Zetasizer 2000, Malvern, Worcestershire, UK), as previously described 12, 
and equaled 128 ± 6 nm and +18 ± 3 mV for the pegylated liposomes and 126 ± 7 nm and 
+45 ± 4 mV for the non-pegylated liposomes.  
For the preparation of lipoplexes, the ONs (stock solution in water) and the liposomes 
(stock solution in 20 mM HEPES, pH 7.4) were diluted in ‘degradation buffer’ (20 mM 
HEPES, 110 mM potassium acetate and 2 mM magnesium acetate, pH 7.4). The pegylated 
lipoplexes used in the FCS and confocal imaging experiments were prepared by mixing 
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15 µL of the pegylated liposome dispersion (400 µM for complexation with PO40-ONs or 
200 µM for complexation with PS20-ONs) and 15 µL of fluorescently double-labeled 
PO40-ONs or PS20-ONs (2 µM), resulting in a +/- ratio of 5 (being the ratio of the number of 
positive charges, originating from the liposomes, to the number of negative charges, 
originating from the ONs). The resulting dispersion was vortexed for 10 seconds and the 
lipoplexes were allowed to equilibrate for 30 minutes at room temperature prior to use. Then, 
120 µL DMEM was added before transferring the pegylated lipoplex dispersion to A549 cells 
grown to 90% confluency on glass-bottomed cover slips (Part No. PG-1.5-14-F, Glass 
bottom No. 1.5, MatTek Corporation). After 4 hours incubation at 37°C and 5% CO2, the 
cells were washed and incubated further in DMEM containing 2 mM glutamine, 10% heat 
deactivated FBS and 1% penicillin-streptomycin. Confocal imaging and FCS measurements 
were performed 2, 4, 8, 12 and 24 hours after applying the pegylated lipoplex dispersion to 
the A549 cells as described below.  
For the determination of the ICAM-1 antisense activity, pegylated or non-pegylated 
lipoplexes were prepared by mixing 80 µL of the pegylated or non-pegylated liposome 
dispersion (400 µM) and 80 µL of PO20-ONs, PS20-ONs or the control ON (4 µM), resulting 
in a +/- ratio of 5. The resulting dispersion was vortexed for 10 seconds and the lipoplexes 
were allowed to equilibrate for 30 minutes at room temperature prior to use. The antisense 
activity was determined as described in Chapter 5.  
  
Confocal Imaging and Fluorescence Correlation Spectroscopy (FCS) 
Confocal imaging and dual-color FCS experiments were performed on a LSM510 
confocal laser scanning microscope equipped with a Confocor2 module (Carl Zeiss, Jena, 
Germany). The excitation light of the argon-ion laser (488 nm, 30 mW) and/or the helium-
neon laser (633 nm, 5 mW) was reflected by a dichroic mirror (HFT 488/633) and focused 
through a Zeiss C-apochromat 40x, NA 1.2 water immersion objective into the sample. The 
fluorescence emission was re-collected by the same objective and split by another dichroic 
mirror (NFT 635) into the green detector (after passing a 505-550 bandpass filter) or into the 
red detector (after passing a 650 longpass filter). The fluorescence emission was detected 
by photon multipliers in the case of confocal imaging and avalanche photodiodes in the case 
of FCS.  
In dual-color FCS measurements two ultrasensitive avalanche photodiode detectors 
monitor in time (typically for 5-10 seconds) respectively the red and green fluorescence in 
the detection volume of the microscope. The red and green fluorescence fluctuates as the 
dual-labeled molecules (ONs in this thesis) move in and out the detection volume. From these 
fluorescence intensity fluctuations auto-correlation curves can be derived that allow 
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calculating both the amount of fluorescent molecules in the detection volume and their 
diffusion time, being the average time it takes them to diffuse through the excitation volume. 
The dual-color FCS system was calibrated using rhodamine green based on the method of 
Schwille et al. 13.  
To assure that we only analyzed vital cells, propidium iodide as a counterstain for 
dead cells was applied to the transfected cells immediately prior to microscopy. Before 
performing intracellular dual-color FCS measurements, first a confocal image of the cell was 
taken. Subsequently we indicated on the confocal image the locations in the cytoplasm 
and/or the nucleus where dual-color FCS measurements had to be performed. At these 
spots, the green and red fluorescence intensities were recorded with laser excitation set to 
488 nm. From the fluorescence fluctuations, the ratio of the red to green fluorescence (R/G 
ratio) was calculated. The auto-correlation curves as obtained by the FCS instrument were 
not further analyzed.  
 
Detection of Intact and Degraded ONs in A549 Cells 
In the intact fluorescently double-labeled ONs, Fluorescence Resonance Energy 
Transfer (FRET) occurs between rhodamine green (donor fluorophore) and Cy5 (acceptor 
fluorophore) 14. As illustrated in Figure 1, upon excitation at 488 nm laser light, in intact ONs 
the energy is transferred from the rhodamine green to the Cy5 fluorophore. This turns the 
ONs more red fluorescent while they become less green fluorescent. In other words, due to 
FRET the ratio of the red to green fluorescence (R/G ratio) increases and becomes higher 
than 1 in the ONs used in this thesis (see Table 1 in Chapter 5). When the ONs degrade, the 
distance between the both fluorophores increases and FRET no longer occurs (Figure 1). 
Hence, the R/G ratio drops (< 1) (see Table 1 in Chapter 5). To detect whether ONs were 
intact or degraded in the cells, the intracellular green and red fluorescence was determined 
by the detectors of both the FCS setup and the confocal microscope, using 488 nm 
excitation light as described above. 
We showed in Chapter 2 that FRET occurs more efficiently in the double-labeled 
PO40-ONs than in the double-labeled anti-ICAM-1 PO20-ONs 14. Consequently, monitoring 
the intracellular degradation of the PO40-ONs by FRET is more straightforward than 
following the degradation of the PO20-ONs. Therefore, in the intracellular confocal imaging 
and FCS measurements we preferred to make use of pegylated liposomes containing 
double-labeled PO40-ONs in stead of double-labeled PO20-ONs, although the PO40-ONs 
do not have an intracellular target. It should be noted, however, that the intracellular confocal 
imaging and FCS measurements on cells transfected with pegylated liposomes containing 
double-labeled PO20-ONs showed the same results as depicted for the PO40-ONs.  
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Figure 1.  FRET as a tool to detect intact and degraded ONs upon excitation at 488 nm. (D) Rhodamine green, 
donor fluorophore, (A) Cy5, acceptor fluorophore and (R/G) ratio of the red to green fluorescence. In the intact 
ONs, FRET occurs which results in a R/G ratio that is higher than 1. When the ONs degrade, FRET no longer 
occurs and the R/G ratio drops to a value lower than 1. 
 
 
RESULTS  
 
Antisense Activity of PO-ONs and PS-ONs delivered by Pegylated and Non-
Pegylated Liposomes  
Figure 2 shows the antisense activity obtained using anti-ICAM-1 ONs with either a 
nuclease sensitive phosphodiester backbone (PO-ONs) or a nuclease resistant 
phosphothioate backbone (PS-ONs). When naked PO-ONs or PS-ONs were administered to 
the A549 cells, no antisense activity was observed. Indeed, the level of expression of the 
ICAM-1 protein equaled the one in the A549 cells that were treated with the naked control 
ONs. When PO-ONs or PS-ONs were complexed with non-pegylated liposomes, the 
PS-ONs but not the PO-ONs were able to down-regulate the ICAM-1 expression. Indeed, 
with the PS-ONs the ICAM-1 expression was about 45% lower than the one found in A549 
cells treated with non-pegylated liposomes containing the control ONs. On the contrary, 
when PO-ONs or PS-ONs were complexed with pegylated liposomes, neither formulation 
was able to realize a substantial antisense effect: when compared to the ICAM-1 expression 
of A549 cells treated with pegylated liposomes containing the control ONs, the decrease in 
the ICAM-1 expression was less than 20%. 
In Chapter 5, the biological activity of non-pegylated lipoplexes was correlated with 
the intracellular distribution and degradation of the delivered ONs, as studied by FCS and 
confocal imaging. In this chapter, we aimed to elucidate why pegylated liposomes failed in 
establishing an antisense effect, both with nuclease sensitive PO-ONs and nuclease 
resistant PS-ONs.  
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Figure 2.  Antisense activity of (A) naked PO20-ONs, (B) naked PS20-ONs, (C, D) respectively PO20-ONs and 
PS20-ONs complexed to non-pegylated liposomes and (E, F) respectively PO20-ONs and PS20-ONs complexed 
to pegylated liposomes. The antisense activity is depicted as the percentage of ICAM-1 expression when 
compared to A549 cells that were treated with the corresponding formulation containing the control ONs (e.g. 
naked or complexed to non-pegylated or pegylated liposomes) as described in the Materials and Methods 
section. The +/- ratio of the lipoplexes was 5. The antisense activity represents the average of three independent 
experiments.   
 
Intracellular Fate of PO-ONs Delivered by Pegylated Liposomes 
A549 cells were transfected with pegylated liposomes containing double-labeled 
PO40-ONs (PO40-PEG-LPXs). The intracellular green and red fluorescence was studied by 
confocal imaging and the FCS setup, using 488 nm excitation light. In that case, the red 
fluorescence comes from excitation of the Cy5 fluorophores due to FRET. 
 Figure 3A-2h shows that fluorescent nuclei were not observed following the 
transfection of A549 cells with pegylated liposomes. When FCS measurements were 
performed in the nuclei of the cells, the fluorescence intensity equaled the autofluorescence 
of the nuclei (5-10 kHz), confirming the absence of PO40-ONs. Alternatively, mainly green 
fluorescent spots are observed in the cytoplasm of the transfected cells (Figure 3A-2h). 
Intracellular, red fluorescent spots do not appear, demonstrating the absence of FRET and 
thus the degradation of the PO40-ONs. Red fluorescence can, however, be clearly detected 
in the PO40-PEG-LPXs outside the A549 cells, flanking the plasma membrane (Figure 
3B-2h). The discrepancy between the green fluorescence inside and the red fluorescence 
outside the cells can also be clearly seen in the merged image (Figure 3C-2h). From the 
fluorescence measured in the cytoplasm of the transfected cells (which was 10-100 fold 
higher than the autofluorescence of the cells) an average R/G ratio of 0.5 ± 0.1 was 
calculated. This in contrast to the average R/G ratio measured in the PO40-PEG-LPXs 
flanking the plasma membrane, which was 5.6 ± 0.6. Taken together, these observations 
suggest that the PO40-ONs degrade as soon as the pegylated lipoplexes have entered the 
cells.  
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Figure 3.  Green (A), red (B) and merged (C) confocal images of A549 cells respectively 2, 4, 8 and 12 hours 
after transfection with P040-PEG-LPXs. As excitation light of 488 nm was used, the red fluorescence in B comes 
from Cy5 excitation due to FRET. In the transmission images (D) a circle was drawn around the nuclei (as also 
around the non-fluorescent nuclei in A, B and C). 
 
At longer incubation times the intracellular disposition did not change: green 
fluorescence was found in cytoplasmic dots, whereas red fluorescence could only be 
detected in the pegylated lipoplexes outside the cells (Figure 3A, B and C – 4, 8 and 12h). 
Also, free PO40-ONs were never detected in the nuclei of the transfected cells, as the 
fluorescence in the nuclei as detected by FCS never exceeded the autofluorescence of the 
cells. Since the detectors of the FCS instrument are highly sensitive and can even detect 
single molecules, this truly indicates that free PO40-ONs never reached the nuclei of the 
A549 cells. 
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Intracellular Fate of PS-ONs Delivered by Pegylated Liposomes 
Subsequently, A549 cells were transfected with pegylated liposomes containing 
double-labeled PS20-ONs (PS20-PEG-LPXs). As for the PO40-PEG-LPXs, the intracellular 
green and red fluorescence was studied by confocal imaging and the FCS setup, using 488 
nm excitation light (Figure 4). In that case, the red fluorescence comes from excitation of the 
Cy5 fluorophores due to FRET. 
 
 
 
Figure 4.  Green (A), red (B) and merged (C) confocal images of A549 cells respectively 2, 4, 12 and 24 hours 
after transfection with PS20-PEG-LPXs. As excitation light of 488 nm was used, the red fluorescence in B comes 
from Cy5 excitation due to FRET. In the transmission images (D) a circle was drawn around the nuclei (as also 
around the non-fluorescent nuclei in A, B and C).  
 
When the A549 cells were transfected with PS20-PEG-LPXs, again no fluorescence 
was detected in the nuclei of the cells (Figure 4-2h). As for the PO40-ONs, FCS 
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measurements pointed out that the nuclear fluorescence equaled autofluorescence (5 to 10 
kHz), confirming that the PS20-ONs delivered by the pegylated lipoplexes did not reach the 
nuclei of the cells. Instead, the fluorescence was mainly located in punctated structures in 
the cytoplasm of the cells. The amount of intracellular fluorescent vesicles increased when 
increasing the incubation time from 2 to 4 hours, indicating further intracellular uptake of the 
PS20-PEG-LPXs (Figure 4-2h and 4h). In contrast to PO40-ONs delivered by pegylated 
lipoplexes, the red fluorescent dots in Figure 4B and the yellow fluorescent dots in the 
merged image (Figure 4C) suggest that, at all incubation times, FRET occurs and the 
cytoplasmic structures contain intact PS20-ONs. This was confirmed by intracellular FCS 
measurements since the average R/G ratio as measured in the cytoplasm of the cells 
equaled 2.3 ± 0.3 which corresponds to intact PS20-ONs (see Table 1 in Chapter 5). The 
R/G ratio of intact PS-ONs reflects a lower FRET efficiency when compared to intact PO40-
ONs (R/G 5.6 ± 0.6). This explains why the intact PS-ONs also appear in the green confocal 
image, while intact PO40-ONs mainly appear in the red confocal image. This also explains 
why intact PS-ONs appear yellow in the merged confocal image (Figure 4C) while the intact 
PO40-ONs appear bright red in the merged confocal image (Figure 3C). As for the 
PO40-ONs delivered by pegylated lipoplexes, the intracellular distribution of PS20-ONs 
delivered by pegylated lipoplexes did not change upon longer incubation times: green and 
red fluorescence was detected in cytoplasmic structures, whereas free PS20-ONs were not 
detected in the nuclei of the cells, not even 24 hours following the delivery of the PS20-ONs 
using pegylated liposomes.  
 
  
DISCUSSION 
 
A major aim in this chapter was to obtain a better insight in the intracellular path of 
ONs delivered by pegylated liposomes. Therefore, we determined the biological effect of the 
antisense molecules and their intracellular distribution and degradation when delivered by 
pegylated liposomes. To fully comprehend the effect of pegylation, the biological effect and 
the intracellular distribution and degradation of antisense molecules delivered by non-
pegylated liposomes was also studied, as described in Chapter 5.  
     
Explanation of the Biological Activity of Pegylated Lipoplexes Based on their 
Intracellular Fate and Structural Properties  
In contrast to non-pegylated lipoplexes rather few studies, if any, describe the 
mechanism behind the formation of pegylated lipoplexes (PEG-LPXs). In Chapter 3, we 
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proposed a mechanism for the formation of PEG-LPXs in which the ONs are present on the 
outside of the pegylated lipoplexes, rather than on the inside. Based on the architecture of 
the PEG-LPXs we define below the intracellular pathway of pegylated liposomes containing 
PO-ONs or PS-ONs in A549 cells, which explains both their intracellular distribution and 
degradation as observed in Figure 3 and Figure 4 and their biological behavior as observed 
in Figure 2. The transfection pathway we propose for PEG-LPXs is depicted in Figure 5A.  
 
 
 
Figure 5.  Proposed intracellular pathway of (A) pre-pegylated lipoplexes and (B) post-pegylated lipoplexes 
containing nuclease sensitive PO-ONs. (1) binding to the cell membrane, (2) internalization by endocytosis, (3) 
endosomal escape, (3a) nuclear accumulation of intact ONs, (4) degradation in the endosomal compartment, (5) 
de-pegylation in the endosomal compartment, (6) intracellular degradation of ONs and (6a) nuclear accumulation 
of degraded ONs. 
 
As for non-pegylated lipoplexes (LPXs), the PEG-LPXs settle on the cell surface and 
are internalized by endocytosis (Figure 5A, step 1). The term endocytosis covers entry in the 
cell in a number of ways such as clathrin-dependent endocytosis, clathrin-independent 
endocytosis (e.g. non-coated vesicles and caveolae), phagocytosis and macropinocytosis. In 
contrast to LPXs, the endocytic mechanism that is involved in the uptake of the PEG-LPXs is 
not yet demonstrated. It could well be that the reduced charge of the PEG-LPXs influences 
the uptake pathway, however, the influence of charge on the mechanism of endocytosis 
remains to be elucidated. Following endocytosis, the PEG-LPXs are present in the early 
endosomes (Figure 5A, step 2), which can either recycle their cargo to the extracellular 
environment or mature to late endosomes. The late endosomes on their turn deliver their 
cargo to the lysosomes. As for the LPXs, the PEG-LPXs have to escape from the 
endosomal compartment and release their ONs in the cytoplasm of the cells in order to exert 
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an antisense effect. At this stage, however, the PEG-chains prevent close contact between 
the lipids from the PEG-LPXs and the endosomal membrane. Therefore, in contrast to LPXs, 
DOPE is not able to destabilize the endosomal membrane and the ONs are not released into 
the cytosol of the cells, precluding their delivery to the nucleus (Figure 5A, step 3 and 3a). 
Instead, the ONs remain entrapped in the endosomal compartment. As in PEG-LPXs the 
ONs are located at the surface and are thus unprotected against nucleases, the PO-ONs in 
the endosomes become degraded while the nuclease resistant PS-ONs remain intact 
(Figure 5A, step 4). The entrapment of the ONs in the endosomal compartment is in 
agreement with the fact that fluorescent nuclei were not observed in A549 cells transfected 
with PEG-LPXs (Figure 3 and 4) and explains why PEG-LPXs were not able to establish an 
antisense effect, neither with PO-ONs nor with PS-ONs (Figure 2). Furthermore, the 
intracellular degradation of PO-ONs could clearly be seen from the numerous green 
fluorescent dots in the cytoplasm in Figure 3, when compared to the green and red 
fluorescent dots that indicated the presence of intact PS-ONs in the cytoplasm of the cells in 
Figure 4. Since the PO-ONs remained intact in the pegylated lipoplexes outside the cells, 
this demonstrates that degradation only occurred after cellular entry of the PEG-LPXs. Up to 
our knowledge, this is the first time that the endosomal degradation of PO-ONs delivered by 
pegylated liposomes was demonstrated this clearly. Also, the observed intracellular behavior 
of PEG-LPXs agrees well with the mechanism for PEG-LPXs formation as proposed in 
Chapter 3.  
 
Future Strategies in the Pegylation of Liposomes   
The fact that PEG-chains at the surface of the PEG-LPXs prevent endosomal escape 
has been reported before by, among others, Meyer et al., Shi et al. and Song et al. 9;15;16. Up 
to our knowledge, we were the first, however, to demonstrate that the PO-ONs are not 
protected against degradation, even when complexed to the PEG-LPXs. Based on the 
relation between the ‘pre-pegylated’ lipoplex structure and the lack of protection against 
enzymatic degradation, we suggest that the following strategies could be of interest in the 
design of pegylated liposomes for ON delivery and other nucleic acids based therapeutics 
such as siRNA and plasmid DNA.  
First, ‘post-pegylation’ should be considered to avoid degradation of the complexed 
ONs. LPXs should be prepared using non-pegylated liposomes (so that the ONs become 
entrapped between the lipid bilayers) with subsequent pegylation of the preformed LPXs. 
Second, the PEG-chains should be removable in the endosomal compartment in order to 
allow endosomal escape. Guo et al. calculated that lipid mixing could be initialized if the 
amount of PEG-lipid in the LPXs is less than 2.3 ± 0.6 mol% 17. Therefore, lowering the 
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amount of PEG-lipid on the liposomes’ surface could improve the endosomal escape and 
hence the biological activity of the ONs delivered by pegylated liposomes. To be able to 
remove the PEG-chains on the liposomes’ surface two strategies are commonly used. One 
approach makes use of PEG-lipids where a pH sensitive group links the PEG to the lipid. 
The PEG chains are then removed in the endosomal compartment due to acidic-catalyzed 
hydrolysis 18-20. Another approach is the use of exchangeable PEG-lipids such as PEG-
ceramides 21. The rate of PEG-ceramide removal from the LPXs depends on the size of the 
PEG moiety as well as on the acyl chain length. It should be noted that there is a possibility 
that ‘post-pegylation’ with removable PEG-derivates will not significantly improve the 
biological activity of PO-ONs complexed to cationic lipids. Indeed, as for the LPXs and the 
PEG-LPXs, the post-pegylated LPXs are expected to bind to the cell membrane and to be 
internalized by endocytosis (Figure 5B, step 1 and 2). Then, removal of the PEG-chains 
should occur in the endosomal compartment (Figure 5B, step 5). Subsequently, endosomal 
escape is expected to occur with release of the PO-ONs in the cytoplasm of the cells 
(Figure 5B, step 3). As this endosomal escape of the PO-ONs will be most likely followed by 
their rapid intracellular degradation (Figure 5B, step 6), mainly degraded PO-ONs are 
expected to accumulate in the nuclei of the cells (Figure 5B, step 6a). Therefore, it could well 
be that cationic lipids are mainly useful in the delivery of nuclease resistant ONs such as 
PS-ONs. However, the question of ‘pre-pegylation’ versus ‘post-pegylation’ of liposomes is 
also highly relevant towards the delivery of other nucleic acid based therapeutics such as 
siRNA and plasmid DNA. 
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ABSTRACT 
 
Plasmid DNA (pDNA) can occur in the compact supercoiled (SC) form, the relaxed 
open circular (OC) form and the linearized form. In this chapter, we investigated the 
transfection efficiency of SC, OC and linearized pDNA complexed to DOTAP/DOPE 
liposomes in Vero cells. Only DOTAP/DOPE liposomes containing SC pDNA showed protein 
expression while DOTAP/DOPE liposomes loaded with OC or linearized pDNA failed. First 
we wondered whether the better transfection properties of the SC pDNA containing 
lipoplexes could be due to a better transcription of SC pDNA in the nuclei of the cells. 
However, microinjecting naked SC, OC or linearized pDNA in the nuclei of the Vero cells 
revealed that the transcription efficiency was mainly dependent on the intranuclear 
concentration of the pDNA, rather than on the pDNA topology. Upon microinjecting 
comparable concentrations of the pDNA topologies in the cytoplasm, however, the SC 
topology resulted in a significantly higher transfection, especially in cells that underwent cell 
division in the period after injection. It appears that, when compared to OC and linearized 
pDNA, SC pDNA is better suited to reach the nuclei of the cells. When compared to OC 
pDNA, the nearly two times more rapid diffusion of the SC topology could account for these 
observations. For the equally rapidly diffusing linearized pDNA, however, most likely the 
additional susceptibility towards enzymatic degradation by exonucleases explains the 
superior transfection efficiencies of the SC topology.   
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INTRODUCTION 
 
Gene therapy aims to replace defective genes with the scope to enhance the 
production of certain proteins. Efficient gene delivery requires the uptake of the plasmid DNA 
(pDNA) in the target cell, release of the pDNA into the cytoplasm and transport to the 
nucleus where transcription takes place.  
It has been reported that intracellular degradation of the pDNA significantly limits the 
gene transfer efficiency 1. There are only a few studies, however, that deal with the nature 
and the extent of pDNA degradation in the cytosol of the cells. Lechardeur et al. estimated 
the apparent half-life of double-stranded DNA in the cytosol of HeLa cells between 50 and 90 
minutes, while Pollard et al. showed that the delivery of pDNA in COS-7 and A549 cells was 
prevented by Ca2+-sensitive nucleases 2;3. Whether or not the nature of intracellular 
degradation is similar in different cell types is not clear, mainly due to the limited research in 
this area. Intracellular degradation is not the only factor influencing the transfection 
efficiency. Kreiss et al. observed that the transfection efficiency depends on the size of the 
pDNA, making it easier for smaller pDNA copies 4. This hypothesizes that smaller pDNA 
copies may diffuse more efficiently through the cytosol to the perinuclear region and/or more 
efficiently translocate into the nucleus via the pores of the nuclear membrane. Lukacs et al. 
showed that DNA fragments up to 100 bp moved freely in the cytosol of HeLa cells. Upon 
increasing the pDNA size, the mobility started to decrease and the pDNA fragments became 
completely immobile in the case of 2000 bp and more 5. Also, the nuclear membrane is 
reported as a major barrier in pDNA delivery 6;7. In non-dividing cells, nuclear import and 
export takes places via the nuclear pore complexes (NPCs). These NPCs have a cutoff value 
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of about 9 nm for passive diffusion, which can be enlarged to about 30 nm for active 
transport mediated by nuclear localization signals (NLS) 8. The passage of larger pDNA 
fragments through the nuclear pores can be enhanced by the coupling of a NLS signal to the 
pDNA, although the nuclear import remains low 9. The nuclear entry of pDNA is, however, 
greatly enhanced upon cell division, when the nuclear membrane is temporarily 
disassembled 10. Understanding how and to what extent the different intracellular barriers 
limit the transfection efficiency of pDNA is important to determine strategies to enhance the 
gene transfer.   
Most studies employing pDNA for the transfection of cells use supercoiled (SC) 
pDNA. Purified pDNA indeed mainly occurs in the compact SC form. It can, however, be 
converted to open circular (OC) and linearized pDNA by respectively a single- and double-
stranded break in the SC pDNA. Up to our knowledge there is only one study, by Cherng et 
al., that compared the transfection efficiencies of respectively SC, OC and linearized 
pDNA 11. Cherng et al. delivered the different pDNA topologies with the cationic polymer 
pDMAEMA and observed that SC pDNA yielded higher transfection efficiencies than its OC 
or linearized analogue. An explanation for these observations was, however, not given. In 
this chapter, we were interested to evaluate whether SC pDNA also generated better 
transfection efficiencies than its OC or linearized analogue when delivered by cationic 
DOTAP/DOPE liposomes, which is indeed the case. We additionally aimed to understand 
why SC pDNA is the best topology to transfect cells. Therefore, the degradation and diffusion 
of the SC, OC and linearized pDNA was evaluated by respectively gel electrophoresis and 
FCS measurements. Also, the gene expression efficiency was evaluated after microinjecting 
the different pDNA topologies in the nucleus or the cytoplasm of the cells.  
  
 
MATERIALS AND METHODS 
 
Plasmid DNA 
The gWIZTM GFP (green fluorescent protein) encoding plasmid (5799 bp) was 
purchased from Gene Therapy Systems INC. (San Diego, USA). Plasmid DNA was extracted 
from E. coli using the Qiagen plasmid Mega kit (Qiagen Benelux B.V., Venlo, The 
Netherlands). The pDNA concentrations were determined by UV spectrophotometry at 260 
nm. SC pDNA was converted to OC by incubating the SC form for 48 hours at 60°C. To 
convert the SC pDNA to linearized pDNA, the restriction enzyme XmnI, which has 1 
recognition site in a non-encoding region of the gWIZTM GFP plasmid, was used according to 
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the manufacturers instructions (Promega, Madison, USA). The topology (SC, OC or 
linearized) of the pDNA was routinely checked by 1% agarose gel electrophoresis.  
 
Preparation of Liposome/pDNA Complexes 
  SC, OC or linearized pDNA was complexed to cationic DOTAP/DOPE liposomes. 
The cationic phospholipid DOTAP (N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethyl-
ammoniumchloride) and the neutral phospholipid DOPE (dioleoylphosphatidylethanolamine) 
were purchased from Avanti® Polar Lipids (Alabaster, AL, USA). The liposomes contained 
DOTAP and DOPE in a 1:1 molar ratio and were prepared as described in Chapter 3. The 
hydrodynamic size and zeta potential of the resulting cationic liposomes was routinely 
checked by respectively dynamic light scattering (DLS, Malvern 4700, Malvern, 
Worcestershire, UK) and surface potential measurements (Zetasizer 2000, Malvern, 
Worcestershire, UK), as previously described 12, and equaled respectively 126 ± 7 nm and 
+45 ± 4 mV.  
Upon mixing positively charged liposomes with negatively charged pDNA, 
spontaneously liposome/pDNA complexes (lipoplexes) were formed. The lipoplexes were 
prepared by mixing equal volumes of a liposome dispersion (5 mM) and a pDNA solution 
(0.7 µg/µL). The resulting dispersion was vortexed for 10 seconds and the lipoplexes were 
allowed to equilibrate for 30 minutes at room temperature prior to use. The lipoplexes had a 
+/- ratio of 2.5, being the ratio of the number of positive charges (originating from the 
liposomes) to the number of negative charges (originating from the pDNA). Before 
transferring the lipoplexes to the Vero cells, the lipoplex dispersions were 1:100 diluted in 
Dulbecco’s modified Eagle’s medium (DMEM). 
 
Transfection of Vero Cells  
Vero cells (African green monkey kidney cells, ATCC number: CCL-81) were cultured 
in DMEM without phenol red (Gibco, Merelbeke, Belgium) containing 2 mM glutamine, 10% 
heat deactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin (culture medium) 
at 37°C in a humidified atmosphere containing 5% CO2. Prior to transfection, 
2.5 x 104 cells/cm² were seeded in a 24-well plate and incubated until 80% confluency. Then, 
the cells were washed twice with phosphate buffer saline (PBS) (Gibco, Invitrogen, 
Merelbeke, Belgium) and incubated for 4 hours with 500 µL of the above mentioned lipoplex 
dispersion. After 4 hours, the lipoplexes were removed and the cells were washed twice with 
PBS. Consequently the cells were incubated for 24 hours in culture medium to allow the 
production of the GFP. Then, the cells were washed twice with PBS and 100 µL trypsin-
EDTA was added to each well to detach the cells from the surface of the wells. After 10 
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minutes incubation at 37°C, 600 µL PBS was added to each well and the detached cells 
were transferred into disposable acrylic cuvets. On these samples the fluorescence (due to 
GFP expression) was measured using excitation and emission wavelengths of respectively 
470 and 520 nm, with an Aminco Bowman® Series 2 spectrofluorometer (Spectronic 
instruments, NY, USA). As a blanc, 100 µL trypsin-EDTA + 600 µL PBS was used.     
 
Microinjection Experiments 
 Microinjection experiments were performed with a Femtojet® microinjector and an 
Injectman® NI 2 micromanipulator (Eppendorf, Hamburg, Germany) coupled to a LSM510 
confocal laser scanning microscope. Vero cells were grown to 80% confluency on glass-
bottomed cover slips (Part No. PG-1.5-14-F, Glass bottom No. 1.5, MatTek Corporation). 
Injections were performed in the cytoplasm or nucleus of Vero cells, using 0.1, 1, 10 or 
100 µg/mL SC, OC or linearized pDNA in water. Injection solutions were supplemented with 
2 mg/mL 70 kDa TRITC-dextran to identify the site of injection. After respectively 4 and 
24 hours the number of GFP expressing cells was counted and compared to the total 
number of injected cells. For each concentration and topology, about 100 cells were injected 
in the nucleus or in the cytoplasm. GFP and TRITC were detected with a SPOT Insight CCD 
Camera (Diagnostic Instruments) coupled to an epi-fluorescence Eclipse TE300D 
microscope (Nikon, Japan). 
 
Degradation of SC, OC and Linearized pDNA 
 pDNA was degraded by incubating pDNA solutions with different concentrations of 
DNase I (Pulmozyme®, 1 unit/µL, Genentech) or DNase II (bovine spleen, type V, 
E.C. 3.1.22.1, 4.7 units/µL, Sigma-Aldrich). The pDNA solutions (5 µg/mL) were prepared in 
a ‘degradation buffer’ (20 mM HEPES, 110 mM potassium acetate and 2 mM magnesium 
acetate, pH 7.4) or an acidic buffer (40 mM acetic acid and 60 mM potassium acetate, 
pH 4.7) for degradation experiments with respectively DNase I and DNase II. 200 µL aliquots 
of the pDNA solutions were placed in a water bath at 37°C and 2 µL of a chosen enzyme 
dilution was added. After the appropriate incubation time, the pDNA aliquots were placed on 
ice and the DNase I or DNase II enzyme was inhibited by addition of 800 µL freshly prepared 
‘inhibitor solution’ (0.1 M iodoacetate, 50 mM EDTA and 10 mM Tris-HCl, pH 7.5). For 
degradation in cytosolic cell extract, pDNA solutions (5 µg/mL) were mixed with an equal 
volume of cytosolic cell extract. The cytosolic cell extract was prepared as described in 
Chapter 2 13.  
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Agarose Gel Electrophoresis 
 To visualize the degradation of pDNA, the pDNA solutions were loaded onto a 1% 
agarose gel and electrophoresed at 80 V for 45 minutes in TBE buffer (10.8 g/L Tris-base, 
5.5 g/L boric acid and 5.8 g/L EDTA, pH 8). Therefore, 35 µL of the pDNA samples was 
mixed with 5 µL of ‘loading buffer’ (50% sucrose solution in TBE). pDNA was stained after 
the run with ethidium bromide and visualized with UV illumination. The agarose gels were 
further analyzed using ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of Health, 
Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2006).       
 
Fluorescence Correlation Spectroscopy (FCS) 
 The diffusion coefficient of SC, OC and linearized pDNA was determined by 
Fluorescence Correlation Spectroscopy (FCS). Therefore, the different pDNA topologies 
were labeled with Cy5 using the Label IT® CyTM5 labeling kit (Mirus Bio Corporation, 
Madison, USA). To prevent conversion from the SC to OC or linearized forms, the labeling 
reaction was performed overnight at room temperature. The labeled pDNA was purified by 
ethanol precipitation, according to the instructions of the manufacturer.    
To measure the diffusion coefficient by FCS, the fluorescence intensity fluctuations, 
caused by the diffusion of fluorescently labeled molecules through the excitation volume of a 
microscope, are registered. From these fluorescence intensity fluctuations an auto-correlation 
curve can be derived 14. The auto-correlation curves G(τ) were analyzed with the Confocor2 
software to calculate the diffusion time τt, being the average time the fluorescently labeled 
molecules need to migrate through the detection volume of the FCS instrument. The auto-
correlation curves were always analyzed using both a single-species fit (equation 1 in 
Chapter 5) and a dual-species fit (equation 2 in Chapter 5) and the sense analysis was 
retained based on the appearance of the residuals of the fit. From the calculated diffusion 
time τt the diffusion coefficient D was calculated using equation 4 (see Chapter 1). 
 The FCS experiments were performed on a LSM510 confocal laser scanning 
microscope equipped with a Confocor2 module (Carl Zeiss, Jena, Germany) using 1 ng/µL 
Cy5 labeled pDNA solutions. The excitation light of a helium-neon laser (633 nm, 5 mW) was 
reflected by a dichroic mirror (HFT 488/633) and focused through a Zeiss C-apochromat 40x, 
NA 1.2 water immersion objective into the sample. The Cy5 fluorescence emission was 
recollected by the same objective and split by another dichroic mirror (NFT 635) into the red 
detector (after passing a 650 longpass filter). The fluorescence intensity fluctuations were 
typically measured for 5 runs of 10 seconds. The FCS instrument automatically generated 
auto-correlation curves from the registered fluorescence intensity fluctuations. The FCS 
system was calibrated using rhodamine green based on the method of Schwille et al. 15. 
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RESULTS  
 
Transfection Properties of SC, OC and Linearized pDNA Delivered by Cationic 
DOTAP/DOPE Liposomes 
Figure 1 shows the GFP expression in Vero cells treated with lipoplexes containing 
respectively SC, OC and linearized pDNA. Only lipoplexes containing SC pDNA resulted in 
GFP expression. When the lipoplexes contained OC or linearized pDNA, no GFP expression 
was observed. When DNase I was added to the lipoplexes containing SC pDNA the GFP 
expression remained, indicating that the lipoplexes well protected the SC pDNA they carried. 
When naked pDNA was used, no GFP expression was obtained. This was expected as the 
negatively charged pDNA needs a carrier to efficiently gain access to the intracellular 
environment. 
 
 
Figure 1.  Transfection of Vero cells using respectively SC, OC and linearized pDNA. The Vero cells were 
exposed to respectively lipoplexes (black bars), lipoplexes to which DNase I was added (light gray bars) and 
naked pDNA (dark gray bars). The fluorescence is a measure for the expression of the GFP protein. The graph 
insert shows the outcome of agarose gel electrophoresis on the SC, OC and linearized pDNA samples used in 
this chapter. 
 
Nuclear Injection of SC, OC and Linearized pDNA 
 To see whether the nuclear machinery behaves differently with regard to SC, OC and 
linearized pDNA, the different pDNA topologies were injected in the nuclei of cells and the 
percentage of GFP expressing cells was counted, respectively 4 and 24 hours after the 
injection.   
Figure 2A and 2B are two examples of Vero cells, successfully injected in the 
nucleus, that showed GFP expression. When SC or OC pDNA was injected in the nucleus, 
the percentage of GFP expressing cells was independent on the pDNA topology but did 
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depend on the concentration of the injected pDNA (Figure 2C). pDNA concentrations of 100, 
10 and 1 µg/mL yielded GFP expression in about 90% of the injected cells while the 
efficiency dropped to about 40% when only 0.1 µg/mL was used. Linearized pDNA (Figure 
2C) yielded a slightly lower percentage of GFP expressing cells 4 hours after intranuclear 
injection when compared to SC and OC pDNA. However, 24 hours after the injection the 
GFP expression efficiency equaled the efficiency obtained in cells injected with SC or OC 
pDNA. It should be noted that at higher pDNA concentrations the percentage of GFP 
expressing cells remained the same. However, the higher the pDNA concentration the 
brighter the fluorescence of the cells, indicating more GFP expression (data not shown). 
 
 
Figure 2.  (A and B) Microscopy images of GFP expressing Vero cells which were injected in the nucleus with a 
pDNA solution containing TRITC-dextran. The TRITC-image points out the site of injection, while the GFP-image 
points out expression of the pDNA. (C) % of Vero cells expressing GFP respectively 4 and 24 hours after nuclear 
injection of SC, OC or linearized pDNA. The concentrations of the injected pDNA solutions were 0.1 µg/mL (black 
bars), 1 µg/mL (white bars), 10 µg/mL (gray bars) or 100 µg/mL (striped bars). 
 
Cytoplasmic Injection of SC, OC and Linearized pDNA 
To express GFP, pDNA has to translocate from the cytoplasm into the nucleus of the 
cells. To see whether SC, OC and linearized pDNA transfect differently after arrival in the 
cytosol, the pDNA topologies were injected in the cytoplasm of the cells. Respectively 4 and 
24 hours after the injection, the GFP expressing cells were counted (Figure 3). 
When the GFP expression was evaluated 4 hours after the cytoplasmic injection, only 
a few of the cells injected with SC or OC pDNA but not with linearized pDNA expressed GFP 
and only if the highest DNA concentration was used (e.g. 100 µg/mL) (Figure 3C, 4h). This 
indicates that only few pDNA copies entered the nucleus within this time.   
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Figure 3.  (A and B) Microscopy images of GFP expressing Vero cells which were injected in the cytoplasm with 
a pDNA solution containing TRITC-dextran, respectively before (A) and after (B) cell division. The TRITC-image 
points out the site of injection, while the GFP-image points out expression of the pDNA. (C) % of Vero cells 
expressing GFP respectively 4 and 24 hours after cytoplasmic injection of SC, OC or linearized pDNA. After 24 
hours, we discriminated between cells that had not divided (24h/mitosis -) and cells that underwent a cell division 
(24h/mitosis +). The concentrations of the injected pDNA solutions were 0.1 µg/mL (black bars), 1 µg/mL (white 
bars), 10 µg/mL (gray bars) or 100 µg/mL (striped bars).  
 
24 hours after the injection GFP expression was observed in both non-divided (e.g. 
Figure 3A) and divided (e.g. Figure 3B) cells. Importantly, in the non-divided cells SC pDNA 
was the most efficient in reaching the nucleus (Figure 3C, 24h/mitosis -). For all pDNA 
topologies, at all concentrations used, a higher number of cells expressed GFP if the cells 
divided in the 24 hours following the injection (Figure 3C, 24h/mitosis +). Like in non-divided 
cells, in divided cells SC pDNA resulted in the highest percentage of GFP expressing cells, 
followed by OC and linearized pDNA. Importantly, cytoplasmic injection of 100 µg/mL SC 
pDNA solution resulted in GFP expression in 90% of the divided cells, thus reaching the level 
as observed upon nuclear injection (Figure 2C). With OC and linearized pDNA, this high 
transfection efficiency was not observed. It should be emphasized that the higher GFP 
expression by cytosolic SC pDNA delivered by microinjection is in line with the superior 
transfection properties of SC DNA delivered by lipoplexes as observed in Figure 1. 
 
Degradation of SC pDNA in Cytoplasmic Vero Cell Lysate 
 To understand why DOTAP/DOPE lipoplexes containing SC pDNA transfect better 
than the ones containing OC or linearized pDNA, it is important to know if after release from 
the cationic liposomes in the cytosol SC pDNA remains supercoiled for a sufficiently long 
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time. Indeed, if SC pDNA would be rapidly converted into OC or linearized pDNA, the SC 
topology itself could not explain the difference in GFP expression by lipoplexes containing 
respectively SC, OC and linearized pDNA. SC pDNA can be converted into OC and/or 
linearized pDNA, depending on the cut profile of the nucleases predominantly present in the 
cytoplasm of Vero cells. Nucleases which break single-strands will convert SC to OC pDNA 
while nucleases which break double-strands will convert SC to linearized pDNA.  
 Figure 4 shows the degradation profile of SC pDNA upon addition of respectively 
DNase I, DNase II and cytoplasmic Vero cell lysate. DNase I is known to cut only one strand 
of the double-stranded DNA at a time, thus converting SC pDNA to OC pDNA 16. Successive 
single-stranded breaks in the OC pDNA eventually results in the formation of linearized 
pDNA as can be clearly followed in Figure 4A. On the contrary, DNase II simultaneously cuts 
both strands of the double-stranded DNA 17;18. This results in the conversion of SC pDNA into 
linearized pDNA, without the OC intermediate as can be seen in Figure 4B. Figure 4C shows 
the degradation of SC pDNA in cytoplasmic Vero cell lysate. We observed that the SC pDNA 
slowly disappears, accompanied by an increase in the amount of OC pDNA. This allows to 
conclude that the nucleases in the cytoplasm of Vero cells predominantly exhibit a 
DNase I-like cut mechanism, resulting in single-stranded breaks in the pDNA. Therefore, 
upon degradation in the cytoplasm of Vero cells, SC pDNA will initially be converted into the 
OC topology.  
 
 
 
Figure 4.  Degradation profiles of SC pDNA upon addition of (A) 0.02 Units DNase I, (B) 0.05 Units DNase II or 
(C) cytoplasmic Vero cell lysate. The % SC (black bars), OC (gray bars) or linearized (striped bars) pDNA was 
determined from the agarose gel using Image J. 
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Degradation of SC pDNA by DNase I  
Figure 4A shows that SC pDNA converts into OC pDNA within the first two minutes 
under the influence of 0.02 Units of DNase I. Since the nucleases in the cytoplasmic Vero 
cell lysate exhibit a DNase I-like cut mechanism, we were interested to follow the turnover of 
SC pDNA into the OC topology at a DNase I concentration lower than in Figure 4A. When 
2 x 10-4 Units DNase I were used, SC pDNA remained detectable on the agarose gel for 15 
minutes after addition of the DNase I enzyme (Figure 5A, black bars). Also, SC pDNA clearly 
converted into OC pDNA (Figure 5A, gray bars). When 1x 10-3 Units DNase I were used, the 
SC pDNA was already degraded within the first two minutes (Figure 5B, black bars). Upon 
longer incubation times, the OC pDNA was further degraded into linearized pDNA, a 
phenomenon that could only be detected using the higher DNase I concentration (Figure 5B, 
striped bars). Comparing Figure 5 and Figure 4C, we can conclude that the DNase I-like 
nuclease activity in the cytoplasm of Vero cells is rather moderate. Indeed, although a 
substantial part of the SC pDNA molecules have been converted into the OC topology after 1 
hour, a significant number of SC pDNA molecules remain to exist in the cytoplasmic Vero cell 
lysate.  
 
 
Figure 5.  Degradation of SC pDNA using (A) 2 x 10-4 and (B) 1 x 10-3 Units DNase I. The % of SC (black bars), 
OC (gray bars) and linearized (striped bars) pDNA was calculated from the agarose gel using Image J. 
 
Size of SC, OC and Linearized pDNA 
 Besides degradation, also the size of the pDNA may influence the amount of intact 
pDNA that reaches the cell nucleus. Using the Stokes-Einstein equation, the size of the 
different pDNA topologies was determined from their diffusion coefficient as measured in 
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buffer by FCS. Figure 6 shows the auto-correlation curves. They were best fitted with a 
dual-species fit, which indicates that the Cy5 labeled pDNA solutions contained two 
populations with a distinct diffusion coefficient, namely slowly diffusing Cy5 labeled pDNA 
molecules and rapidly diffusing remaining free Cy5 fluorophores. SC and linearized pDNA 
had a similar diffusion coefficient of respectively 1.91 ± 0.06 x 10-12 m²/s and 
1.86 ± 0.04 x 10-12 m²/s (the black and green auto-correlation curves in Figure 6A almost 
completely overlap), while OC pDNA diffused about 1.8 times slower with a diffusion 
coefficient of 1.05 ± 0.02 x 10-12 m²/s (the red auto-correlation curve in Figure 6A declines 
more slowly). The slower diffusion of OC pDNA indicates a larger hydrodynamic radius as 
calculated from the Stokes-Einstein equation, namely 207 ± 4 nm when compared to 
114 ± 4 nm and 117 ± 3 nm for respectively SC and linearized pDNA. 
 
 
 
Figure 6.  (A) Auto-correlation curves and dual-species fit as obtained from FCS measurements on Cy5-labeled 
SC (black), OC (red) or linearized (green) pDNA. Representative fluorescence fluctuations are shown in (B). (C) 
and (D) show the residuals of the fit after fitting the auto-correlation data of OC pDNA with respectively a 
single-species fit (C) and a dual-species fit (D). The residuals of the fit for SC or linearized pDNA were similar as 
for OC pDNA and show that the data were best fitted with a dual-species fit. 
 
 
DISCUSSION 
 
Plasmid DNA can occur in the compact supercoiled (SC) form, the relaxed open 
circular (OC) form and a linearized form. Although all three pDNA topologies have the same 
primary structure, we observed that SC pDNA complexed to cationic DOTAP/DOPE 
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liposomes yields significantly higher transfection than its OC or linearized analogue. Also 
Cherng et al. has observed that SC pDNA results in better transfection than OC or linearized 
pDNA upon delivery of the pDNA using the cationic polymer pDMAEMA 11. Understanding 
why cationic liposomes with SC pDNA transfect better may help us in further improving the 
outcome of (non-viral) pDNA therapies. 
One hypothesis to explain the better transfection properties of SC pDNA containing 
lipoplexes could be that SC pDNA is more efficiently transcribed than OC and linearized 
pDNA. However, upon injection of the different pDNA topologies in the nuclei of Vero cells 
we found that the concentration of the pDNA rather than the pDNA topology determined the 
level of GFP expression (Figure 2C). Indeed, the nuclear microinjection experiments showed 
that there is no substantial difference in transfection efficiency of SC, OC and linearized 
pDNA at comparable intranuclear concentrations, especially at longer incubation times. The 
reason for the lower level of GFP expression by lipoplexes containing OC and linearized 
pDNA should thus be found outside the cell nuclei, namely in the cytoplasmic barriers that 
prevent OC and linearized pDNA, and to a lesser extent SC pDNA, to reach and enter the 
cell nucleus in an intact way.  
The amount of pDNA that reaches the cells nucleus is influenced by the amount of 
pDNA that is present in the cytoplasm of the cells. Indeed, Figure 3C shows that for all the 
pDNA topologies, the amount of GFP expressing cells increases upon microinjection of 
higher concentrations of pDNA in the cytoplasm of the cells. The higher expression by SC 
pDNA containing lipoplexes, compared to the ones containing OC or linearized pDNA 
(Figure 1), could be due to a higher cytosolic concentration of pDNA when SC pDNA 
lipoplexes are used. This on its turn could result from a higher intracellular uptake of the 
SC/lipoplexes and/or a better release of the SC topology from the lipoplexes in the cytoplasm 
of the cells. However, even at comparable intracellular concentrations, naked SC pDNA 
appears to be more efficient in reaching the nuclear machinery from the cytoplasmic 
compartment when compared to naked OC and linearized pDNA (Figure 3C). Indeed, 
microinjecting the same concentration of SC, OC and linearized pDNA in the cytosol of the 
Vero cells yields higher transfection efficiencies when SC pDNA is used, both in non-divided 
and divided cells. This indicates that not only the intracellular concentration upon delivery, 
but also the topology of the pDNA in the cytosol influences the gene expression efficiency. 
The fact that SC pDNA, present in the cytosol, shows better transfection may result from (a) 
a better stability of SC pDNA in the cytoplasm of the cells, (b) a faster diffusion of SC pDNA 
towards the nuclei of the cells and/or (c) a more efficient entry into the nuclei of the cells.  
Up to our knowledge, the turnover of SC, OC and linearized pDNA into 
‘non-transfecting’ degradation products is not well documented. In other words, it is unclear 
whether, when SC pDNA is used, biologically active DNA remains present in the cytosol for a 
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significant long time. We observed that the nucleases in the cytosolic cell extract of Vero 
cells predominantly degrade SC pDNA into the OC topology, thus revealing a 
single-stranded cut mechanism. It should be emphasized that one single-stranded cut is 
sufficient to relax SC pDNA to OC pDNA, while OC pDNA needs successive single-stranded 
breaks to be converted into linearized pDNA. For example, Figure 5B shows that in buffer 
with 1 x 10-3 Units DNase I it takes only 2 minutes for SC pDNA to be converted into the OC 
topology, while it takes a significantly longer time for OC pDNA to further degrade into 
linearized pDNA. From this point of view, SC pDNA has a shorter half-life (when defined as 
keeping its topology) when compared to OC pDNA. It is, however, important to note that 
while the presence of the SC topology guarantees transcriptionally active pDNA molecules, 
the OC topology does not necessarily imply that the pDNA remained transcriptionally active. 
Successive single-stranded breaks in the OC pDNA sequence could indeed affect the 
transcription efficiency without affecting the pDNA topology. Unfortunately, at the moment it 
is unclear how many single-stranded cuts the OC pDNA can bear before it becomes 
transcriptionally inactive.  
Lechardeur et al. estimated the apparent half-life of SC pDNA between 50 and 90 
minutes 2. This is well in agreement with the disappearance of SC pDNA in the presence of 
cytoplasmic Vero cell lysate as observed from agarose gel electrophoresis in Figure 4C. The 
SC pDNA molecules (which need only a single nuclease attack to convert to OC) remained 
detectable on the agarose gel for a substantial time, thus indicating only a moderate 
nuclease activity in the cytoplasm of the Vero cells. As SC pDNA molecules are not 
immediately degraded in the cytoplasm of Vero cells, we hypothesize that the better 
transfection efficiency of SC pDNA (when compared to OC and linearized pDNA) may be 
related to a faster diffusion of SC pDNA towards the nuclei of the cells and/or a more efficient 
entry into the nuclei of the cells during the time SC pDNA molecules remain present in the 
cytoplasm of the Vero cells.  
It has been shown that higher transfection efficiencies are achieved with smaller 
pDNA molecules 4;19, which was attributed to a better diffusion through the cytoplasm of the 
cells or an enhanced uptake through the nuclear pore complexes. One could suggest that 
the more compact SC pDNA could more easily pass the pores in the nuclear membrane. 
From diffusion measurements, however, we calculated a hydrodynamic radius of about 
210 nm for the OC pDNA and about 115 nm for the SC and linearized topologies. When 
compared to the maximal size of the nuclear pore complexes, which is about 30 nm in the 
case of active transport, it seems rather unlikely that either one of the pDNA topologies used 
in this chapter could make it through the nuclear pore complexes. There are, however, 
several studies which demonstrate that larger DNA fragments (> 2000 bp) can make it 
through the nuclear pore complexes 20-22. The effect of the pDNA topology on the 
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translocation of the pDNA molecules has not been reported before. We observed that SC 
pDNA is apparently more efficient in passing the nuclear pore complexes than OC or 
linearized pDNA, since SC pDNA and to a lesser extent OC and linearized pDNA generated 
GFP expression in at least some of the non-divided cells injected in the cytoplasm (Figure 3C 
(4h and 24h, mitosis -)).  
An important observation was that the transfection efficiency significantly increased 
upon cell division of the cells injected in the cytoplasm (Figure 3C), a phenomenon which has 
been reported before 6;23. During cell division, the nuclear membrane of a parent cell is 
temporarily broken down and restored in the two daughter cells. This gives the pDNA in the 
parent cell the opportunity to be enclosed in the nuclear environment of the two daughter 
cells without the need to pass the nuclear pore complexes. Nuclear injections pointed out 
that the level of GFP expression is dependent on the amount of pDNA in the nucleus rather 
than on the pDNA topology. Also, Figure 3C (24h/mitosis +) pointed out that following 
microinjection in the cytosol, SC pDNA is the most efficient in generating GFP expression. 
Together, these observations indicate that a higher amount of intact SC pDNA molecules is 
able to enter the nucleus upon cell division, when compared to OC and linearized pDNA. In 
our opinion this indicates that more SC pDNA was present around the nucleus at the time of 
cell division, what on its turn suggests that SC pDNA more easily makes its way to the 
perinuclear region, when compared to the OC or linearized pDNA topology.   
The actin cytoskeleton, which has an estimated mesh size of about 100-150 nm, is 
suggested as the principle determinant of size-dependent DNA mobility 24. It has indeed been 
shown that larger DNA fragments (> 2000 basepares) are largely immobile in the cytoplasm 
of cells 5. The calculated hydrodynamic radius of OC pDNA used in this chapter was about 
210 nm, thus possibly larger than the mesh size of the actin cytoskeleton. In the case of OC 
pDNA, the lower amount of GFP expressing cells upon cell division could result from an 
obstructed diffusion of the OC pDNA towards the perinuclear region. SC and linearized 
pDNA (~ 115 nm) should be equally able to diffuse to the perinuclear region. The stretched 
linearized pDNA may, however, become more entangled in the actin network slowing down 
its movement. Also, linearized pDNA is additionally accessible to exonucleases. Both factors 
could explain why linearized pDNA, when compared to SC pDNA, results in a lower 
transfection upon cytoplasmic injections (Figure 3C). 
Passive diffusion of pDNA molecules through the actin cytoskeleton may not be the 
only way to reach the perinuclear region. A recent study by Vaughan et al. has suggested 
that the diffusion of pDNA through the cytoplasm is mediated by microtubules, with the 
involvement of dynein as motor protein 25. Possibly, SC pDNA makes better use of this 
transport pathway due to a better diffusion towards the microtubules and/or an increased 
binding to the microtubules. Also, Salman et al. demonstrated that nuclear localization signal 
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(NLS) peptides improve the transport of the NLS-containing cargo to the nucleus by dynein-
dependent motion along microtubules 26. This, in our opinion, demonstrates the importance 
of the microtubules in the transfection process, since higher transfection by NLS-coupled 
pDNA 9;27;28 could actually result from an increased pDNA concentration in the perinuclear 
region due to this NLS-mediated transport along the microtubules.  
When non-viral gene delivery systems are used to deliver plasmid DNA to the 
intracellular environment, it is clear that the time and place of release of the pDNA will play 
an important role in generating a therapeutic outcome. Ideally, the delivery system should 
release the pDNA close to the nuclear membrane. Since the translocation of the pDNA to the 
cell nucleus is greatly enhanced upon cell division, the time between release of the pDNA 
and cell division should be as short as possible to avoid degradation of the pDNA in the 
waiting period. Therefore, delivery systems where the release of pDNA is triggered by cell 
division could greatly enhance the transfection efficiency. Another approach could be to 
develop delivery systems that become entrapped in the cell nucleus during cell division and 
release their pDNA directly in the cell nucleus afterwards. Recently, our laboratory developed 
nanogels that show potential for that purpose 29. The biodegradable dextran-based nanogels 
are designed to slowly degrade in the intracellular environment, thereby releasing their 
cargo. Ideally, the degradation properties of the nanogels should be such that not yet 
degraded nanogels become entrapped in the cell nucleus during cell division, followed by 
degradation of the nanogels and release of the pDNA directly in the cell nucleus. Whether or 
not such non-viral pDNA carriers will significantly improve the transfection remains to be 
elucidated. 
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Several disorders originate from the presence or absence of specific proteins. In 
antisense therapy, short oligonucleotides (ONs) with a sequence complementary to the 
target mRNA are administered with the aim to inhibit the production of disease-causing 
proteins. In this way for example viral infections and cancer can be treated by the inhibition of 
vital proteins in the viral reproduction process or specific oncogenes respectively. Gene 
therapy aims to induce protein production by the administration of plasmid DNA (pDNA) that 
encodes the desired protein. This finds its application in DNA vaccinations or the treatment of 
genetic disorders such as Cystic Fibrosis. For gene therapy to be successful, the nucleic 
acids should reach the cytoplasm (in the case of ONs) or the nucleus (in the case of pDNA) 
of the target cells. Also, the nucleic acids should remain intact as their sequence is 
necessary to maintain their biological activity.   
The broad application of antisense and gene therapy is mainly limited by delivery 
problems of the nucleic acids. Indeed, naked nucleic acids are prone to degradation, poorly 
taken up by the target cells or do not reach their target cells at all. Several viral and non-viral 
vectors are under investigation for the advanced delivery of nucleic acids. Viral vectors 
provide high transfection efficiencies but can possibly evoke severe immune responses. 
Non-viral vectors are less expensive, easier and safer to make, but suffer from the limited 
current transfection efficiencies. As described in Chapter 1, non-viral carriers aim to help the 
nucleic acids to enter their target cells, escape from the endosomal compartment and reach 
the cytoplasm or the nucleus of the cells. Also, they should protect the nucleic acids against 
enzymatic degradation during the different steps of the delivery process. In this thesis, we 
especially focused on the latter barrier: we aimed to elucidate the role of the intracellular 
degradation of the nucleic acids in limiting their therapeutic effect.  
There are only limited methods that allow to follow the on site degradation of nucleic 
acids in living cells. In Chapter 2, we evaluated the use of an advanced light microscopy 
technique, namely Fluorescence Correlation Spectroscopy (FCS), for that purpose. FCS 
makes use of very sensitive avalanche photodiode detectors to determine the amount of 
fluorescently (e.g. green or red) labeled molecules in a small confocal volume and their 
diffusion characteristics. In ‘dual-color’ Fluorescence Cross-Correlation Spectroscopy 
(FCCS), also the amount of fluorescently double-labeled molecules (e.g. green and red) can 
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be determined. We aimed to apply FCCS to follow the degradation of fluorescently double-
labeled ONs by a decrease in the amount of double-labeled molecules when degradation 
takes place. Also, the shorter degradation products were expected to move more rapidly 
through the detection volume of the FCS instrument. 20 mer and 40 mer phosphodiester 
ONs (PO20-ONs or PO40-ONs) and 20 mer phosphothioate ONs (PS20-ONs) were double-
labeled with a rhodamine green fluorophore at the 3’ end and a Cy5 fluorophore at the 5’ 
end. The degradation of the ONs was followed in buffer after the addition of DNase I, 
DNase II and cytosolic cell extract, or after microinjecting the ONs in the cytoplasm of living 
cells. Rather surprisingly, dual-color FCCS was not able to accurately determine the amount 
of double-labeled ONs in the solution. From the fluorescence fluctuation profiles as 
registered by the FCS instrument, it could be concluded that Fluorescence Resonance 
Energy Transfer (FRET) occurred between the rhodamine green and the Cy5 fluorophores. 
Upon excitation of the rhodamine green, donor fluorophore, part of the excitation energy is 
transferred to the Cy5, acceptor fluorophore. This results in a decrease of the rhodamine 
green fluorescence and an increase in the Cy5 fluorescence when compared to the situation 
in which FRET does not occur. An important condition for proper FCCS measurements is 
that the fluorescence of one fluorophore is not influenced by the presence or absence of the 
other fluorophore. In the case of FRET, however, this condition is not fulfilled explaining why 
FRET between the both fluorophores disturbed the applicability of dual-color FCCS to 
monitor the time-dependent degradation of the double-labeled ONs.  
The occurrence of FRET seemed, however, useful to determine the integrity of the 
double-labeled ONs in a different way. An important condition for FRET is the close proximity 
of the rhodamine green, donor fluorophore and the Cy5, acceptor fluorophore, as occurs in 
the intact ONs. When the ONs are degraded, this condition is no longer fulfilled. The 
degradation of the ONs and thus the disappearance of FRET could be easily followed by 
monitoring the ratio of the red, donor fluorescence to the green, acceptor fluorescence (R/G 
ratio) upon excitation of the rhodamine green fluorophore. The ultrasensitive detectors of the 
FCS instrument proved to be very accurate in measuring the green and red fluorescence 
intensities, both in buffer and in living cells. Furthermore, FCS allows monitoring the 
fluorescence intensities originating from a single molecule. Therefore, the R/G ratio can also 
be determined in these situations where the concentration of the fluorescent molecules is too 
low to be detected by conventional fluorescence microscopy, as could occur upon the 
intracellular delivery of the double-labeled ONs by non-viral gene delivery systems.  
In a next step, FCS was applied to study the protection against enzymatic 
degradation of the double-labeled ONs upon complexation with non-viral carriers such as 
cationic liposomes and cationic polymers. Upon mixing these cationic carriers with the 
negatively charged ONs, spontaneously interpolyelectrolyte complexes are formed due to 
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electrostatic interactions. These complexes are aimed at increasing the uptake and delivery 
of the ONs in the target cells. Furthermore, the complexed ONs should be protected against 
enzymatic degradation during the different steps of the delivery process. In Chapter 3, 
double-labeled PO40-ONs were complexed with respectively non-pegylated and pegylated 
cationic liposomes and their protection against enzymatic degradation was followed by 
means of the R/G ratio as determined by FCS. Pegylation by the coupling of 
polyethyleneglycol (PEG) at the surface of the liposomes is a frequently used strategy to 
improve the extracellular behavior of DNA/liposome complexes (lipoplexes). Pegylation of 
lipoplexes prevents their aggregation and subsequent opsonization by the reticulo 
endothelial system thereby preventing their clearance from the bloodstream. Pegylation, 
however, appears to decrease the efficiency of lipoplexes at the intracellular level. In 
Chapter 3 we found that pegylation also influences the protection against enzymatic 
degradation that non-pegylated and pegylated lipoplexes offer to the ONs they are carrying. 
Non-pegylated lipoplexes initially adequately protected the complexed ONs against 
enzymatic degradation. This agrees with the mechanism of lipoplex formation as can be 
found in literature. In a first step, negatively charged ONs bind to the surface of the cationic 
liposomes. This triggers fusion of different liposomes, resulting in the formation of 
multilamellar particles in which the ONs are entrapped between the lipid bilayers from the 
individual liposomes (see Chapter 3, Figure 11A). The ONs are thus shielded from the 
environment in which the nucleases are present. However, the protection of the ONs against 
enzymatic degradation decreased as a function of the incubation time (a few hours) of the 
lipoplexes. From the fluorescence fluctuation profiles, as registered by the FCS instrument, it 
became obvious that non-pegylated lipoplexes aggregate during prolonged incubation times, 
accompanied by the gradual release of the ONs as a function of time (see Chapter 3, Figure 
8). Therefore, it could be concluded that not the complexed ONs, but the slowly released 
ONs became accessible to degradation by nucleases.     
When pegylated liposomes were used to complex the ONs, initially, a substantial 
fraction of the ONs became degraded immediately upon exposure of the pegylated 
lipoplexes to nucleases. This points out that, in contrast to non-pegylated liposomes, the 
ONs were still accessible to nucleases when complexed to pegylated liposomes. In literature, 
almost no information is available regarding the mechanism behind the formation of 
pegylated lipoplexes. Based on experimental evidence, we proposed a mechanism for 
pegylated lipoplex formation that can account for the observed degradation of the complexed 
ONs (see Chapter 3, Figure 11B). As occurs in the formation of non-pegylated lipoplexes, the 
anionic ONs are expected to bind to the cationic surface of the pegylated liposomes due to 
electrostatic interactions. The PEG-chains at the surface, however, most likely prevent the 
fusion of different pegylated liposomes and thus the encapsulation of the ONs between 
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successive lipid-bilayers originating from the individual pegylated liposomes. Therefore, the 
ONs remain unprotected at the surface of the pegylated liposomes, still accessible to 
nucleases in the surrounding environment. 
Cationic polymers form another class of widely studied non-viral gene delivery 
systems. Polyethyleneimine (PEI) is such a cationic polymer that is considered as a 
promising candidate for antisense delivery. Pegylation of PEI is an attractive strategy to 
improve the solubility of the PEI/DNA complexes (polyplexes), decrease their cytotoxicity and 
to prevent their aggregation and clearance from the bloodstream. In Chapter 4 we evaluated 
whether pegylation of PEI influenced the protection of ONs against enzymatic degradation as 
offered by the PEI polymers. Therefore, double-labeled PO40-ONs were complexed to 
respectively PEI and polyethyleneglycol-polyethyleneimine (PEG-PEI) polymers and their 
protection against enzymatic degradation was followed by means of the R/G ratio as 
determined by FCS. Both PEI and PEG-PEI initially adequately protected the complexed 
ONs against enzymatic degradation as more than 70% of the ONs remained intact upon 
exposing the polyplexes to nucleases. This protection was maintained in the PEI polyplexes 
during the 30 hours incubation time. In PEG-PEI polyplexes, however, eventually up to 70% 
of the complexed ONs became degraded during the 30 hours incubation time. As was 
observed for the cationic lipid-based carriers in Chapter 3, pegylation thus also seemed to 
decrease the protection efficiency of the cationic polymer-based carriers that were studied in 
Chapter 4. Again an explanation could be found in the proposed mechanism of complex 
formation between the ONs and the pegylated and non-pegylated PEI polymers. The 
polyplexes essentially consist of a core containing multiple ONs and multiple polymer chains, 
held together by electrostatic interactions. In the case of PEG-PEI, this core is additionally 
surrounded by a shield of PEG-chains. It seems that both for PEI and PEG-PEI, a fraction of 
the complexed ONs is situated at the edge of the polyplexes’ core, as could be deduced from 
the initial degradation of the ONs upon exposing the polyplexes to nucleases. In the case of 
PEG-PEI, however, more ONs seem to become accessible to nucleases as a function of the 
incubation time. It can be expected that the electrostatic interactions which keep the ONs 
and the polymer-chains together are constantly broken and reformed, resulting in a 
continuous reorganization of the polyplexes’ core. During this process, ONs from the inner 
part of the core can supposedly relocate to the edge of the polyplexes’ core, where they can 
interact with nucleases in the surrounding environment. From the fluorescence fluctuation 
profiles, as registered by the FCS instrument, it could be concluded that the ONs are bound 
less tightly by the PEG-PEI polymers, when compared to the PEI polymers. As the 
electrostatic interactions between the ONs and the PEG-PEI polymers seem to be more 
easily disturbed, this could indicate that the reorganization of the PEG-PEI polyplexes is 
more pronounced when compared to the PEI polyplexes, leading to more frequent occasions 
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for the ONs to relocate to the edge of the PEG-PEI polyplexes’ core, where they 
subsequently become the subject of enzymatic degradation.       
 Chapter 3 and Chapter 4 pointed out that FCS is a valuable tool to study the 
protection of ONs against enzymatic degradation, both with lipid-based and polymer-based 
gene delivery systems. Some caution was needed, however, in the interpretation of the R/G 
ratio derived from the complexed ONs. Upon complexation, multimolecular complexes are 
formed by the association of different double-labeled ONs and different non-labeled cationic 
lipids or polymers in the lipoplexes and polyplexes, respectively. Due to the compaction of 
the ONs, FRET may not only occur between both fluorophores of an individual ON, but 
possibly also between fluorophores originating from different neighbouring ONs in the 
complexes. In this case, however, the R/G ratio is not representative for the amount of intact 
ONs in the complexes as FRET may also occur when the neighbouring ONs are degraded. 
Another phenomenon that may occur, is the quenching of the rhodamine green and Cy5 
fluorescence upon compaction of the ONs, as was seen for the PEI and PEG-PEI polyplexes 
(see Chapter 4, Figure 4). The nearly complete disappearance of the green and red 
fluorescence in the polyplexes made the R/G ratio meaningless as a measure for the amount 
of intact complexed ONs. Both for the lipid-based and polymer-based gene delivery systems 
as studied in this thesis, the R/G ratio of the complexed ONs was thus no longer correlated 
with their integrity. When the ONs were displaced from the lipoplexes and polyplexes by the 
addition of respectively sodiumdodecylsulfate (SDS) and dextran sulfate, however, the 
correlation between the R/G ratio and the ONs’ integrity was restored. Therefore, the ONs 
were always released from the complexes (after a certain incubation time and inhibition of 
the nucleases) before interpretation of the R/G ratio.   
An important question in this thesis was to what extent the degradation of the DNA 
molecules, delivered by non-viral carriers, was responsible for limiting their biological effect. 
In Chapter 5 we determined the biological activity of ONs with a nuclease sensitive 
phosphodiester backbone (PO-ONs) or a nuclease resistant phosphothioate backbone 
(PS-ONs) upon delivery with non-pegylated liposomes. We found that the liposomes failed in 
generating an antisense effect with PO-ONs, while they succeeded with the chemically 
modified PS-ONs. The protection of the PO-ONs against enzymatic degradation in the non-
pegylated lipoplexes as observed in Chapter 3, did thus not translate into a biological effect 
of the PO-ONs. In order to explain these observations, double-labeled PO-ONs and PS-ONs 
were complexed to non-pegylated liposomes and their intracellular distribution and 
degradation was followed by means of FCS and confocal imaging. Lipoplexes were 
efficiently taken up by the cells by endocytosis. Consequently, the lipoplexes were present in 
endosomal vesicles, from which they should escape in order to prevent their degradation in 
the lysosomal compartment. Also, the complexed ONs should be released in the cytoplasm 
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of the cells to allow them to execute their antisense effect. Confocal imaging demonstrated 
that the endosomal escape of the lipoplexes was accompanied by the efficient release of 
both the PO-ONs and the PS-ONs into the cytoplasm of the cells. Furthermore, the released 
ONs rapidly accumulated into the cell nucleus. Both FRET imaging and the R/G ratio as 
determined by FCS pointed out that the released PO-ONs were rapidly degraded, while 
intact PS-ONs could be detected during at least 8 hours following their delivery. As the 
complexed PO-ONs seemed to remain intact in the intracellular environment, this pointed out 
that degradation only occurred after release of the PO-ONs from the non-pegylated 
lipoplexes. Therefore, we concluded that the protection against enzymatic degradation of 
PO-ONs as offered by non-pegylated liposomes did not translate into a biological effect due 
to the too efficient release and subsequent degradation of the PO-ONs at the step of the 
endosomal escape of the lipoplexes. In the case of PS-ONs, the ONs are not degraded upon 
release at the time of the endosomal escape, creating a pool of intact, biologically active 
PS-ONs.  
Both PO-ONs and PS-ONs failed in generating an antisense effect when pegylated 
liposomes were used as a delivery system. In Chapter 6 the intracellular distribution and 
degradation of the double-labeled PO-ONs and PS-ONs was followed by FCS and confocal 
imaging upon their administration to the target cells using pegylated liposomes. As observed 
for the non-pegylated lipoplexes, the pegylated lipoplexes were efficiently internalized by 
endocytosis. The pegylated lipoplexes, however, did not succeed in protecting the PO-ONs 
against enzymatic degradation in the endosomal compartment. This agrees with the 
structural properties of the pegylated lipoplexes as proposed in Chapter 3, where the ONs 
are situated at the surface of the pegylated liposomes, unshielded from nucleases present in 
the intracellular environment. One could thus conclude that degradation of the PO-ONs is 
responsible for the lack of biological activity. The PS-ONs, however, also failed in generating 
an antisense effect, although both FCS and confocal imaging clearly demonstrated that the 
PS-ONs remained intact in the intracellular environment. An explanation for the lack of 
biological activity could be found in the endosomal escape of the pegylated lipoplexes that 
failed to occur. The PEG-chains at the surface of the pegylated lipoplexes can be hold 
responsible for the inhibition of the endosomal escape. It is indeed known that interaction 
between the lipids from the lipoplexes and the lipids from the endosomal membrane plays an 
important role in the destabilization of the endosomal membrane and the subsequent release 
of the complexed DNA molecules in the cytoplasm of the cells. The PEG-chains at the 
lipoplexes’ surface, however, prevent these lipid-lipid interactions. As a consequence, the 
delivered ONs are trapped in the endosomal compartment, separated from their biological 
target in the cytoplasm or the nucleus of the cells. This explains why both PO-ONs and 
PS-ONs failed in generating an antisense effect. The inhibitory effect of pegylation at the 
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step of the endosomal escape can be overcome by reversible pegylation, where the PEG-
chains leave the surface of the lipoplexes in the endosomal compartment. The rapid 
intracellular degradation of the PO-ONs, however, raises the concern that suitable delivery 
systems for PO-ONs may not be found. Also, with the recent discovery of small interfering 
RNA (siRNA), the future interest in antisense therapy with ONs may be questioned. siRNAs 
are small, double-stranded RNA molecules that, via the ‘RNA induced silencing complex’ 
(RISC), result in a very efficient down-regulation of the targeted protein expression. Also, 
double-stranded siRNAs seem to be much more resistant against enzymatic degradation in 
the intracellular environment, when compared to the single-stranded PO-ONs. Although the 
delivery problems with siRNA and antisense ONs are essentially the same, the siRNA field 
makes rapid progress. This while antisense ONs, that have already been studied for many 
years, resulted in only a few (rather inefficient) antisense therapeutics that are actually on the 
market. The increased efficiency of siRNAs, however, also comes with the increased risk of 
off-target effects. Therefore, it remains to be seen if the therapeutic potential of siRNA will 
live up to its promise, leaving the well known antisense ONs behind.           
In contrast to antisense therapy, gene therapy with plasmid DNA (pDNA) aims to 
induce novel genes or repair mal-functioning genes. As the sequence of the pDNA is crucial 
to allow the expression of the encoded proteins, pDNA should remain intact during the 
delivery process. pDNA can occur in the compact supercoiled (SC) form, the relaxed open 
circular (OC) form and the linearized form. In Chapter 7, we found that mainly the SC 
topology resulted in gene expression upon delivery with non-pegylated liposomes. Nuclear 
injections of the different pDNA topologies proved that not the pDNA topology, but rather the 
concentration of pDNA in the nucleus determined the transcription efficiency. Upon injection 
in the cytoplasm, however, both the pDNA concentration as well as the topology determined 
the transfection efficiency. Gene expression was most efficient when using SC pDNA at the 
highest injection concentration. Furthermore, the amount of transfected cells drastically 
increased when the cells divided in the period following the injection, indicating that the 
nuclear membrane was an important barrier in pDNA delivery. As more SC pDNA molecules 
seemed to reach the nucleus upon cytoplasmic injections, we questioned if a difference in 
degradation of the pDNA topologies could account for these observations. SC pDNA, 
however, was degraded at least as rapidly as the OC or the linearized form. In a next step, 
the diffusion characteristics of the different pDNA topologies were investigated by FCS. The 
nearly two times slower diffusing OC topology could explain why the faster diffusing SC 
pDNA molecules were more efficient in reaching the cell nucleus. The diffusion of the 
linearized pDNA topology did, however, not differ from that observed for the SC pDNA 
molecules. Therefore, in the case of linearized pDNA, the additional susceptibility towards 
exonucleases most likely explains the lower transfection efficiency when compared to the SC 
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form. The observation that nuclear accumulation of pDNA is greatly enhanced during cell 
division raises the idea that non-viral gene delivery systems that optimally guide their pDNA 
to the nucleus of the daughter cells during the process of cell division could greatly enhance 
the level of gene expression. Furthermore, the delivery system should protect the pDNA 
against enzymatic degradation in the period before cell division occurs. An interesting 
strategy could be to develop DNA nanoparticles that are entrapped in the nuclei of the 
daughter cells during cell division. Indeed, after nuclear entrapment, the DNA nanoparticles 
are expected to release their pDNA directly in the cell nucleus of the daughter cells, thereby 
avoiding degradation of the pDNA in the cytoplasm and overcoming the need to pass the 
nuclear membrane.  
 This thesis demonstrated that FCS measurements can be applied to answer the 
question why particular non-viral carriers are suitable to induce a biological effect while other 
carriers fail. Since FCS measurements are performed in a limited confocal volume, many 
times smaller than the dimensions of a single cell, it mainly generates information on the 
specific intracellular situation in a well-defined compartment of the cell. This in contrast to 
conventional microscopy or the more recently developed Single Particle Tracking (SPT) 
which map the intracellular pathways throughout the entire intracellular environment. It is 
expected that the combination of conventional microscopy with advanced microscopy 
systems such as FCS and SPT, each with their own advantages and limitations, will continue 
to guarantee further breakthroughs in the complex study of the intracellular behavior of non-
viral DNA/carrier complexes. The increasing knowledge on the intracellular barriers in 
antisense- and gene therapy is expected to contribute on its turn to the rational design of a 
new generation of ‘intelligent’ gene delivery systems.   
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Een waaier van aandoeningen vindt zijn oorsprong in de aan- of afwezigheid van 
bepaalde proteïnen. Gentherapie wenst op de oorzaak van deze aandoeningen in te werken 
door de productie van dergelijke proteïnen respectievelijk te inhiberen of te stimuleren. In 
antisense therapie worden korte, enkelstrengige DNA moleculen (oligonucleotiden (ONs)) 
toegediend die de juiste sequentie bevatten om de productie van het ongewenste proteïne te 
verhinderen. Zo kunnen bijvoorbeeld virale infecties worden behandeld door 
levensnoodzakelijke virale proteïnen stil te leggen. Ook kunnen bepaalde kankers bestreden 
worden via de inhibitie van kankerspecifieke proteïnen. Bij gentherapie met plasmide DNA 
(pDNA) worden circulaire, dubbelstrengige DNA moleculen toegediend die de genetische 
informatie bevatten voor de productie van het gewenste proteïne. Dit vindt zijn toepassing in 
onder andere DNA vaccinaties en de behandeling van genetische defecten zoals Cystische 
Fibrose. Aangezien zowel ONs als pDNA inwerken op cellulair niveau, waar de genetische 
informatie zich bevindt, dienen ze binnenin de doelcellen te geraken vooraleer ze hun functie 
kunnen uitoefenen. Bovendien dienen deze DNA moleculen intact te blijven aangezien hun 
sequentie noodzakelijk is voor het bekomen van het gewenste therapeutische effect.  
De huidige toepasbaarheid van antisense- en gentherapie wordt voornamelijk 
gelimiteerd door toedieningsproblemen: naakte DNA moleculen zijn onderhevig aan afbraak, 
bereiken hun doelcellen niet of worden slechts in geringe mate opgenomen. Verscheidene 
virale en niet-virale dragers worden onderzocht voor de geavanceerde toediening van DNA 
moleculen. Alhoewel virale dragers voor een efficiënte toediening van DNA moleculen 
zorgen, vertonen ze problemen zoals het mogelijks opwekken van een ernstige 
immuunrespons. Niet-virale dragers daarentegen zijn veiliger en gemakkelijker in gebruik, 
maar blijken tot op heden onvoldoende efficiënt in het bekomen van een therapeutisch effect. 
Zoals werd besproken in Hoofdstuk 1, wordt van de ideale niet-virale drager verwacht dat hij 
efficiënt wordt opgenomen in de doelcellen en zijn DNA moleculen vrijstelt in het cytoplasma 
(voor ONs) of in de kern (voor pDNA) van de cellen. Bovendien dienen de DNA moleculen 
beschermd te worden tegen afbraak gedurende het volledige toedieningsproces. Het is 
voornamelijk deze laatste stap die het onderwerp vormt van dit proefschrift: we wensten te 
achterhalen in welke mate de afbraak van DNA moleculen aan de basis ligt van het uitblijven 
van een therapeutisch effect.  
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Er zijn slechts een gering aantal methoden die toelaten om de afbraak van DNA 
moleculen te volgen in levende cellen. Daarom werd in Hoofdstuk 2 de bruikbaarheid van 
Fluorescentie Correlatie Spectroscopie (FCS) nagegaan voor deze toepassing. FCS is een 
techniek die gebruik maakt van zeer gevoelige fluorescentie detectoren teneinde het aantal 
fluorescent (voorbeeld groen of rood) gemerkte moleculen in een klein volume te bepalen 
samen met hun diffusietijd. In ‘twee-kleuren’ Fluorescentie Cross-correlatie Spectroscopie 
(FCCS) kan bovendien het aantal dubbel fluorescent (groen en rood) gemerkte moleculen 
worden bepaald. FCCS kan dus worden aangewend om de afbraak van dubbel fluorescent 
gemerkte ONs te volgen aan de hand van een daling van het aantal dubbel fluorescent 
gemerkte deeltjes. Bovendien kan er worden verwacht dat de kleinere degradatieproducten 
een snellere diffusie vertonen. 20 of 40 basenparen lange ONs met een nuclease gevoelige 
phosphodiester ruggengraat (PO20-ONs of PO40-ONs) of 20 basenparen lange ONs met 
een nuclease resistente phosphothioate ruggengraat (PS20-ONs) werden dubbel fluorescent 
gemerkt met een rhodamine groen fluorofoor (groene fluorescentie) op hun 3’ uiteinde en 
een Cy5 fluorofoor (rode fluorescentie) op hun 5’ uiteinde. De afbraak van de ONs werd 
onderzocht in buffer na incubatie met de nucleasen DNase I, DNase II, in cytosolisch 
celextract en in levende cellen na micro-injectie in het cytoplasma. Tot onze verbazing was 
‘twee-kleuren’ FCCS niet in staat om het aantal dubbel fluorescent gemerkte ONs in 
oplossing accuraat te bepalen. Uit de analyse van de geregistreerde groene en rode 
fluorescentie kon worden afgeleid dat Fluorescentie Resonantie Energie Transfer (FRET) 
optrad tussen het rhodamine groen en het Cy5 fluorofoor. Bij FRET wordt na excitatie van 
het rhodamine groen, donor fluorofoor een deel van de excitatie energie overgedragen naar 
het Cy5, acceptor fluorofoor. Dit resulteert in een daling van de groene fluorescentie en een 
stijging van de rode fluorescentie ten opzichte van de situatie waarin FRET niet optreedt. 
Een belangrijke vereiste voor FCCS is dat de fluorescentie van het ene fluorofoor niet wordt 
beïnvloed door de aan- of afwezigheid van het andere fluorofoor. Dit verklaart waarom in het 
geval van FRET tussen beide fluoroforen FCCS niet geschikt bleek te zijn om het aantal 
intacte, dubbel fluorescent gemerkte ONs te volgen in functie van de tijd.   
Het optreden van FRET in de dubbel fluorescent gemerkte ONs bleek echter op een 
andere manier geschikt om de afbraak van de ONs te volgen. Een belangrijke voorwaarde 
voor FRET is dat de beide fluoroforen zich in elkaars nabijheid bevinden. Wanneer de 
ruggengraat van de ONs degradeert, is aan deze voorwaarde echter niet meer voldaan. De 
afbraak van de ONs, en dus het verdwijnen van FRET, kon gemakkelijk gevolgd worden aan 
de hand van de verhouding tussen de rode (acceptor) fluorescentie en de groene (donor) 
fluorescentie (R/G ratio) in functie van de tijd bij excitatie van het rhodamine groen fluorofoor. 
De gevoelige detectoren van het FCS instrument bleken zeer geschikt om de groene en rode 
fluorescentie intensiteiten te bepalen en dit zowel in buffer als na micro-injectie van de ONs 
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in levende cellen. FCS biedt bovendien het voordeel dat de fluorescentie van een enkele 
molecule kan worden gedetecteerd. Hierdoor kan de R/G ratio ook bepaald worden in die 
situaties waar de intracellulaire concentratie van fluorescent gemerkte moleculen te laag is 
om te worden gedetecteerd met conventionele FRET microscopie, zoals het geval kan zijn 
na intracellulaire toediening van ONs met niet-virale dragers.  
In een volgende stap werd FCS aangewend om de bescherming van dubbel 
fluorescent gemerkte ONs na te gaan wanneer deze zijn gebonden aan niet-virale dragers  
zoals kationische lipide-partikels (liposomen) of kationische polymeren. Wanneer deze 
kationische dragers worden gemengd met de negatief geladen ONs, worden spontaan 
complexen gevormd door elektrostatische interacties. Deze complexen hebben als doel de 
opname en vrijgave van de ONs in de doelcellen te verhogen. Bovendien dienen de ONs, 
gebonden aan de niet-virale drager, beschermd te worden tegen afbraak in de extracellulaire 
en intracellulaire omgeving. In Hoofdstuk 3 werd de bescherming van ONs nagegaan na 
complexatie met kationische liposomen die frequent worden gebruikt in het kader van 
antisense therapie. Hiertoe werden dubbel fluorescent gemerkte PO40-ONs gecomplexeerd 
met zowel gepegyleerde als niet-gepegyleerde liposomen en werd hun afbraak gevolgd aan 
de hand van de R/G ratio met behulp van FCS. Pegylatie, door koppeling van 
polyethyleenglycol (PEG) aan het oppervlak van de liposomen, is een frequent aangewende 
strategie om de extracellulaire eigenschappen van lipide/DNA complexen (lipoplexen) te 
verbeteren. Pegylatie van lipoplexen verhindert hun aggregatie en opsonisatie door het 
reticulo endotheliaal systeem, wat hun circulatietijd in de bloedbaan doet toenemen. Op 
intracellulair niveau blijkt pegylatie echter een aantal negatieve invloeden te hebben, zoals 
het verminderen van de endosomale vrijstelling van de gepegyleerde lipoplexen. In 
Hoofdstuk 3 konden we waarnemen dat pegylatie ook een invloed heeft op de bescherming 
tegen degradatie die gepegyleerde en niet-gepegyleerde liposomen bieden aan de 
gecomplexeerde ONs. Niet-gepegyleerde liposomen vertoonden initieel een goede 
bescherming van de gecomplexeerde ONs tegen afbraak, hetgeen overeenkomt met het in 
de literatuur beschreven mechanisme van lipoplex formatie. Na binding van de ONs aan de 
kationische liposomen induceren de ONs het samensmelten van verschillende niet-
gepegyleerde liposomen. Dit  resulteert in de vorming van multilamellaire lipoplexen waarin 
de ONs gevangen zitten tussen de opeenvolgende lipide-dubbellagen van de individuele 
liposomen (zie Hoofdstuk 3, Figuur 11A). Bijgevolg worden de gecomplexeerde ONs 
afgeschermd van de omgeving waarin de nucleasen zich bevinden. We konden echter 
vaststellen dat de bescherming van de ONs tegen afbraak afnam naarmate de incubatietijd 
(enkele uren) van de lipoplexen toenam. Aan de hand van de fluorescentie fluctuaties, zoals 
geregistreerd met het FCS instrument, kon worden aangetoond dat niet-gepegyleerde 
lipoplexen aggregeren in functie van de tijd met een graduele vrijstelling van de ONs tot 
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gevolg (zie Hoofdstuk 3, Figuur 8). Dit bracht ons tot de conclusie dat niet de 
gecomplexeerde ONs, maar eerder de vrijgestelde ONs toegankelijk werden voor afbraak 
door nucleasen. 
In het geval van gepegyleerde liposomen toonde de daling van de R/G ratio in functie 
van de tijd aan dat een groot deel van de gecomplexeerde ONs onmiddellijk werd 
afgebroken na blootstelling van de lipoplexen aan nucleasen. Dit duidt erop dat, in 
tegenstelling tot de niet-gepegyleerde lipoplexen, de ONs in gepegyleerde lipoplexen nog 
steeds toegankelijk zijn voor afbraak door nucleasen. In de literatuur is zo goed als geen 
informatie terug te vinden betreffende het mechanisme van complexvorming tussen ONs en 
gepegyleerde liposomen. We stelden echter een mechanisme voor betreffende de formatie 
van gepegyleerde lipoplexen dat de substantiële initiële afbraak van de gecomplexeerde 
ONs kan verklaren (zie Hoofdstuk 3, Figuur 11B). Naar analogie met de niet-gepegyleerde 
liposomen kan worden verondersteld dat de ONs in eerste instantie aan het oppervlak van 
de gepegyleerde liposomen binden. De aanwezigheid van de PEG-ketens aan het oppervlak 
verhindert echter de versmelting van verschillende gepegyleerde liposomen, met als gevolg 
dat de insluiting van ONs tussen opeenvolgende lipide-dubbellagen van de gepegyleerde 
liposomen wordt voorkomen. Bijgevolg blijven de ONs onbeschermd aan het oppervlak van 
de individuele gepegyleerde liposomen, waar ze nog steeds in contact kunnen komen met 
de omgeving waarin de nucleasen zich bevinden.  
Naast kationische liposomen worden ook vaak kationische polymeren aangewend als 
niet-virale drager in antisense therapie. Een frequent onderzocht kationisch polymeer is 
polyethyleenimine (PEI). Ook voor PEI is pegylatie een veel voorkomende strategie om de 
oplosbaarheid te bevorderen, de cytotoxiciteit te verminderen en de aggregatie in de 
bloedstroom met klaring van de PEI/DNA complexen (polyplexen) te vermijden. In 
Hoofdstuk 4 werd geëvalueerd in welke mate de bescherming van de gecomplexeerde ONs 
tegen enzymatische afbraak wordt beïnvloed door pegylatie van PEI. Hiertoe werden dubbel 
fluorescent gemerkte PO40-ONs gecomplexeerd met zowel gepegyleerde als niet-
gepegyleerde PEI polymeren en werd hun afbraak gevolgd aan de hand van de R/G ratio 
met behulp van FCS. Zowel PEI als PEG-PEI vertoonden initieel een goede bescherming 
van de ONs tegen enzymatische afbraak: meer dan 70% van de gecomplexeerde ONs bleef 
intact in de aanwezigheid van nucleasen. In de PEI polyplexen werd deze bescherming 
behouden gedurende de 30 uren incubatietijd met het DNase I enzym. In de PEG-PEI 
polyplexen werd uiteindelijk tot 70% van de gecomplexeerde ONs afgebroken gedurende de 
30 uren incubatietijd. Naar analogie met de lipide-gebaseerde niet-virale dragers, bleek 
pegylatie dus ook de beschermende eigenschappen van polymeer-gebaseerde niet-virale 
dragers te verminderen. Opnieuw kon een verklaring worden gevonden in de 
complexvorming tussen ONs en PEI en PEG-PEI polymeren. De polyplexen bestaan in 
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essentie uit een kern waarin verschillende ON-strengen en verschillende polymeerketens 
door elektrostatische interacties bij elkaar worden gehouden. In het geval van PEG-PEI, 
wordt deze kern bovendien omgeven door een mantel van PEG-ketens. De initiële 
degradatie van de gecomplexeerde ONs wijst erop dat een fractie van de gecomplexeerde 
ONs zich aan de rand van de polyplex kern bevindt, zowel in PEI als in PEG-PEI gebaseerde 
polyplexen. In het geval van PEG-PEI blijken echter meerdere ONs toegankelijk te worden 
voor enzymatische afbraak in de loop van het incubatieproces. Er kan verwacht worden dat 
de elektrostatische interacties tussen de ONs en de polymeerketens in de polyplexen continu 
kunnen verbroken en terug aangegaan worden, met een voortdurende reorganisatie van de 
polyplex kern tot gevolg. Tijdens dit proces kunnen intacte ONs uit het binnenste van de 
polyplex kern vermoedelijk relokaliseren naar het oppervlak van de kern waar ze bijgevolg 
toegankelijk worden voor enzymatische afbraak. Een grondige analyse van de fluorescentie 
fluctuatieprofielen, zoals geregistreerd met het FCS instrument, duidde erop dat de ONs 
minder ‘sterk’ gebonden zijn in de kern van de PEG-PEI polyplexen. Aangezien de 
elektrostatische interacties tussen PEG-PEI polymeren en ONs gemakkelijker kunnen 
verbroken worden, kan dit verklaren waarom een groter deel van de gecomplexeerde ONs 
tijdens het incubatieproces naar het oppervlak van de polyplex kern relokaliseert, waar ze 
vervolgens kunnen worden afgebroken door nucleasen.    
Zowel in Hoofdstuk 3 als 4 werd aangetoond dat FCS uitermate geschikt is om de 
bescherming van ONs tegen enzymatische afbraak na te gaan en dit zowel met lipide-
gebaseerde als met polymeer-gebaseerde niet-virale dragers. Enige voorzichtigheid was 
echter geboden bij de interpretatie van de R/G ratio van de gecomplexeerde ONs. Bij 
complexatie werden multimoleculaire complexen gevormd door associatie van vele dubbel 
fluorescent gemerkte ONs en vele liposomen of polymeerketens in respectievelijk de 
lipoplexen en de polyplexen. Door de compactie van de ONs in de complexen bleek het 
mogelijk dat FRET niet enkel optrad tussen de fluoroforen van een enkele ON-streng, maar 
ook tussen naburig gecomplexeerde ONs. In dit geval kon FRET dus ook optreden wanneer 
de fluoroforen van gedegradeerde ONs zich in elkaars nabijheid bevonden. Bijgevolg was 
het FRET signaal en dus de R/G ratio niet meer representatief voor het aantal intacte ONs in 
de complexen. Een ander fenomeen dat optrad ten gevolge van de compactie van de ONs 
was de onvoorziene uitdoving van de fluorescentie van het rhodamine groen en het Cy5 
fluorofoor, zoals werd waargenomen voor de PEI-gebaseerde en PEG-PEI gebaseerde 
polyplexen (zie Hoofdstuk 4, Figuur 4). Het nagenoeg volledig wegvallen van het groene en 
rode fluorescent signaal zorgde ervoor dat de correlatie tussen de berekende R/G ratio en 
het al dan niet aanwezig zijn van intacte ONs in de polyplexen volledig verloren ging. Zowel 
voor lipide-gebaseerde als voor polymeer-gebaseerde niet-virale dragers bleek de R/G ratio 
van de gecomplexeerde ONs dus niet langer representatief te zijn voor hun integriteit. 
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Wanneer de ONs echter van de lipoplexen of polyplexen werden vrijgesteld door toevoeging 
van respectievelijk sodiumdodecylsulfaat (SDS) of dextraan sulfaat, kon de R/G ratio van de 
vrijgestelde ONs opnieuw aangewend worden om hun afbraak te evalueren. Daarom werden 
de ONs steeds vrijgesteld van de complexen (na een bepaalde inwerktijd en inhibitie van de 
aanwezige nucleasen) vooraleer de R/G ratio werd bepaald.  
Een belangrijke vraag in dit proefschrift was in welke mate de afbraak van DNA 
moleculen aan de basis ligt van het uitblijven van een therapeutisch effect. In Hoofdstuk 5 
werd de biologische activiteit nagegaan van nuclease gevoelige PO-ONs en nuclease 
resistente PS-ONs na toediening met niet-gepegyleerde liposomen. We stelden vast dat 
enkel PS-ONs gecomplexeerd met niet-gepegyleerde liposomen in staat waren de productie 
van het doelwit proteïne te verminderen. De bescherming van PO-ONs tegen enzymatische 
afbraak door niet-gepegyleerde liposomen, zoals aangetoond in Hoofdstuk 3, bleek dus niet 
te resulteren in een biologisch effect. Om deze waarnemingen te verklaren werden, na 
toediening van de ONs aan de cellen met niet-gepegyleerde liposomen, de intracellulaire 
vrijgave en afbraak van dubbel fluorescent gemerkte PO-ONs en PS-ONs gevolgd met 
behulp van FCS en confocale microscopie. Niet-gepegyleerde lipoplexen werden efficiënt in 
de cellen opgenomen door endocytose. Aangezien na endocytose de lipoplexen aanwezig 
zijn in endosomale vesikels, dienden de lipoplexen uit de endosomen te ontsnappen om 
degradatie in de lysosomen te vermijden. Bovendien dienden de ONs te worden vrijgegeven 
in het cytoplasma om hun therapeutisch effect te kunnen uitoefenen. We stelden vast dat de 
endosomale vrijgave van niet-gepegyleerde lipoplexen gepaard ging met een efficiënte 
vrijgave van zowel de PO-ONs als de PS-ONs in het cytoplasma van de cellen. De 
vrijgestelde ONs accumuleerden vervolgens snel in de celkern. Uit zowel confocale 
microscopie als uit de R/G ratio kon worden afgeleid dat de vrijgestelde ONs snel werden 
afgebroken in het geval van PO-ONs, terwijl intacte PS-ONs gedetecteerd werden 
gedurende minstens 8 uur volgend op hun toediening met niet-gepegyleerde lipoplexen. 
Aangezien de nog gecomplexeerde PO-ONs grotendeels intact bleken te zijn, wees dit erop 
dat de degradatie slechts plaats vond na hun intracellulaire vrijgave van de niet-
gepegyleerde lipoplexen. Niettegenstaande de goede bescherming tegen afbraak in de niet-
gepegyleerde lipoplexen bleek de snelle degradatie van de vrijgestelde PO-ONs dus aan de 
oorsprong te liggen van het uitblijven van een antisense effect. Dit in tegenstelling tot de 
vrijgestelde PS-ONs, die voldoende lang intact bleven in het intracellulaire milieu om een 
biologisch effect teweeg te brengen.  
Wanneer de antisense activiteit van PO-ONs en PS-ONs werd nagegaan na 
toediening met gepegyleerde liposomen, bleken de PO-ONs, noch de PS-ONs de productie 
van het doelwit proteïne te doen afnemen. Naar analogie met Hoofdstuk 5 werd in 
Hoofdstuk 6 de intracellulaire vrijgave en afbraak van dubbel fluorescent gemerkte PO-ONs 
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en PS-ONs nagegaan na toediening met gepegyleerde liposomen. Zoals niet-gepegyleerde 
lipoplexen werden de gepegyleerde lipoplexen efficiënt opgenomen in de cellen door 
endocytose. De gepegyleerde lipoplexen bleken echter niet in staat de PO-ONs te 
beschermen tegen degradatie in de intracellulaire omgeving. Dit komt overeen met de 
vooropgestelde opbouw van gepegyleerde lipoplexen in Hoofdstuk 3, waarbij de PO-ONs 
zich aan het oppervlak van de gepegyleerde liposomen bevonden en bijgevolg nog steeds 
toegankelijk waren voor intracellulaire nucleasen. De afbraak van PO-ONs in het 
intracellulair milieu zou dus aan de basis kunnen liggen van het uitblijven van een antisense 
effect. Met de nuclease resistente PS-ONs werd er echter ook geen antisense effect 
vastgesteld, alhoewel FCS en confocale microscopie duidelijk aantoonden dat de PS-ONs 
intact bleven in de intracellulaire omgeving. Een verklaring voor het uitblijven van een 
antisense effect kon worden gevonden in het niet optreden van de endosomale vrijgave van 
de gecomplexeerde ONs. Bijgevolg bleven de ONs, aanwezig in de endosomale vesikels, 
afgeschermd van hun therapeutisch doelwit dat zich in het cytoplasma of de kern van de 
cellen bevindt. De PEG-ketens aan het oppervlak van de gepegyleerde lipoplexen zijn 
verantwoordelijk voor het verhinderen van de endosomale vrijstelling van de 
gecomplexeerde ONs. Het is bekend dat het contact tussen de lipiden van de lipoplexen en 
de lipiden van de endosomale membraan een belangrijke factor is voor de verstoring van de 
endosomale membraan met vrijstelling van de gecomplexeerde DNA moleculen in het 
cytoplasma tot gevolg. De PEG-ketens aan het oppervlak van de gepegyleerde liposomen 
voorkomen echter deze lipide-lipide interacties waardoor ze de cytoplasmatische vrijgave 
van de gecomplexeerde ONs verhinderen. Dit verklaart waarom zowel nuclease gevoelige 
PO-ONs als nuclease resistente PS-ONs niet in staat waren een antisense effect teweeg te 
brengen na toediening met gepegyleerde liposomen. Het inhiberend effect van de PEG-
ketens op de endosomale vrijstelling kan worden overkomen door gebruik te maken van 
reversibele pegylatie, waarbij de PEG-ketens het oppervlak van de liposomen verlaten in de 
endosomale vesikels. De snelle intracellulaire afbraak van PO-ONs doet echter de vraag 
rijzen of het al bij al mogelijk is om geschikte toedieningssystemen te ontwikkelen die de 
PO-ONs in staat zullen stellen een antisense effect uit te voeren. Bovendien kan met de 
recente opgang van het smal interferentie RNA (siRNA) de toekomst van antisense ONs in 
het algemeen worden in vraag gesteld. siRNAs zijn kleine, dubbelstrengige RNA moleculen 
die met behulp van het ‘RNA induced silencing complex’ (RISC) zeer efficiënt de expressie 
van een doelwit proteïne kunnen stil leggen. Bovendien blijken dubbelstrengige RNA 
moleculen vele malen stabieler in de intracellulaire omgeving dan de enkelstrengige 
PO-ONs. Alhoewel de toedieningsproblemen met siRNA in essentie dezelfde zijn als met 
antisense ONs, blijkt het siRNA veld een veel snellere vooruitgang te boeken. Dit terwijl het 
therapeutisch potentieel van antisense ONs reeds vele jaren wordt onderzocht, met slechts 
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enkele (bovendien weinig efficiënte) klinische toepassingen tot gevolg. Door hun grotere 
effectiviteit vertonen siRNAs echter ook meerdere neveneffecten zoals het inwerken op 
andere proteïnen dan het beoogde doelwit proteïne. Hierdoor valt nog af te wachten of de 
therapeutische mogelijkheden van het siRNA zullen ingelost worden en of de reeds lang 
gekende antisense ONs naar de achtergrond zullen verdwijnen. 
 Naast inhibitie van de productie van proteïnen met antisense therapie vindt 
gentherapie met plasmide DNA (pDNA) zijn toepassing in die situaties waar men bepaalde 
proteïnen intracellulair wenst aan te maken. Aangezien de sequentie van het toegediende 
pDNA de noodzakelijke informatie voor de productie van het gewenste proteïne bevat, is het 
van belang dat de pDNA moleculen intact blijven tijdens het toedieningsproces. De 
dubbelstrengige pDNA moleculen kunnen voorkomen in een supercoiled vorm (SC), een 
open circulaire vorm (OC) of in een lineaire vorm. In Hoofdstuk 7 werd vastgesteld dat 
voornamelijk de SC vorm resulteert in de productie van het gewenste proteïne na toediening 
van de verschillende pDNA vormen aan cellen met niet-gepegyleerde liposomen. Nucleaire 
injecties van de verschillende pDNA vormen toonden aan dat, eens in de kern, de pDNA 
concentratie en niet de pDNA topologie de efficiëntie van de proteïne productie bepaalde. Bij 
injectie in het cytoplasma bleek echter zowel de concentratie als de pDNA topologie een rol 
te spelen: voornamelijk de hoogst geïnjecteerde pDNA concentraties resulteerden in 
proteïne productie, waarbij de SC pDNA topologie het meest efficiënt bleek. De efficiëntie 
nam bovendien sterk toe in cellen die een celdeling ondergingen in de periode na injectie, 
wat erop wijst dat de nucleaire membraan een grote barrière is in de toediening van pDNA 
moleculen. Aangezien de SC pDNA topologie het meest efficiënt bleek in het bereiken van 
de celkern, werd met behulp van gel electroforese nagegaan of een verschil in afbraak aan 
de oorsprong zou kunnen liggen van het hogere aantal SC pDNA moleculen dat de celkern 
bereikte. SC pDNA bleek echter minstens even snel af te breken als de OC of lineaire vorm. 
Vervolgens werden, met behulp van FCS, de diffusie-eigenschappen van het pDNA 
nagegaan. De nagenoeg twee maal tragere diffusie van de OC vorm in vergelijking met de 
SC vorm zou kunnen verklaren waarom SC pDNA efficiënter is in het bereiken van de 
celkern dan OC pDNA. Het lineaire pDNA vertoonde echter dezelfde diffusietijd als zijn SC 
analoog. In het geval van lineair pDNA diende de lagere efficiëntie ten opzichte van de SC 
vorm vermoedelijk gezocht te worden in de extra afbraak van het lineair pDNA door 
exonucleasen. De aanwijzingen dat pDNA moleculen zich, tijdens de celdeling, op efficiënte 
wijze een toegang verschaffen tot de celkern doen vermoeden dat niet-virale dragers die hun 
pDNA, tijdens de celdeling, optimaal in de kernen van de dochtercellen binnenloodsen, de 
efficiëntie van gentherapie sterk zouden kunnen doen toenemen. Verder blijft de vereiste dat 
het pDNA, in de periode die de celdeling voorafgaat, maximaal dient beschermd te worden 
tegen afbraak in het cytoplasma. Een interessante strategie zou bijgevolg kunnen zijn om 
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DNA nanopartikels te ontwikkelen die tijdens de celdeling worden ingesloten in de celkern 
van de dochtercellen, waarna ze rechtstreeks hun pDNA kunnen vrijstellen in de celkern van 
de dochtercellen. Hierdoor zou zowel de afbraak van het pDNA in het cytoplasma als de 
barrière van het nucleaire membraan kunnen vermeden worden.  
 Dit proefschrift toonde aan dat FCS metingen kunnen aangewend worden in de vraag 
waarom een bepaalde niet-virale drager al dan niet geschikt is om een biologisch effect 
teweeg te brengen. Aangezien FCS metingen uitgevoerd worden in een zeer beperkt 
volume, vele malen kleiner dan de dimensies van een cel, wordt voornamelijk informatie 
bekomen over de specifieke intracellulaire situatie in een welbepaald celcompartiment. Dit in 
tegenstelling tot conventionele microscopische beeldvorming of het recent ontwikkelde 
Single Particle Tracking (SPT) die de intracellulaire processen in een volledige cel in beeld 
brengen. Er wordt verwacht dat de combinatie van conventionele microscopie met 
geavanceerde microscopie systemen zoals FCS en SPT, elk met hun specifieke voor- en 
nadelen, in de toekomst verdere doorbraken zal blijven verzekeren in de complexe studie 
van het intracellulair gedrag van DNA/drager complexen.  Onze verwachting is dat de 
toenemende kennis betreffende de intracellulaire barrières in antisense- en gentherapie op 
haar beurt zal bijdragen tot het rationeel ontwerpen van een nieuwe generatie van 
‘intelligente’ DNA toedieningssystemen. 
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